Mechanisms controlling the KEAP1-NRF2 signaling pathway in lung cancer by Hast, Bridgid Elizabeth
 
 
 
 
 
MECHANISMS CONTROLLING THE KEAP1-NRF2 SIGNALING PATHWAY IN 
LUNG CANCER 
 
 
 
 
Bridgid Elizabeth Hast 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill 
in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Department of Cell and Molecular Physiology. 
 
 
 
Chapel Hill 
2013 
 
 
 
 
Approved by: 
 
Michael Ben Major, PhD 
 
Dale Ramsden, PhD 
 
Doug Cyr, PhD 
 
D. Neil Hayes, MD, MPH 
 
Patrick Brennwald, PhD         
 ii 
    ABSTRACT  BRIDGID ELIZABETH HAST: Mechanisms controlling the KEAP1-NRF2 signaling 
pathway in lung cancer  
(Under the direction of Michael Benjamin Major) 
 
 
 
The ability to effectively regulate intracellular reactive oxygen species is 
imperative to prevent conditions of oxidative stress, and ultimately aberrant cell death. 
The primary means by which cells control reactive species is through the KEAP1-NRF2 
signaling pathway. NRF2 is a transcription factor that is constitutively degraded by the 
proteasome in a KEAP1-dependent manner, where KEAP1 acts as the E3 ligase substrate 
adaptor for the E3 ligase CUL3. The canonical mechanism for NRF2 activation states 
that when intracellular levels of reactive oxygen species rise, KEAP1 is inactivated, thus 
inhibiting degradation of NRF2. NRF2 then translocates to the nucleus where it drives 
transcription of several genes including reactive oxygen species-scavenging genes, drug 
efflux genes, and cell survival genes.  
 
NRF2 interacts with KEAP1 via two amino acid motifs, the ETGE and DLG, 
which position NRF2 in a sterically favorable position for ubiquitination. An emerging 
alternative mechanism for activation of NRF2, referred to as the Competitive Binding 
Model, proposes that NRF2 activation occurs when KEAP1 interacting proteins 
containing an amino acid sequence similar to the ETGE motif of NRF2 compete with 
NRF2 for binding to KEAP1. We have identified several interacting proteins that bind to 
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KEAP1 in an ETGE-dependent manner, including the dipeptidase DPP3. Identification of 
these interacting proteins not only validate the Competitive Binding Model, but also 
introduce DPP3 as a protein relevant for NRF2 activation in cancer. 
 
In addition to competitive binding, somatic mutations in KEAP1 have been shown 
to activate NRF2. Unlike activating mutations in NRF2, which cluster to the ETGE and 
DLG motifs, mutations in KEAP1 are present throughout the entirety of the protein. How 
these somatic mutations affect KEAP1 function is currently not known. We have 
characterized 18 mutations in KEAP1 derived from The Cancer Genome Atlas lung 
squamous cell carcinoma cohort. In addition to determining that the majority of KEAP1 
mutations are hypomorphic with respect to suppression of NRF2 transcriptional activity, 
we also identify a novel class of KEAP1 mutations that bind NRF2 and facilitate the 
ubiquitination, but not the degradation of NRF2. 
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I. CHAPTER ONE: INTRODUCTION 
 
1.A Oxidative Stress and Cellular Coping Mechanisms 
Cells are continuously exposed to a host of stressors and toxicants capable of 
causing intracellular damage. Originating from several sources, such as mitochondrial 
respiration and environmental exposure, nearly all of these compounds have the potential 
to participate in oxidation-reduction (redox) reactions. The reactive moieties of these 
compounds modify intracellular molecules to produce unstable intermediates, which act 
in a cascade of redox reactions, and when in excess culminate in global cellular damage. 
Consequently, the ability to maintain redox balance, as well as effectively mitigate 
harmful redox cascades is essential for cellular fitness and survival. 
 
Uncontrolled oxidative damage resulting from redox reaction cascades produces 
an intracellular state called oxidative stress. Oxidative stress is characterized by an acute 
spike in reactive oxygen (ROS) and reactive nitrogen (RNS) species, damage to 
macromolecules, including DNA adducts, fatty acid oxidation, and protein oxidation and 
adduct formation [1-2]. This process drives the upregulation of ROS scavenging genes, 
global cellular stress response genes, detoxifying and drug efflux enzymes, as well as 
drug metabolizing enzymes. If these cellular responses to oxidative stress are able to 
quickly alleviate the acute spike in ROS, processes including DNA damage repair and 
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protein degradation are executed to promote cell survival; otherwise, cellular death 
pathways such as necrosis and apoptosis will occur [3-4]. 
 
1.A.1 Reactive oxygen and reactive nitrogen species 
The most common reactive oxygen and reactive nitrogen species include 
hydrogen peroxide (H2O2), superoxide (•O2-), hydroxyl radical (•OH-), nitric oxide (NO), 
peroxynitrite (ONOO-), and reactive lipid species (RLS) [4-5]. All of these species are 
short lived, and they are all capable of reacting non-specifically and rapidly with DNA, 
lipids, carbohydrates, and proteins [6]. Superoxide is commonly referred to as the 
primary reactive oxygen species, because it gives rise to other forms of ROS [6], and is 
directly synthesized by complex I and complex II of the mitochondrial respiration chain 
[5-7]. Due to the electronegativity of oxygen, superoxide is one of the most stable 
reactive oxygen species, and can even act as both an oxidant and reductant [6]. Hydrogen 
peroxide is less stable than superoxide, which makes it both a more potent and more 
reactive species. The enhanced reactivity of hydrogen peroxide enables the modification 
of enzyme active sites that include residues susceptible to oxidation, like cysteine and 
methionine, to alter enzymatic function [8]. Finally, the most reactive—and most short-
lived—reactive oxygen molecule is the hydroxyl radical. The high reactivity of this 
molecule makes for the most non-specific modifications of biological macromolecules, 
such as lipid oxidation [6]. The hierarchy of reactivity, as well as the molecules modified, 
is similar with reactive nitrogen species.  
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Endogenously, most RNS and ROS are produced by reactions in the endoplasmic 
reticulum, mitochondria, and peroxisomes. Reactive oxygen species, however, are not 
just produced as byproducts of other enzymatic reactions. Enzymes such as NADPH 
oxidases (NOX) produce superoxides as their sole enzymatic product, and these 
superoxides are then utilized in a multitude of downstream cellular functions, including 
proliferation, migration, membrane receptor signaling, and signaling within the 
extracellular matrix [6, 9].  Additionally, a number of different cell types produce ROS as 
a means to execute non-autonomous cellular signaling cascades. For example, phagocytes 
and activated astrocytes utilize ROS to initiate inflammatory responses to microbial 
invasion and neuronal injury, respectively [6].  
 
In addition to ROS and RNS produced by endogenous pathways, such as in 
organelles and by NOX enzymes, exposure to environmental toxicants can also 
contribute to rising intracellular levels of reactive species. Reactive moieties on small 
molecules and environmental toxicants are capable of undergoing redox reactions with 
intracellular ROS, such as superoxide, often at the cost of producing a more reactive 
species like hydroxyl radicals and hydrogen peroxide [1, 10]. Additionally, 
environmental toxicants can react directly with biological molecules, including forming 
adducts with DNA and proteins. The various means by which ROS, RNS, and small 
molecules can participate in intracellular redox reactions underscores the importance of 
cells maintaining the ability to quickly and efficiently mitigate acute spikes in ROS that 
may lead to situations of oxidative stress.  
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 1.A.2 NRF2-dependent mechanisms to control oxidative stress 
Buffering the intracellular levels of reactive species requires multiple levels of 
regulation, including enzymes capable of neutralizing endogenously produced RNS and 
ROS, and exogenously introduced environmental toxins. Detoxifying, or drug 
metabolizing (DME) enzymes are used to neutralize reactive species, and are divided into 
two general classes—phase I DMEs, and phase II DMEs. Phase I DMEs include the very 
large and diverse family of cytochrome P450 genes. These enzymes are receptor 
mediated, and binding of small molecules to receptors based on structural and 
biochemical characteristics activates expression of specific phase I enzymes [2]. While 
these enzymes are capable of modifying small molecules, often via a redox reaction that 
enhances hydrophilicity to promote excretion via the urine or bile [11], they are primarily 
used as the first step in modifying a compound for further metabolism by phase II 
enzymes or other stress response proteins [2].  
 
Phase II enzymes, also known as conjugating enzymes, act to increase 
hydrophilicity and enhance secretion of toxic compounds. However, whereas phase I 
DMEs tend to be expressed in response to a more ubiquitous range of stimuli and with 
limited substrate specificity, phase II DMEs exhibit greater substrate specificity and more 
direct pathways for induction. Many phase II DMEs have an antioxidant response 
element (ARE) sequence in the promoter region of the gene [1-2]. In response to 
oxidative stress, the transcription factor nuclear factor (erythroid-derived)-like 2, 
NFE2L2 (NRF2) binds to the promoter ARE to drive transcription of phase II DMEs [1, 
12]. NRF2-dependent phase II enzymes can be further classified into four main 
5  
categories: glutathione homeostasis, drug metabolism, stress response and iron 
metabolism, and drug efflux [13]. The activity of the enzymes contained within some of 
these categories can be altered by global metabolic changes, such as glutathione 
homeostasis via pentose phosphate pathway (PPP) flux; however, it should be noted that 
NRF2 is ultimately required for the gene expression changes that contribute to alterations 
in flux [13-14]. Regulation of NRF2 will be discussed in a later section, and a brief 
overview of some NRF2-dependent phase II drug metabolizing enzymes follows. 
 
Glutathione, also known as γ–glutamyl-cysteinyl glycine (GSH), is the primary 
cytosolic molecule responsible for ROS scavenging [13, 15]. It is synthesized in a two-
step reaction involving first glutamate-cysteine ligase (GCL), followed by glutathione 
synthetase (GS). Ligation of glutamate to cysteine, which is catalyzed by GCL, is the 
rate-limiting step of glutathione synthesis, and this enzyme is required to maintain 
adequate intracellular levels of GSH [15-16]. Through a reaction catalyzed by glutathione 
S-transferase (GST), GSH becomes conjugated to electrophilic molecules to enhance 
secretion of the modified molecule. Intracellular levels of glutathione must be replenished 
to maintain a high ratio of reduced (GSH) to oxidized (GSSG) glutathione, which is in 
part accomplished by the activity of glutathione peroxidase (GPX) and glutathione 
reductase (GSR) [15]. Genes involved in GSH synthesis and turnover, including GCL and 
to a lesser extent GS, GPX, and GSR, are regulated by NRF2 transcriptional activity [13]. 
In addition to regulating the transcription of gluthathione synthesis genes, recent studies 
suggest that NRF2 also regulates the expression of several pentose phosphate pathway 
genes [14]. Increased flux through the PPP increases levels of intracellular GSH, as well 
6  
as the ribose-5-phosphate, which plays a critical role in purine synthesis. Pentose 
phosphate pathway flux and intermediates will be discussed in the section on NRF2 
function in cancer.  
 
Glutathione homeostasis acts as a ubiquitous regulatory process to control 
intracellular ROS levels, whereas the other functions of NRF2-dependent phase II DMEs 
are more specific. NAD(P)H quinone oxidoreductase I (NQO1) is one of the drug 
metabolizing phase II enzymes that acts to neutralize reactive endogenous and exogenous 
quinones. Quinones, whether produced via an endogenous reaction, such as the oxidation 
of certain hormones [13, 17], or present in the chemical structure of an environmental 
toxin, can participate in reactions that produce superoxide and hydrogen peroxide [8, 12]. 
A redox reaction wherein NQO1 transfers two electrons to reduce the quinone inhibits 
formation of superoxide or hydrogen peroxide. Another NRF2-dependent drug 
metabolizing enzyme is UDP-glucuronosyltransferase (UGT). Unlike NQO1, which 
participates in a redox reaction, UGT conjugates glucuronic acid to reactive moieties of 
small molecules to inhibit production of ROS and/or adduct formation with DNA and 
proteins [12].  
 
Like the drug metabolizing enzymes NQO1 and UGT, ferritin and heme 
oxygenase-1 (HMOX1) are induced by NRF2-dependent transcription and participate in 
the iron metabolism-mediated stress response. Ferritin is an iron binding protein that 
sequesters free iron, which would otherwise produce hydroxyl radicals via redox 
reactions, in the cytosol [12]. In addition to NRF2-mediated transcription, the expression 
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of ferritin is also positively regulated by the presence of free iron. A portion of the free 
iron that regulates ferritin expression is formed in the primary reaction catalyzed by 
HMOX1.  Using the cytochrome c and the heme biological precursor Fe-protoporphyrin-
IX as a substrate, HMOX1 catalyzes an oxidative cleavage reaction that produces 
biliverdin, carbon monoxide, and free iron [18]. The free iron goes on to contribute to 
enhance ferritin expression, and the biliverdin is rapidly converted to bilirubin, which 
also acts an intracellular antioxidant [18-19].  
 
Finally, genes regulating drug efflux are also targets of the NRF2-ARE response 
pathway. Acquired resistance to chemotherapeutics is a complex process that represents a 
major clinical hurdle in the treatment of cancer, and drug efflux is thought to be a 
primary contributing factor [13, 20]. The membrane-bound family of drug efflux genes 
consists of multidrug resistance proteins (MDR) and multidrug resistance-associated 
proteins (MRP), and act in an ATP-dependent manner to transport small molecules out of 
the cell [21-22]. While MDR and MRP enzymes also contribute to clearing natural 
products from cells, members of this gene family are overexpressed in several cancers, 
including lung, ovarian, and breast cancer [21], and this expression promotes efflux of 
chemotherapeutics. In accordance with this functional role, in lung cancer moderate to 
high expression of MRP correlates with poor prognosis [23-24]. Knockdown of members 
of this gene family results in increased sensitivity to chemotherapeutics, further 
underscoring their importance in chemotherapeutic resistance [25]. Intriguingly, the 
function of one MRP protein, MRP1, requires the presence of GSH to transport 
unmodified chemotherapeutics through biological membranes [26], suggesting that the 
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many facets of NRF2-mediated regulation of oxidative stress can may act collectively to 
enhance the overall fitness of cancer cells. 
 
1.B KEAP1 and NRF2: Structure, Regulation, and Mechanism 
Since the early 1950s, it has been known that small quantities of certain 
xenobiotic agents were capable of reducing the incidence of cancer in rats fed large 
quantities of carcinogens [27-28]. Nearly forty years elapsed before it was discovered 
that these compounds mediate this protective effect by inducing phase II DMEs [27, 29-
30], and that expression of these phase II enzymes was regulated by antioxidant response 
element (ARE) sequences in the promoters of the genes [27, 31]. In 1996 a screen to 
identify transcription factors that bind ARE sequences lead to the discovery of NRF2 
[32]; shortly thereafter, Kelch-like ECH-associated protein 1 (KEAP1) was found to be a 
negative regulator of NRF2 activity [33]. While the discovery of NRF2, KEAP1, and their 
role in regulating oxidative stress took over fifty years to appreciate, the field has since 
made great strides in identifying not only how critical KEAP1-NRF2 signaling is for 
inducing cell stress responses, but also the importance this signaling pathway holds in 
multiple diseases.  
 
1.B.1 NRF2 domains and structure 
NRF2 belongs to a family of cap’n’collar transcription factors, which share a 
basic leucine zipper homology. In addition to NRF2, the family contains five other 
members—nuclear factor (erythroid-derived) 2 (NF-E2), nuclear factor (erythroid-
derived) like 1 (NRF1), nuclear factor (erythroid-derived) like 3 (NRF3), and two more 
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distantly related members, BTB and CNC homology 1, basic leucine zipper transcription 
factor 1 (BACH1) and BTB and CNC homology 1, basic leucine zipper transcription 
factor 2  (BACH2) [27]. NF-E2 and NRF3 exhibit expression specific to erythroid cells 
and the placenta, respectively, while both NRF1 and NRF2 are ubiquitously expressed 
[34-35]. The knockout mouse for Nrf1 is embryonic lethal [34], and while Nrf2 knockout 
mice are viable and survive well into adulthood [35], they exhibit subtle phenotypes that 
will be discussed later.  
 
The NRF2 protein is made up of six domains, Neh1-6, with each mediating 
different functional aspects of NRF2 (Fig. 1.1.A). The Neh1 domain is responsible for 
DNA binding, as well as regulating binding to interacting partners, namely small Maf 
proteins, on chromatin [36]. Domains Neh4 and Neh5 are the transactivation domains, 
and Neh3 recruits the helicase coactivator CHD6, making it indispensible for NRF2 
function [36-37]. A functional role for the Neh6 domain is currently not known. Finally, 
the Neh2 domain contains seven lysine residues (K44, K50, K52, K53, K56, K64, K68), 
which are targeted for ubiquitination in a KEAP1-dependent manner [38]. In addition to 
the seven lysine residues, the Neh2 domain also contains two critical regulatory motifs—
the ETGE and DLG—which are essential for the recognition and binding of NRF2 to 
KEAP1 [39].  
 
1.B.2 KEAP1 domains and structure 
The discovery of KEAP1 was made using a yeast two-hybrid screen identifying 
proteins that would bind to the Neh2 domain of NRF2 [33, 40]. Following its discovery 
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as the suppressor of NRF2, it was noted that KEAP1 is very cysteine-rich protein, 
containing 27 cysteines within the 624 residue protein. Due to the inherent reactivity of 
the thiol group of cysteines, it was proposed that one or more of the cysteine residues 
within KEAP1 act as sensors of oxidative stress, thus mediating NRF2 function [41]. 
Modification of these residues by ROS and xenobiotic compounds do, in fact, modulate 
KEAP1 activity, making these cysteines function as intracellular biosensors [30, 38, 40-
43]. 
 
The KEAP1 protein consists of three domains: the N-terminal BTB (broad 
complex, tramtrack, and bric-a-brac), an intervening region (IVR), and the C-terminal 
KELCH domain (Fig. 1.1.B). KEAP1 is thought to act intracellularly as a quaternary 
homodimer structure [44]. The BTB domain (residues 1-179) is responsible for this 
homodimerization, and is also the domain that interacts with the E3 ligase cullin-3 
(CUL3). The KELCH domain (residues 315-624) is the substrate-binding domain, and 
forms a six-bladed beta propeller structure, the center of which forms a substrate-binding 
pocket [27, 45]. Additionally, the KELCH domain is in part responsible for the largely 
cytosolic localization of KEAP1, as interaction between the actin cytoskeleton and 
KEAP1 occurs via this domain [46-47]. Finally, the intervening region (residues 180-
314), which is indispensible for KEAP1 function [38], contains several of the reactive 
cysteine residues previously described [38, 41-43]. Single particle electron microscopy 
and structural modeling confirm biochemical interaction data for each domain of KEAP1, 
as well as demonstrating that KEAP1 does, indeed, form a forked-stem homodimer (Fig. 
1.1.C) [48].  
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Crystal structure analysis of the KELCH domain of KEAP1 indicates that NRF2, 
in particular the N-terminal Neh2 domain, binds in the pocket of the KELCH domain 
[45]. Endogenous interaction between KEAP1 and NRF2 is thought to occur in a 2:1 
KEAP1:NRF2 ratio, where the two regulatory ETGE and DLG sequences within NRF2 
each bind a KEAP1 molecule to span the KEAP1 homodimer [39, 45, 48-49] (Fig. 
1.1.C). The residues within the KEAP1 KELCH domain that interface with the ETGE 
motif of NRF2 are: R483, S508, R415, S363, R380, N382, Q530, S555, S602, and Y334 
[50]. The three arginine residues are referred to as an “arginine triad”, which facilitates 
NRF2 binding via electrostatic interactions with the aspartic and glutamic residues within 
the NRF2 regulatory sequences [51]. Binding within the pocket of the KELCH domain 
via the ETGE positions NRF2 in a sterically favorable position for ubiquitination of the 
seven lysine residues that mediate degradation [52].  
 
The cysteine reactivity of KEAP1 provides an elegant mechanism for KEAP1 to 
respond to both oxidative and xenobiotic cellular stimuli. Although cysteine residues are 
located throughout the entirety of the KEAP1 protein, several independent studies have 
shown that many of the key cysteines required for modulation of KEAP1-NRF2 function 
lie within the IVR [38, 41-43]. These residues include C257, C273, C299, C297, and 
C151 (Fig. 1.1.B). Interestingly, C151 is also required for a post-translational 
modification of KEAP1, which results in the formation of an SDS-resistant dimer [38, 
53]. Given the cysteine enrichment of KEAP1, it was proposed that these residues act as 
sensors of electrophilic and xenobiotic insult, and that each cysteine residue may have 
differential reactivity depending on the insult. Consistent with this hypothesis, it was 
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determined that C151 was primarily reactive with electrophilic compounds, whereas 
C273 and C288 exhibited more reactivity with heavy metal and alkenal insult, 
respectively [54]. Furthermore, structural analysis of the amino acid microenvironment 
surrounding these residues revealed that C151, C273, and C288 are surrounded primarily 
by strongly basic amino acids. Consequently, the pKa of the thiol group is lowered, 
making those cysteines more reactive to specific small electrophilic molecules. Further 
studies are required to elucidate the contribution of the other putatively reactive cysteines 
to the stress-sensing abilities of KEAP1, as well as whether disease-derived mutations in 
KEAP1 may alter cysteine reactivity to impact KEAP1 function. 
 
1.B.3 E3 ligase-mediated degradation of NRF2 
E3 ligases exert an effect at the level of protein degradation; consequently, 
regulation of proteins via an E3 ligase enables a faster cellular response than a 
transcriptionally mediated process. In situations of oxidative stress, regulation of stress 
response proteins via an E3 ligase-based mechanism is ideal, because it allows cells to 
mitigate acute spikes in ROS quickly to avoid execution of the apoptotic cascade. Under 
homeostatic conditions, NRF2 has a half-life of less than fifteen minutes [55]; however, 
upon ROS or xenobiotic stimuli, NRF2 is rapidly stabilized to facilitate NRF2-mediation 
transcription of target genes. Another slower pathway for NRF2 exists in the nucleus [27, 
56-57], presumably to facilitate turnover of transcriptionally active NRF2.  
 
Regulation of proteins via the ubiquitin-proteasome system is a multi-step process 
that begins with a ubiquitin activating enzyme (E1), which forms a thioester bond with 
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the small protein ubiquitin. The E1 then transfers ubiquitin to a ubiquitin conjugating 
enzyme (E2), at which point the ubiquitin moiety is activated. Following the E1 to E2 
transfer of ubiquitin, a ubiquitin ligase (E3) enzyme then accepts the activated ubiquitin 
from the E2 to transfer it to lysine residues within the targeted substrate [27, 58]. While 
specificity of the ubiquitin-proteasome system enzymes occurs at the E3 ligase, these 
enzymes may require the substrate to be scaffolded with other proteins to provide a 
sterically favorable environment for ubiquitination [58]. These scaffolding proteins are 
typically referred to as E3 ligase adaptor proteins. As previously stated, KEAP1 acts as 
the E3 ligase adaptor subunit in the CUL3 ubiquitin ligase complex. 
 
KEAP1 was identified as the adaptor subunit for CUL3 based on the observation 
that several BTB-containing proteins were substrate adaptor proteins for the CUL3 E3 
ligase complex [33]. Further studies identified the IVR region of KEAP1 as facilitating 
the KEAP1-CUL3 interaction in addition to the BTB domain [59]. Initially it was 
predicted that regulation of NRF2 degradation occurred through a direct mechanism in 
which modification of KEAP1 via ROS or electrophilic agents caused the dissociation of 
the E3 ligase complex. Indeed, the addition of pathway agonists, such as tert-
butylhydroquinone (tBHQ) and sulforaphane, demonstrate that these compounds inhibit 
degradation of NRF2. Site-directed mutagenesis in which cysteine 273 and 288 were 
mutated to serine indicates that these residues are required for NRF2 suppression under 
basal cell culture conditions only. Unexpectedly, however, when C151 was mutated to a 
serine, unlike C273 or C288 NRF2 degradation occurred regardless of the presence of 
agonist [27, 38, 40, 59]. Additionally, it was also observed that treatment of cells with 
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pathway agonists did not result in dissociation of NRF2 from KEAP1 despite an 
intracellular stabilization of NRF2 [27, 42, 60]. Collectively, these results indicate that 
the interaction between KEAP1 and NRF2, as well as post-translational inactivation of 
KEAP1 via reactive cysteine residues is more dynamic than a simplistic complex 
dissociation model of regulation.  
 
1.B.4 KEAP1 regulation of NRF2: The hinge and latch mechanism 
The regulatory DLG and ETGE sequences within NRF2 are two evolutionarily 
conserved sequences that reside within the Neh2 domain, and comprise residues 29-31 
and 79-82 of the NRF2 primary protein sequence, respectively [39, 49, 52] (Fig. 1.1.A). 
While both sequences are required for NRF2 to be degraded in a KEAP1- and CUL3-
dependent manner, it is thought that the ETGE motif is required for interaction with 
KEAP1 [50], whereas the DLG is required for NRF2 ubiquitination and degradation, but 
not KEAP1 interaction [52, 61-62]. The seven lysine residues that are ubiquitinated by 
CUL3 reside upstream of the ETGE motif [27, 40] on an alpha helix that spans residues 
39-71 [40]. With the exception of the secondary alpha helix structure, the Neh2 domain 
of NRF2 is intrinsically unstructured and flexible [52], which likely facilitates the 
binding dynamics that mediate KEAP1 regulation of NRF2.  
 
Mutation of the residues within the DLG and ETGE motifs indicate that the acidic 
aspartic and glutamic acid residues of the DLG and ETGE, respectively, mediate 
electrostatic interactions with the KELCH domain of KEAP1 [49]. Furthermore, 
isothermal calorimetry shows that the binding affinities of these two sequences differ 
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dramatically: the binding constant of the DLG motif is approximately 1.0X106M-1, 
whereas the binding constant of the ETGE is 1.9X108M-1 [49, 52]. Structural studies 
using both nuclear magnetic resonance (NMR) and X-ray crystallography also 
demonstrate that while the KEAP1 homodimer is structurally capable of binding two 
molecules of NRF2, it is more likely that the binding ratio is 2:1 for KEAP1:NRF2 [52]. 
In addition to the observed electrostatic potentials and affinities of the ETGE and DLG 
sequences in mediating KEAP1 binding, the notion that conformational changes in 
KEAP1 may also mediate regulation of NRF2 lead to the proposal of the “hinge-and-
latch” mechanism for NRF2 activation and degradation.  
 
The basis of the hinge-and-latch mechanism is the discrepancy in binding 
constants of the DLG and ETGE sequences. The ETGE motif is required for binding to 
KEAP1, and has a smaller binding constant, making it act as the “hinge” in the model. 
While the DLG is required for NRF2 stability and degradation, the lower affinity of the 
DLG for the binding pocket of KEAP1 allows for dynamic binding and disassociation 
from the other KEAP1 KELCH domain, making this sequence the “latch”. When both the 
DLG and ETGE sequences are bound to KEAP1, meaning the latch is closed, the alpha 
helix containing the ubiquitinated lysines is in a steric conformation that favors 
ubiquitination and subsequent degradation of NRF2 (Fig. 1.2, top). However, when 
cysteine residues within KEAP1 become oxidized by either ROS or electrophilic species, 
a conformational change in the KEAP1 homodimer occurs (Fig. 1.2, bottom left) [38-39, 
42-43, 52, 54]. Consequently, the lower affinity DLG sequence dissociates from the 
structure, rendering NRF2 unable to be ubiquitinated due to steric constraints. Newly 
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translated NRF2, which would otherwise be degraded in a KEAP1-dependent manner, is 
then available to translocate to the nucleus to drive transcription of target genes. This 
model, also referred to as the “saturation model” because intracellular levels of KEAP1 
become saturated in an inactive complex with NRF2, predicts that turnover of the 
inactivated KEAP1-NRF2 complex will occur until excessive ROS or xenobiotic agents 
are cleared [27]. A combination of the hinge-and-latch and saturation models also support 
the previously discussed observation that treatment of cells with tBHQ and sulforaphane 
do not disrupt the KEAP1-NRF2 interaction, despite resulting in enhanced NRF2 
transcriptional activity and stabilization.  
 
The cysteine residues within KEAP1 act as the biological sensors of the 
intracellular redox state. A hinge-and-latch model of regulation, however, also helps 
define another function of KEAP1—acting as a molecular switch following oxidative 
stress sensing. The saturation model coupled with the hinge-and-latch mechanism 
predicts that inactive KEAP1-NRF2 complex will be turned over via the proteasome. 
Once a period of oxidative stress passes, newly synthesized KEAP1 will bind and repress 
free NRF2. Consequently, signaling through KEAP1 is ultimately self-limiting, and 
follows a sinusoidal pattern. More specifically, KEAP1 senses oxidative stress via 
oxidation and modification of cysteine residues to “switch on” NRF2 signaling. When 
reactive species are no longer present in excess, unmodified KEAP1 “switches off” 
NRF2 signaling by reinitiating KEAP1-dependent NRF2 degradation. Dysregulation of 
this pattern of signaling is implicated in many diseases, and will be discussed in a later 
section. 
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The hinge-and-latch model of KEAP1-NRF2 signaling enables a rapid and 
effective response to oxidative stress; however, the protein interaction dynamics of this 
model are also the basis of an emerging alternative means of regulation, referred to as the 
competitive binding model. The competitive binding model suggests that proteins 
containing motifs and sequences with affinities for KEAP1 or NRF2 can activate NRF2 
independently of oxidative or xenobiotic stress by disrupting binding of the DLG “latch” 
to KEAP1 (Fig. 1.2, bottom right). The first indication of the competitive binding model 
came with the observation that the mitochondrial protein phosphoglycerate mutase family 
member 5 (PGAM5) was not only a KEAP1 binding partner, but also that this interaction 
was mediated via an ESGE sequence in PGAM5 [63-64]. Under homeostatic conditions 
KEAP1 targeted PGAM5 for proteasome-mediated degradation. Interestingly, however, 
both sulforaphane and quinone-induced oxidative stress inhibited KEAP1-mediated 
PGAM5 degradation [64]. Additionally, siRNA-mediated knockdown of PGAM5 was 
found to activate NRF2 in a manner similar to knockdown of KEAP1 [63-64], suggesting 
that the PGAM5-KEAP1 interaction may be more significant than merely targeting 
PGAM5 for degradation.  
 
It was later determined that the while PGAM5 was degraded in a KEAP1-
dependent manner, the KEAP1-PGAM5 interaction also served to sequester a pool of 
intracellular KEAP1 at the mitochondrial membrane [64]. Furthermore, NRF2 was part 
of this complex, indicating that a ternary complex of KEAP1, PGAM5, and NRF2 was 
localized to the mitochondria. As mitochondria are one of the main intracellular 
producers of ROS, it was hypothesized that the KEAP1-PGAM5-NRF2 ternary complex 
18  
facilitated ROS sensing at the mitochondrial membrane [64]. In addition to a pool of 
KEAP1 that localizes to the mitochondria with NRF2, cytosolic puncta containing 
KEAP1 are also present intracellularly, suggesting that multiple pools of KEAP1 are 
primed to respond to different oxidative and xenobiotic stimuli. 
 
While PGAM5 does not activate NRF2 via a competitive binding mechanism—in 
fact, it facilitates its degradation under homeostatic conditions—PGAM5 set the 
precedent for protein interactions with KEAP1 or NRF2 to alter pathway activity 
independently of oxidative stress. The first protein to be identified to activate NRF2 
independently of oxidative stress was the cyclin kinase inhibitor, p21 (p21/WAF1/CIP1) 
[65], although it should be noted that p21 expression is increased in response to oxidative 
stress [66-69]. p21 function is linked to multiple cellular processes, including DNA 
damage, cell cycle regulation, apoptosis, and even oxidative stress [67, 70-72]. The p21 
protein contains a KRR domain, which is biochemically similar to the arginine triad 
(K380, R415, and R483), and mediates interaction of the acidic residues of the DLG and 
ETGE of NRF2 with the KELCH domain of KEAP1 [65]. Consequently, both the DLG 
and ETGE exhibit binding to the KRR sequence of p21, although endogenous interaction 
with the DLG appears to be more significant. Overexpression of p21 results in activation 
of NRF2, because it facilitates dissociation of the DLG from the KELCH domain.  
 
Currently, proteins that bind to KEAP1 in a competitive manner with NRF2 are 
more common than those that directly bind to NRF2, and several have been identified. 
The first was p62/sequestosome-1 (p62/SQSTM), an autophagy-related protein, which 
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binds to the arginine triad via a KIR motif (DPSTGE) in the KELCH domain in a manner 
similar to the acidic ETGE and DLG sequences in NRF2 [73]. Like p21, this interaction 
facilitates dissociation of the DLG of NRF2 from KEAP1, thus promoting NRF2 
transcriptional activity. In addition to p62, several other proteins have been found to bind 
the KELCH domain of KEAP1, via an ETGE or ESGE motif [74-76]. Importantly, 
accumulation of these ETGE-containing proteins predicts that the self-limiting 
mechanism of KEAP1-NRF2 signaling will be perturbed, resulting in constitutive NRF2 
activation. Intriguingly, we found one of these proteins, DPP3, activates NRF2 signaling 
via the competitive binding model [74], and that expression of this protein correlates with 
a NRF2 gene signature in squamous cell lung cancer [74, 77]. Proteins such as DPP3 
underscore the need to further characterize how protein-protein interactions modulate 
KEAP1-NRF2 activity in disease. Additionally, we have identified other proteins that 
interact with KEAP1 in an ETGE- or ESGE-dependent manner (Fig. 2.1.B) [74], 
although the majority of these proteins do not appear to activate or suppress NRF2 
mediated transcription (Fig. 2.2.F). However, we cannot rule out the possibility that these 
proteins function similarly to PGAM5 to sequester KEAP1 and/or the KEAP1-NRF2 
complex via competitive binding. Furthermore, these alternative ETGE-containing 
proteins may function in regulating NRF2-independent functions of KEAP1.  
 
1.B.5 Alternative substrates of KEAP1 
In addition to identifying novel protein interactions that alter KEAP1-NRF2 
signaling, some KEAP1 interacting proteins have been found to be alternative substrates. 
The first substrate of KEAP1 to be found outside of NRF2 was IκB kinase (IKKβ). IKKβ 
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targets IκBα, the inhibitory protein of nuclear factor κB (NFκB), for degradation [78]. 
Similar to regulation of NRF2, NFκB is a transcription factor that is constitutively 
degraded, but NFκB is degraded in an IκBα-dependent manner. Signaling through NFκB 
is largely considered to be tumorigenic because of the myriad of downstream targets of 
NFκB related to cell growth, proliferation, and survival [78-82]. When IKKβ is targeted 
for degradation in a KEAP1-dependent manner, IκBα is stabilized, thus keeping 
intracellular levels of NFκB low. Consequently, if KEAP1 expression is lost, or if 
KEAP1 function is compromised, IκBα is targeted for degradation in an IKKβ-dependent 
manner, and NFκB signaling is activated.  
 
Two other substrates of KEAP1 are the mitochondrial pro-survival proteins B-cell 
CLL/lymphoma 2 (BCL-2) and BCL-2 like 1 (BCL-xL) [83-85]. When the apoptotic 
cascade is executed, the pro-apoptotic protein BCL-2-associated X protein (BAX) 
translocates to the mitochondrial membrane, forming pores that allow the release of 
cytochrome c [86]. Both BCL-2 and BCL-xL exert their anti-apoptotic effects by 
complexing with and sequestering BAX, to inhibit mitochondrial pore formation [83-84]. 
Under homeostatic conditions KEAP1 degrades BCL-2 and BCL-xL, which promotes the 
dissociation of BCL-2-BAX and BCL-xL-BAX complexes. This dissociation increases 
the levels of free intracellular BAX, which promotes apoptosis. Degradation of both 
BCL-2 and BCL-xL depends on the PGAM5-KEAP1 interaction to tether KEAP1 to the 
mitochondrial membrane [63]. Likewise, xenobiotics that adduct to KEAP1 antagonize 
the KEAP1-BCL-xL and KEAP1-BCL-2 interaction, stabilizing both anti-apoptotic 
proteins [63, 83-84], which may play a role in cancer cell survival.  
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Whether through activation of NRF2 via the competitive binding model, or 
through modulation of alternative KEAP1 substrates, it is clear that protein interactions 
play a critical role in the importance of KEAP1-NRF2 signaling. Further studies are 
required to identify new proteins that act as either competitive binding activators or novel 
KEAP1 substrates. These proteins, like those documented above, may hold clinical 
significance for the role of KEAP1-NRF2 in disease.  
 
1.C The Role of KEAP1 and NRF2 in Disease 
Maintaining an appropriate balance between the activity of KEAP1 and NRF2 is 
of paramount importance for homeostasis within an organism. Signaling via the KEAP1-
NRF2 pathway is often referred to as a “double edged sword”, because both hyperactivity 
and hypoactivity of the pathway is a contributing factor to several disease pathologies. 
Diseases in which KEAP1-NRF2 dysregulation occurs share common ground in that 
reactive oxygen and nitrogen species cannot be properly regulated, with most diseases 
skewing toward conditions of oxidative stress. A notable exception is cancer, which will 
be reviewed at the end of the section. Perhaps unsurprisingly, much of the observed 
oxidative stress can be linked to mitochondrial malfunction and dysregulation of other 
endogenous ROS- and RNS-producing enzymes. More recently, however, KEAP1-NRF2 
signaling has been found to respond to a growing list of noncanonical sources of 
oxidative stress, including aberrant proteomic and autophagic regulation, inflammatory 
responses, and necrosis and apoptosis. Collectively, these observations suggest that the 
extent to which the KEAP1-NRF2 pathway is utilized by organisms to control oxidative 
stress and prevent disease is only beginning to be fully appreciated. 
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1.C.1 KEAP1 and NRF2 knockout mouse phenotypes 
The Keap1 knockout mouse exhibits a post-natal lethal phenotype caused by 
hyperkeratosis of the upper gastrointestinal system, which leads to obstructive lesions and 
ultimately malnutrition [1, 87]. In mice containing a floxed Keap1 allele, reduced 
expression of Keap1 was observed, particularly in heterozygous Keap1 lox/- animals [88]. 
These knockdown Keap1 mice are viable, and display increased nuclear Nrf2 
accumulation and Nqo1 expression. Additionally, they exhibit hyperkeratosis of the 
esophagus and upper stomach; however, neither the Nrf2 accumulation nor esophageal 
hyperkeratosis is as exacerbated as in Keap1 knockout mice. No other gross phenotypes 
are noted in Keap1 knockout or knockdown mice. Interestingly, the Keap1 knockout 
phenotype can be completely reversed by crossing animals with Nrf2 deficient animals 
[1, 87]. 
 
Unlike Keap1 knockout mice, Nrf2 null animals are viable and display no gross 
phenotype associated with loss of Nrf2 expression [35]. Phenotypes associated with Nrf2 
knockdown are typically only observed when mice are exposed to stressors. Accordingly, 
Nrf2 knockout mice are more susceptible to hepatotoxicity [89-90], DNA adduct 
formation [91], cigarette smoke-induced emphysema [92-93], pulmonary fibrosis [94], 
and lung injury [92, 94-95]. Only a relatively mild inflammatory phenotype is noted in 
Nrf2 knockout mice in the absence of insult. Knockout animals are more likely than wild 
type littermates to develop spontaneous chronic inflammatory disorders including 
glomerulonephritis, immune-related hemolytic anemia, and multi-organ autoimmune 
inflammation [1, 96-97].  
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1.C.2 Finding an ideal balance of KEAP1 and NRF2 
One of the hallmarks of diseases associated with perturbations in KEAP1-NRF2 
signaling is aberrant cell death, such as in neurodegenerative disorders, or lack thereof, as 
in cancer. Intracellular levels of ROS are one metric used to determine whether a cell 
executes the apoptotic cascade. If ROS levels overcome endogenous ROS-scavenging 
mechanisms, such as glutathione, apoptosis occurs; however, cell stress response and 
survival pathways may be executed if ROS levels are not prohibitively high. Under 
circumstances where an acute spike in ROS initiates the apoptotic cascade, late apoptotic 
stage accumulation of ROS can result in necrotic death of surrounding cells [98]. These 
cell death processes contribute to the pathologies associated with neurodegenerative 
disorders, as well as is cancers exhibiting intratumoral necrosis.  
 
As depicted in Figure 1.3, disease prevention offered by KEAP1-NRF2 signaling 
is optimal when neither KEAP1 nor NRF2 is present in excess. For example, in a NRF2-
null situation, ROS levels will be elevated due to decreased expression of ROS-
scavenging and pro-survival NRF2-target genes, enhancing the risk of ROS-induced 
apoptosis and necrosis. Under these conditions, an organism is more susceptible to 
neurodegenerative disorders and some cardiovascular diseases. Conversely, in a KEAP1-
null setting, NRF2-target genes will be present in excess, producing an intracellular 
environment that is particularly adept at neutralizing ROS and clearing xenobiotics and 
other toxicants. Consequently, cells are at a greater risk to “miss” ROS-dependent 
apoptotic cues, resulting in enhanced susceptibility to cancer. Interestingly, augmented 
NRF2 activity, particularly activation through intermittent exposure to antioxidants and 
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chemopreventive agents, has been correlated with reduced incidence of cancer [99]. 
While this observation seemingly confounds reports that NRF2 is overactive in many 
cancers, these conflicting ideas may be reconciled by understanding the importance of 
temporal regulation and context of NRF2 activation. 
 
1.C.3 Neurodegenerative disorders 
Neurodegenerative diseases, such Parkinson’s disease, Alzheimer’s disease, and 
amyotrophic lateral sclerosis (ALS), share many pathological features, including protein 
aggregation from proteasomal and autophagic dysregulation, inflammation, and 
mitochondrial dysfunction [100]. Most of the pathological hallmarks of 
neurodegeneration either contribute to, or result from oxidative stress. For example, high 
levels of ROS can result in the formation of oxidized proteins, which exhibit reduced 
folding and produce intracellular aggregates. Additionally, deficiencies in autophagic 
processes result in damaged mitochondria that accumulate because of poor 
autophagosome formation, which can become a source of toxic reactive oxygen species.  
 
Given the host of NRF2 target genes associated with ROS-scavenging, redox 
homeostasis, and cell survival, it is unsurprising that adequate NRF2 function has been 
implicated as having a role in the prevention of neurodegenerative disorders. Most 
evidence stems from observations in primary neuronal cultures from both wild-type and 
Nrf2 deficient mice. First, it has been shown that glutathione metabolism via shunting 
through the pentose phosphate pathway in primary neurons contributes a cytosolic 
reducing environment that inhibits apoptosis [101]. Although flux through the PPP in 
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neurons has not yet been conclusively linked to NRF2, recently it was found that NRF2 
directs metabolic reprogramming of the pentose phosphate pathway in cancer [14]. 
Modulation of metabolic pathways, including the pentose phosphate pathway, is a 
baseline defense to prevent acute spikes in ROS to hinder oxidative stress. Likewise, 
treatment of neurons with oxidative stressors and mitochondrial toxins that selectively 
inhibit components of the electron transport chain result in upregulation of NRF2 
expression [102-105]. Collectively these data suggest NRF2 activity is a first-line defense 
for mitigating neuronal oxidative stress. Furthermore, Nrf2 null neurons are more 
susceptible to models of oxidative stress than wild-type neurons [100, 102, 106]. 
Together these studies demonstrate that NRF2 plays a critical role in maintaining a 
proper neuronal redox environment, which may prevent intracellular events leading to 
enhanced susceptibility to neurodegenerative disease. 
 
In addition to direct neuronal cell-autonomous functions for NRF2, the emerging 
importance of the interaction between glial cells and neurons in maintaining neuronal 
integrity also appears to rely on NRF2 function. Co-culture experiments in which Nrf2-/- 
neurons were grown with astrocytes from wild-type mice demonstrated that astrocytes 
expressing Nrf2 have a protective effect on Nrf2-/- neurons exposed to oxidative stress 
[107]. Similarly, even astrocytes derived from an ALS mouse model were able to provide 
a protective effect in a co-culture model when NRF2 was activated [107-109], suggesting 
that NRF2 may have potential as a therapeutic target in neurodegeneration. The 
mechanism of action behind this observation is thought to involve shunting of 
metabolites between astrocytes and neighboring neurons. Astrocytes secrete glutathione, 
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which is used by neurons to help maintain a high intracellular reducing environment 
[100, 105, 107]. Enhanced NRF2-dependent glutathione secretion from astrocytes to 
neurons would certainly contribute to the protective effects of astrocyte in co-culture 
experiments. However, recent studies in astrocytes also indicate that NRF2 activation 
causes global changes in astrocyte gene expression, supporting the idea that NRF2 has a 
role in glial cell biology that extends beyond glutathione secretion and metabolite 
shunting.  
 
1.C.4 Cardiovascular disease 
Like neurodegenerative disorders, diseases of the cardiovascular system have 
several commonalities, in particular mitochondrial deficiency and inflammation. The 
cardiovascular system is unique, however, in that it is an organ system that relies heavily 
on the production of reactive oxygen and reactive nitrogen species for homeostatic 
signaling. Consequently, regulation of NRF2 within this system must not only function to 
mitigate oxidative stress caused by toxicants and inflammatory processes, but it must also 
function in equilibrium with enzymes producing ROS and RNS to maintain physiological 
homeostasis. 
 
Atherosclerosis is a thickening of the walls of arteries and vasculature most 
commonly associated with the abnormal accumulation of lipids in the endothelium. In 
addition to lipid accumulation, particularly accumulation of low-density lipoprotein 
(LDL), atherosclerosis is an inflammatory condition, and biological processes such as 
viral infection, physical damage, and toxicant exposure can lead to atherosclerotic 
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plaques [110-112]. The inflammatory response mounted against these stressors to the 
cardiovasculature is a major contributing factor to the oxidative stress associated with 
atherosclerosis [111], and it is for this reason that a significant role for NRF2 signaling in 
this disease has come to light. 
 
Early accumulations of atherosclerotic plaques begin to alter blood flow within 
vessels from that of laminar (unidirectional) to oscillatory, or turbulent, flow [113-114]. 
The direction and force of blood flow through the vasculature stimulates the endothelium 
to produce nitric oxide, NO, via NADPH oxidases (NOX enzymes) in the cell membrane 
[6]. Protective NO release during laminar flow helps regulate blood pressure through 
vasodilation; however, when flow is oscillatory, the release of protective NO release is 
replaced by secretion of superoxides [115-117]. Production of superoxides from 
oscillatory flow results in the oxidation of LDL, which infiltrates the endothelium, and 
stimulates the migration of inflammatory cells to the site, further compounding oxidative 
stress [111-112]. Cellular coping mechanisms during turbulent blood flow depend on 
NRF2 in primarily two ways: first, NRF2 is upregulated in the endothelium of 
vasculature during shear stress [118], and second, macrophages that infiltrate sites of 
atherosclerotic plaques upregulate expression of NRF2 [119-121]. Upregulation of NRF2 
in macrophages helps, in part, to maintain macrophage integrity in such a ROS-rich 
environment [110, 121]. The endothelium, however, also uses NRF2 to combat 
atherosclerosis, primarily through the NRF2 target gene HMOX1 [122-126]. In addition 
to the production of previously described ROS-scavenging byproducts, expression of 
HMOX1 is associated with downregulation of matrix metalloproteinase 9 (MMP9) [127-
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128]. MMP9 works to degrade collagens within the extracellular matrix, and is associated 
with plaque destabilization [110, 127-128]. Consequently, reduced expression of MMP9 
in an HMOX1-dependent manner helps prevent disruption of plaque sites, which could 
lead to a stroke event. In addition to HMOX1, the other NRF2 target genes GCL and 
NQO1 are associated with protection against atherosclerosis [129-131]. Furthermore, low 
serum levels of glutathione and the NRF2 target gene GPX are considered risk factors for 
heart disease [129-130]. These data suggest that NRF2 not only plays a critical role in the 
cellular response to atherosclerosis, but also that NRF2 could be a therapeutic target for 
the prevention of atherosclerotic disease. 
 
Like atherosclerosis, hypertension is associated with increased levels of oxidative 
stress, mostly through the dysregulation of NOX enzymes. Activation of some NOX 
enzymes, such as NOX1, results in the upregulation of NRF2, particularly during 
intermittent hypoxia [132-133]. This data is suggestive of a relationship wherein 
feedback regulation between NOX enzymes and NRF2 expression promote normal blood 
pressure while supplying ROS-scavenging mechanisms to reduce the potential for 
oxidative stress that may facilitate hypertension. More significantly, however, is the role 
that NRF2 plays in regulating blood pressure through expression of HMOX1. HMOX1 
exhibits hypotensive effects, primarily through the production of carbon monoxide (CO) 
[134-136]. In addition to possessing vasodilatory effects that act independently of NO, 
carbon monoxide is a potent inhibitor of endothelin, a vasoconstrictor [110, 134-136]. 
The role of HMOX1 in maintaining normal blood pressure was confirmed in 
hypertensive rats, where HMOX1 activity correlated with reduced blood pressure [134].  
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1.C.5 Inflammation 
Inflammation is a common pathology of multiple diseases, including 
neurodegenerative and cardiovascular disease previously discussed, and is undoubtedly a 
unifying factor in diseases associated with KEAP1-NRF2 dysregulation. There are two 
general types of inflammation: 1) acute inflammation, which is associated with innate 
immune processes and is typically a beneficial process, and 2) chronic inflammation, 
which is now widely accepted to predispose organisms to chronic illness, including 
cancer [137-138]. Inflammatory processes are characterized by the migration of a host of 
immune cells to sites of injury or stress, secretion of cytokines, chemokines, and 
metabolites, and importantly, oxidative stress. Much of the oxidative stress that helps 
define an immune response is due to a “respiratory burst” when mast cells and leukocytes 
release ROS upon migration to a site of damage [137-139]. In addition to having a 
physiological role during an immune response, including the destruction of invading 
microorganisms, the respiratory burst also serves as a signaling mechanism to recruit 
other immune cells to the site of inflammation.  
 
Changes in signal transduction pathway activity are also a hallmark of 
inflammatory responses, and include alterations in many pathways, including NFκB, 
STAT3, AP-1, T cell activation, TNF, TGFβ, and NRF2 signaling [137-141]. Importantly, 
alterations of signaling within these pathways are not cell autonomous; neighboring cells 
and tissues are also affected, which contributes to damage created during chronic 
inflammatory disorders. The host of inflammatory disorders that Nrf2 knockout mice 
spontaneously develop further underscores the importance of KEAP1-NRF2 in 
30  
inflammation. These conditions include glomerulonephritis, immune-related hemolytic 
anemia, and multi-organ autoimmune disorders [140, 142-146].  
 
Similar to the need to balance KEAP1 and NRF2 activity to achieve optimal 
disease prevention, balance between pro- and anti-inflammatory signals aid in ensuring 
acute inflammatory responses do not escalate to a chronic condition. This balance is 
achieved through the production of another set of cytokines and chemokines, which act as 
antagonists to their pro-inflammatory counterparts [137-139, 147]. Thus, homeostatic 
immune responses follow a cyclical pattern similar to KEAP1-NRF2 signaling: just as 
KEAP1 acts as a switch to turn off NRF2 signaling following activation, anti-
inflammatory cytokines counteract pro-inflammatory signals to ensure an acute immune 
response remains self-limiting. When constitutive activation of some inflammatory 
pathways, such as NFκB, occurs, the balance between pro- and anti-inflammatory 
cytokine signaling skews to favor pro-inflammatory signals [138]. Several factors 
contribute to constitutive activation of pro-inflammatory pathways, many of which are 
outside the scope of this review; however, crosstalk between NFκB and KEAP1-NRF2 
signaling is particularly noteworthy.  
 
Functions of both KEAP1 and NRF2 act in the repression of NFκB activity. As 
previously stated, the E3 ligase activity of KEAP1 suppresses NFκB through the 
degradation of IKKβ, which targets the NFκB repressor IκBα for destruction [78, 85]. 
Consequently, when KEAP1 function is intact, NFκB activity is low. Similarly, NRF2 
activity suppresses NFκB signaling through activation of ROS scavenging genes. 
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Reactive oxygen species activate NFκB signaling, therefore, when NRF2 activity is 
intact, both ROS levels and NFκB activity remain low [78-79, 81-82, 138, 143, 145]. 
When either KEAP1 or NRF2 function is compromised, as is frequently observed in 
cancer, the sinusoidal patterns of both KEAP1-NRF2 signaling and the inflammatory 
response are perturbed. In this situation, NRF2 and NFκB both exhibit constitutive 
activation, resulting prolonged NRF2 availability to mitigate ROS, while the downstream 
effects of NFκB signaling promote cell proliferation, growth, and survival.   
 
1.D KEAP1 and NRF2 in Cancer 
The role of KEAP1 and NRF2 in cancer is not only the most defined and studied 
subject regarding KEAP1-NRF2 redox biology, but seemingly also the most dynamic. 
Nearly every biological process that KEAP1 and NRF2 function in, including ROS 
scavenging, metabolism, and inflammation, can be linked to an attribute of cancer that 
affects survival, proliferation, or tumorigenicity. Additionally, multiple genetic 
alterations to KEAP1 and NRF2, such as somatic mutation, copy number amplification, 
and epigenetic modification, are not only prevalent in cancer, but also often correlate 
with poor prognosis and survival. Finally, emerging evidence suggests that the cellular 
context in which KEAP1-NRF2 is deregulated is likely the key to understanding the 
“double-edged sword” nature of this pathway.  
 
1.D.1 NRF2-mediated metabolic reprogramming in cancer 
Since the mid-1950s it has been known that cancer cells display metabolic 
alterations that contribute to their growth and survival [27, 148]. This observation, most 
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commonly known as The Warburg Effect, has been continuously evolving since its 
discovery. Today it is appreciated that cancer metabolism, in particular mitochondrial 
metabolism, is reprogrammed to specifically meet the needs of macromolecular synthesis 
required by cancer cells [148]. Non-proliferating cells, such as terminally differentiated 
and quiescent cells, utilize glycolysis and the tricarboxylic acid (TCA) cycle to 
completely oxidize glucose to carbon dioxide (CO2). Metabolizing glucose in this manner 
ensures that cells have an adequate amount of ATP to meet the requirements of cellular 
homeostasis.  
 
One requirement of cells fully oxidizing glucose to CO2, however, is a relatively 
insignificant need for macromolecular synthesis of molecules such as DNA, RNA, 
proteins, and lipids [149-151]. Although hydrolysis of ATP is sufficient for providing 
energy to catalyze multiple cellular reactions, it is not particularly useful in anabolic 
processes. Synthetic reactions require molecules containing reduced carbon and nitrogen, 
which is gained via the reductive potential of molecules such as NADPH. Increased 
levels of TCA cycle intermediates are also of paramount importance, as they act as 
common precursors for many macromolecules [148, 152]. Additionally, flux through the 
pentose phosphate pathway is the source of intermediate molecules for purine production 
used in synthesis of nucleic acid for DNA and RNA. The anabolic and energetic demands 
of cancer cells culminate in global metabolic reprogramming, in which mitochondria are 
used primarily as synthetic organelles [14, 148]. Much of the metabolic reprogramming is 
growth factor dependent, as growth factors act as liaisons between the availability of 
nutrients in the extracellular environments and downstream signaling events such as re-
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entry into the cell cycle. Perhaps unsurprisingly, activating mutations in growth factor 
receptors common to many cancers contribute to the initiation of cancer-specific global 
metabolic changes. Recent findings, however, have elucidated a striking and important 
role for NRF2 in affecting cancer cell metabolic reprogramming. 
 
The primary axis of where NRF2 functions in metabolic reprogramming is by 
driving transcription of multiple genes in the pentose phosphate pathway (Fig. 1.4). 
Enhanced flux through the PPP produces an excess of several molecules that are 
beneficial to cancer cell survival (Fig. 1.4) [14, 148]. As previously stated, glutathione-
mediated ROS scavenging is required to maintain cytosolic redox homeostasis. In 
addition to de novo synthesis of glutathione, the regeneration of the reduced form (GSH) 
occurs through the catalytic activity of glucose-6-phosphate dehydrogenase (G6PD), 
which produces the reducing equivalent NADPH as a byproduct. Expression of G6PD is 
also NRF2-dependent, suggesting that in addition to targeting expression of genes 
involved in glutathione synthesis, NRF2 modulates the availability of reduced glutathione 
through transcription of G6PD. NRF2 regulates the expression of three other enzymes 
that produce NADPH—malic enzyme 1 (ME1), isocitrate dehydrogenase 1 (IDH1), and 
phosphogluconate dehydrogenase (PGD) [14]. Both ME-1 and IDH1 act within the TCA 
cycle, creating pyruvate precursor for fatty acid synthesis, and α-ketoglutarate, 
respectively. Thus, in addition to increased levels of NADPH, NRF2-mediated 
expression of ME1 and IDH1 support anabolic processes via production of metabolic 
intermediates [151].  
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Phosphogluconate dehydrogenase is another PPP gene, and along with expression 
of two other NRF2 target genes, tansaldolase (TALDO1) and transketolase (TKT), 
critically enhance flux through the PPP [99]. Regeneration of GSH occurs in the early 
steps of this pathway; however, the final enzymatic reactions of the PPP culminate into 
the production of ribose-5-phosphate, a main precursor for nucleotide synthesis. 
Enhanced production of ribose-5-phosphate occurs via expression of phosphoribosyl 
pyrophosphate amidotransferase (PPAT) and methylenetetrahydrofolate dehydrogenase 2 
(MTHFD2). It should be noted that expression of these two genes correlates with 
expression of NRF2, but NRF2 is not found to be associated with the promoters of PPAT 
or MTHFD2, as it is with G6PD, PGD, ME-1, IDH1, TKT, and TALDO1 [107]. 
Regardless, increased availability of nucleotide precursors, such as ribose-5-phosphate, 
allows proliferating cancer cells to meet the demands of rapid cell division through 
synthesis of purines and pyrimidines for DNA and RNA.  
 
While the mechanistic downstream effects of NRF2-dependent metabolic 
reprogramming clearly augment cancer cell fitness, a cancer cell must first upregulate 
expression of NRF2. Genetic alterations in KEAP1 or NRF2, which will be discussed in 
the next section, are the primary source of elevated levels of NRF2 in cancer; however, 
KEAP1- and NRF2-independent changes also impact expression. For example, 
mutational lesions and epigenetic modification in v-akt murine thymoma viral oncogene 
homolog 1 (AKT) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA) that 
alter signaling have been shown to upregulate NRF2 expression (Fig. 1.4) [148, 153-154]. 
In addition to somatic mutations in both AKT and PIK3CA, these two proteins are also 
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downstream of many growth factor receptors. Activating mutations in growth factor 
receptors are one of the first steps toward cancer-specific metabolic reprogramming, as 
mentioned earlier [148-151, 153, 155-160]. Furthermore, it was recently discovered that 
activating mutations in KRAS, BRAF, and MYC are also capable of activating NRF2, and 
that this activation assists in ROS detoxification in murine cancer models [161-162]. 
Consequently, increase in NRF2 expression is likely to occur to some degree in most 
cancers irrespective of activating NRF2 or inactivating KEAP1 mutations due to 
amplified signaling through growth factors and their downstream effectors.   
 
1.D.2 Genetic alterations in KEAP1 and NRF2 in cancer 
Several genetic changes in KEAP1 and NRF2 have been noted in cancer (Fig. 1.5) 
[163-166], and more recently, it has been proposed that KEAP1 and NRF2 exhibit a 
tumor suppressor-oncogene relationship, respectively [167-168]. Much of the speculation 
surrounding this relationship is due to the distribution of somatic mutations throughout 
each gene. Mutations within NRF2 cluster specifically within the DLG and ETGE motifs 
(Fig. 1.5.A), a pattern similar to clustered mutations seen in most oncogenes [21, 33, 163-
164]. When mutations occur within the ETGE motif, NRF2 association with KEAP1 is 
disrupted, allowing NRF2 to evade degradation and accumulate in the nucleus to drive 
transcription of target genes. Mutations within the DLG also function to activate NRF2, 
but this activation occurs through a slightly different mechanism. NRF2 maintains an 
association with KEAP1 with mutations in the DLG; however, the KEAP1-NRF2 
interaction in this case produces a protein complex in which KEAP1 is unable to degrade 
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NRF2. Consequently, newly synthesized NRF2 is able to accumulate without subsequent 
degradation, resulting in increased NRF2 transcriptional activity.  
 
Somatic mutations in KEAP1 are distributed throughout the entirety of the gene 
(Fig. 1.5.A and Table S3.1), similar to the distribution of mutations found in tumor 
suppressor genes [169]. While some mutations resulting in a truncated protein product 
have been observed, most mutations are missense. Studies have determined that missense 
mutations in KEAP1 result in both hypomorphic and dominant negative phenotypes 
[170]. Perhaps more significant than functional outcomes of KEAP1 mutations, however, 
is a recent observation suggesting that at least a 75% reduction in wild type KEAP1 
activity is required for stabilization of NRF2 [88]. This hypothesis becomes clinically 
relevant due to the observation that in cancer, specifically lung cancer, mutations in 
KEAP1 are often heterozygous. Since KEAP1 acts as a homodimer, three permutations 
are possible when there is a heterozygous somatic mutation in KEAP1: a wild type 
homodimer, a wild type:mutant heterodimer,  and a mutant:mutant homodimer. Both a 
wild type:mutant homodimer and mutant:mutant heterodimer will result in a 
hypomorphic or inactive KEAP1 complex, therefore a 75% reduction in KEAP1 activity 
is easily achieved, resulting in NRF2 stabilization. Interestingly, recent studies from The 
Cancer Genome Atlas (TCGA) Research Network determined that in squamous cell lung 
carcinoma, expression of KEAP1 alleles in not 50:50 (Table 1.1). While this finding does 
not alter the need for a 75% reduction in KEAP1 activity to stabilize NRF2, it 
underscores the importance that relative allelic expression in cancer may not be easily 
predicted. Accordingly, predicting whether somatic mutations in KEAP1 will support 
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enhanced expression of NRF2 will likely require further study to determine the 
mechanisms driving relative expression of KEAP1 alleles, as well as the combined 
functional outcome of the mutation and relative allelic expression. 
 
Epigenetic modifications, such as KEAP1 promoter hypermethylation, also result 
in NRF2 stabilization (Fig. 1.5.B). Hypermethylation of the KEAP1 promoter region is 
observed in several cancers, including lung, prostate, and colorectal cancers, as well as 
gliomas [165, 171-174]. Additionally, some cell lines exhibit KEAP1 promoter 
hypermethylation, including the lung adenocarcinoma line A549 [173]. Alterations in 
promoter methylation result in reduced KEAP1 expression, which allows for NRF2 
stabilization. Copy number amplification of NRF2 was also recently found in lung 
squamous cell adenocarcinoma [74, 77]. Copy number amplification correlated with an 
enhanced NRF2 gene signature, suggesting that increased expression of NRF2 is 
sufficient to overcome KEAP1 suppression, even in a wild type KEAP1 background [74].  
 
1.D.3 Alternative mechanisms of NRF2 stabilization 
Recent findings have elucidated novel pathways of KEAP1 inactivation and 
NRF2 stabilization that act independently of genetic alterations. One of these pathways 
involves post-translational modification of KEAP1 and appears to be cancer specific. The 
other pathway involves alternative KEAP1 and NRF2 interaction partners and the 
competitive binding mechanism mentioned during discussion of the hinge-and-latch 
mechanism of regulation. Although this second pathway is not necessarily engaged only 
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in situations of carcinogenesis, emerging evidence suggests that several cancers do take 
advantage of this mechanism of activation. 
 
Modulation of TCA cycle activity for use in producing anabolic precursors 
frequently occurs in cancer; however, in addition to altered flux, mutations in several 
metabolic enzymes have been discovered to potentially play a role in cancer cell fitness. 
Most mutations in metabolic enzymes result in the buildup of oncometabolites, or 
metabolic intermediates that are found specifically in cancerous cells. One of these 
oncometabolites is fumarate, the endogenous substrate for fumarate hydratase (FH). 
Some cancers, including papillary renal carcinoma, exhibit inactivating somatic 
mutations in FH, which result in a buildup of fumarate [175-176]. Fumarate possesses 
low electrophilic activity; however, when fumarate levels are excessive it modifies 
KEAP1 in a redox reaction that results in KEAP1 succinylation at reactive cysteine 
residues (Fig. 1.4 and 1.5.C) [177]. Intriguingly, HMOX1 activity is required for cell 
viability in FH deficient cells, and siRNA-mediated knockdown of HMOX1 is sufficient 
to induce synthetic lethality [178]. Collectively these findings suggest that metabolite-
mediated post-translational modification of KEAP1 enhances cancer cell fitness, and 
further, FH is now being examined as a therapeutic candidate because of this observed 
synthetic lethality phenotype. Several other oncometabolites have been identified, some 
of which do not yet have defined functions in the cell, such as the mutant IDH1 and IDH2 
product 2-hydroxyglutarate [148, 151, 179]. Further studies to determine whether these 
oncometabolites may also create cysteine modifications of KEAP1 may yield novel 
therapeutic targets, such as in the case of fumarate hydratase.  
39  
In addition to post-translational modification of KEAP1, protein-protein 
interactions of KEAP1 and NRF2 have also been shown to indirectly activate NRF2 
through a competitive binding mechanism (Fig. 1.5.E). Intriguingly, several of the 
proteins that are known to stabilize NRF2 through binding competition are overexpressed 
in neoplastic lesions and cancer, or in response to spikes in ROS. The autophagic protein 
p62/SQSTM, which binds to the KELCH domain of KEAP1 in a competitive manner 
with NRF2 [73], is overexpressed in hepatocellular carcinoma [180]. Moreover, 
overexpression of p62/SQSTM has also been observed in neoplastic prostate tissue, 
suggesting that NRF2 stabilization through competitive binding could facilitate 
progression to malignant neoplasia [181]. We have also shown that the dipeptidyl 
peptidase DPP3 contributes to NRF2 activation through competitive binding (Fig. 1.5.E). 
Furthermore, analysis of the TCGA squamous cell lung carcinoma dataset revealed that 
DPP3 overexpression correlates with the NRF2 gene signature [74]. These data suggest 
that DPP3 overexpression could contribute to NRF2 activation in lung cancer. In addition 
to lung squamous cell carcinoma, studies have shown that DPP3 is also overexpressed in 
ovarian and endometrial carcinoma [182-183]. Importantly, enhanced NRF2 activity is 
also observed in epithelial ovarian carcinoma, even in the absence of KEAP1 or NRF2 
mutation [184]. Further studies are required to determine if DPP3 overexpression 
correlates with the observed NRF2 activity in ovarian cancer. 
 
1.D.4 KEAP1-NRF2 pathway activity in cancer: the importance of timing and context 
The KEAP1-NRF2 signaling pathway, more specifically activation of the 
pathway, is intriguing because of the importance that temporal regulation and the context 
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in which activation occurs appear to have in disease. Transcriptional activity of NRF2 is 
required for the global cellular health of an organism—it is the main defense against 
oxidative stress that would otherwise result in DNA damage, protein and lipid oxidation, 
and ultimately aberrant cell death. In diseases where reduced NRF2 activity is observed, 
such as cardiovascular disease and neurodegeneration, pathway agonists may hold the 
key to inhibiting disease progression, and even reversing tissue and cellular damage. 
Sustained NRF2 activation, as seen in chronic inflammation and cancer however, is now 
being seen as an indicator of disease progression and poor prognosis [94, 185-186]. 
Reconciling these seemingly confounding aspects of KEAP1-NRF2 signaling 
underscores the importance of understanding the context in which NRF2 activation 
occurs.  
 
Any deviation from homeostasis elicits an intracellular response, typically in the 
form of signaling pathway modulation resulting in gene expression changes. Healthy 
cells constantly receive information from the microenvironment, meaning they are 
subject to both activating and inhibitory cues, thus enabling cell responses to stimuli to be 
self-limiting. When a cell sustains DNA damage that produces cancer-driving mutations, 
however, the cell may become cell-autonomous and no longer responsive to extracellular 
and intracellular signaling that regulate proliferation and survival. Thus constitutive 
activation of pathways that are otherwise beneficial in a non-transformed cell becomes 
the driving mechanism behind progression toward malignancy. This concept is perhaps 
best illustrated by the observation that chronic inflammation is a risk factor for cancer. 
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Acute inflammatory responses are absolutely required to maintain organismal 
homeostasis. Release of cytokines and migration of inflammatory cells to sites of damage 
ensure invading microorganisms are destroyed, terminally damaged cells undergo 
apoptosis and subsequent phagocytosis, and cells in acute stress initiate cytokine-
dependent survival pathways. As release of reactive oxygen species is a hallmark of 
inflammation, it is of paramount importance that NRF2 is activated to prevent excessive 
ROS-mediated damage. While acute inflammatory responses are self-limiting due to anti-
inflammatory cytokine release, misregulation of the pathway results in continued pro-
inflammatory responses. The long-term presence of inflammatory cells results in 
increased levels of ROS and DNA damage, which contribute to neoplastic progression 
[185]. NRF2 pathway activity also remains constitutively high, and when coupled with 
mutations from excessive DNA damage creates a situation in which these now cell-
autonomous neoplastic cells are acutely adept at coping with cellular stress.  
 
The number of mutations found within a tumor type is highly variable and tissue 
specific. Mutation rates range from approximately 9 in some forms of leukemia and 
pediatric tumors, to more than 200 in melanoma and lung cancer [187-191]. Determining 
which of these mutations actually contribute to tumor progression, as opposed to those 
that do not impart any advantageous phenotype is one of the most important goals 
currently emerging in cancer research. Carcinogenesis is thought to begin with a “gate 
keeping” mutation, which provides a selective growth advantage to the cell. More 
mutations within that cell can occur, but only those that further facilitate growth and 
proliferation are considered “driver” mutations. All other mutations are labeled as 
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“passenger” mutations [189]. Importantly, NRF2 itself is not sufficient to induce 
carcinogenesis, and is even associated with chemoprevention [21, 164, 192-193]. 
Together these findings imply the need for at least one other independent gate keeping 
mutation in NRF2-dependent cancers. However, observations that some cancers and 
many cell lines appear to require NRF2 for viability certainly imply that NRF2 is a driver 
mutation. Mutations in KEAP1 that promote NRF2 activation are also likely to be driver 
mutations, and the fact that KEAP1 and NRF2 mutations are mutually exclusive supports 
this hypothesis [74, 77]. As previously stated, many of the KEAP1 mutations in cancer 
are hypomorphic with respect to suppression of NRF2. While these mutations likely 
contribute to NRF2 activity within a tumor, it is intriguing to think about NRF2-
independent functions of KEAP1 with respect to KEAP1 mutations acting as driver 
mutations. It is feasible that hypomorphic KEAP1 mutations also promote tumorigenesis 
through inefficient degradation of other KEAP1 substrates, such as cell cycle 
components. The putative NRF2-independent functions of KEAP1 underscore the need to 
further elucidate the importance of KEAP1 as a driver gene in cancer.  
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Figure 1.1. NRF2 is a transcription factor that binds to the E3 ubiquitin ligase 
adaptor KEAP1 via two regulatory motifs. (A) NRF2 has six Neh domains. The 
Neh2 binds to KEAP1 via the ETGE and DLG amino acid motifs; the seven lysines 
targeted for ubiquitination reside between the regulatory motifs. (B) KEAP1 has three 
main domains: BTB, IVR, and KELCH. The KELCH domain has six KELCH repeats. 
Reactive cysteines (red) and residues that interface with NRF2 (purple) are annotated 
above each domain. (C) KEAP1 forms a homodimer through binding of the BTB 
domain. The ETGE and DLG of one NRF2 molecule each bind a KELCH domain of 
the KEAP1 homodimer.
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Figure 1.2. NRF2 is subject to proteasome-mediated degradation in a KEAP1-
dependent manner under homeostatic conditions, but can be activated via two 
distinct mechanisms. Under homeostatic conditions NRF2 is ubiquitinated in a 
KEAP1-dependent manner, after which it is degraded via the proteasome (top). The 
“Hinge and Latch” mechanism occurs when oxidative stress modifies cysteines within 
KEAP1, causing dissociation of the DLG to allow NRF2 to evade degradation and drive 
transcription of target genes (left). The “Competitive Binding” mechanism proposes that 
proteins may interact with either KEAP1 or NRF2 in a manner that disrupts the 
KEAP1-NRF2 association. NRF2 is no longer degraded and can drive transcription of 
target genes (right). 
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NRF2-mediated transcription, enzymes in purple are indirectly activated by NRF2, 
and NADPH annotated in red can contribute to anabolic reactions.
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Mutation Allelic 
Fraction 
P318L 0.2 
 
E493D 0.377778 
R260Q 0.391753 
D422N 0.16129 
V155F 0.30303 
L310P 0.373016 
S243C 0.652174 
G480W 0.88 
R15L 0.036145 
G423V 0.555556 
V167F 0.411765 
I506V 0.880952 
Q75* 0.535211 
V418L 0.3 
R470C 0.35 
G480W 0.653061 
L231V 0.395062 
W544C 0.891892 
V369L 0.75 
R470C 0.236364 
R320Q 0.194175 
S224Y 0.304878 
N469fs 0.408602 
V155F 0.337838 
 
Table 1.1. Lung squamous cell carcinoma with KEAP1 mutations exhibit varied expression of the 
mutant allele. The allelic fraction is defined to be (t_alt_count)/(t_alt_count + t_ref_count), where 
t_alt_count is the read count for the mutant allele, and t_ref_count is the read count for the reference 
allele.  
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II. CHAPTER TWO: PROTEOMIC ANALYSIS OF UBIQUITIN LIGASE KEAP1 
REVEALS ASSOCIATED PROTEINS THAT INHIBIT NRF2 UBIQUITINATION 
 
1
Somatic mutations in the KEAP1 ubiquitin ligase or its substrate NRF2 (NFE2L2) 
commonly occur in human cancer, resulting in constitutive NRF2-mediated transcription of 
cytoprotective genes. However, many tumors display high NRF2 activity in the absence of 
mutation, supporting the hypothesis that alternative mechanisms of pathway activation exist. 
Previously, we and others discovered that via a competitive binding mechanism, the proteins 
WTX (AMER1), PALB2 and SQSTM1 bind KEAP1 to activate NRF2. Proteomic analysis 
of the KEAP1 protein interaction network revealed a significant enrichment of associated 
proteins containing an ETGE amino acid motif, which matches the KEAP1 interaction motif 
found in NRF2. Like WTX, PALB2, and SQSTM1, we found that the dipeptidyl peptidase 3 
(DPP3) protein binds KEAP1 via an ‘ETGE’ motif to displace NRF2, thus inhibiting NRF2 
ubiquitination and driving NRF2-dependent transcription. Comparing the spectrum of 
KEAP1 interacting proteins with the genomic profile of 178 squamous cell lung carcinomas 
characterized by The Cancer Genome Atlas revealed amplification and mRNA over-
expression of the DPP3 gene in tumors with high NRF2 activity but lacking NRF2 stabilizing 
mutations. We further show that tumor-derived mutations in KEAP1 are hypomorphic with 
2.A. OVERVIEW 
                                                        1 The following manuscript has been previously published in the journal Cancer Research. 
The manuscript, figures, and tables contained within this chapter can be found using the 
reference: Hast, B.E., et al., Proteomic analysis of ubiquitin ligase KEAP1 reveals associated 
proteins that inhibit NRF2 ubiquitination. Cancer Res, 2013. 73(7): p. 2199-210. 
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respect to NRF2 inhibition and that DPP3 over-expression in the presence of these mutants 
further promotes NRF2 activation. Collectively, our findings further support the competition 
model of NRF2 activation and suggest that ‘ETGE’-containing proteins like DPP3 contribute 
to NRF2 activity in cancer.  
 
2.B. INTRODUCTION 
Constitutive activation of the NF-E2-related factor 2 (NRF2) cap-n-collar 
transcription factor is emerging as a prominent molecular feature of many tumors.  When 
active, NRF2 controls the expression of ~200 genes that collectively function to maintain a 
healthy intracellular reduction-oxidation (redox) balance, clear electrophilic xenobiotics, and 
degrade damaged and misfolded proteins [1-2]. The leading hypothesis posits that whereas 
short-term NRF2 activation antagonizes oncogenesis by curtailing oxidative damage, 
constitutive activation promotes the survival of metabolically stressed cancer cells, as well as 
cancer cells under chemotherapeutic insult.  Indeed, depletion of NRF2 from cancer-derived 
cell lines results in apoptosis and increased sensitivity to chemotherapeutic agents [3].  In 
human non-small cell lung cancer, tumors showing high levels of NRF2 protein are 
associated with a poor outcome and increased resistance to therapy [4-6].   
  
At basal state, NRF2 protein level and activity is maintained at low levels through 
ubiquitin-dependent proteasomal degradation [7-9].  The mechanics of this ubiquitination, 
which is conceptualized in the ‘hinge-and-latch’ model, involves a homodimeric E3 ubiquitin 
ligase complex comprising the KEAP1 substrate recognition module and a cullin-3 scaffold 
[10-11] (Fig. 2.1.A).  An amino-terminal DLG and ETGE motif within NRF2 independently 
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binds two KEAP1 monomers within the complex, yielding a 2:1 stoichiometry of 
KEAP1:NRF2. The intermolecular protein dynamics governing ubiquitination of NRF2 relies 
on the differential affinities between the ETGE and DLG motifs for KEAP1; the ETGE motif 
binds KEAP1 with approximately 100-fold greater affinity than the DLG [10].  In response 
to oxidative stress, modification of reactive cysteines within KEAP1 induces a 
conformational change within the homodimer.  This architectural re-structuring releases the 
low affinity DLG motif from KEAP1, thus re-positioning NRF2 in a conformation 
unfavorable for ubiquitination [10-13]. 
  
Recent cancer genomic studies reported somatic mutation of NRF2 or KEAP1 in 34% 
of squamous cell lung carcinoma and 12% of lung adenocarcinoma [5, 14].  Consistent with 
the direct inhibition of NRF2 by KEAP1, mutations striking both KEAP1 and NRF2 within 
the same tumor are typically not observed [15].  Moreover, whereas activating mutations 
within NRF2 almost invariably target the DLG or ETGE motifs, mutations within KEAP1 
span the entire length of the protein [15-16].  Genomic alterations in KEAP1 or NRF2 have 
also been reported in a variety of other cancers, including gastric carcinoma, colorectal 
carcinoma, hepatocellular carcinoma, and ovarian cancer [17-21].  In addition to mutation, 
hypermethylation of the KEAP1 promoter and NRF2 copy number amplifications promote 
NRF2 activity in lung, colon and prostate cancer [21-23]. 
  
Although we have an understanding of how oxidative stress and genetic mutation 
activate NRF2 signaling, the identity and function of proteins that physically interact with 
KEAP1 and NRF2 has been comparatively understudied.  A growing body of evidence 
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suggests that cancer-associated increases in NRF2 transcript and protein can occur in the 
absence of genomic alteration [15, 17, 24], underscoring the importance of identifying the 
full complement of regulatory mechanisms governing NRF2 activity.  We recently reported 
that the WTX tumor suppressor protein physically binds KEAP1 to competitively inhibit 
NRF2 ubiquitination [25].  Similarly, p62/SQSTM1, PALB2, and p21 bind KEAP1 or NRF2 
to sterically inhibit NRF2 ubiquitination [26-28].  For WTX and PALB2, the association with 
KEAP1 is achieved through an ETGE motif, which mimics the NRF2 binding interface. As 
expected, these proteins activate NRF2-mediated transcription in the absence of oxidative 
stress, through ETGE-dependent competition with NRF2 for KEAP1 binding.  Here, we 
sought to comprehensively define all ETGE or ESGE containing proteins within the KEAP1 
protein interaction network, determine whether they functionally control NRF2 and evaluate 
their expression within human tumors, particularly in relation to NRF2 activity. 
 
2.C. MATERIALS AND METHODS 
Tissue Culture, Transfections, and Small Interfering RNAs 
HEK293T and H2228 cells were obtained from the American Tissue and Culture 
Collection, which authenticates cells line using short tandem repeat analysis. Cell lines were 
not passaged for more than 6 months after resuscitation. HEK293T cells were grown in 
DMEM supplemented with 10% FBS and 1% GlutaMAX (Life Technologies) in a 37°C 
humidified incubator with 5% CO2. H2228 cells were grown in RPMI supplemented with 
10% FBS. KEAP1 -/- mouse embryo fibroblasts (MEFs) were cultured in IMDM 
supplemented with 10% FBS. The KEAP1 -/- MEFs were kindly provided by Thomas 
Kensler and Nobunao Wakabayshi. Expression constructs were transfected in HEK293T 
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cells with Lipofectamine 2000 (Life Technologies) and KEAP1 -/- MEFs as with Fugene HD 
(Roche). Transfection of siRNA was performed with Lipofectamine RNAiMAX (Life 
Technologies).  
siRNA sequences: DPP3#1 (CAC CAA AUC CAA UGC UCC UCA CAU A), DPP3#2 
(GCU UAC CAU CCU GUC UAC CAG AUG A), DPP3#3 (CCC UCC AUU CGU GUG 
UGU AUU UAG G), NRF2 (GUA AGA AGC CAG AUG UUA A), KEAP1 (GGG CGU 
GGC UGU CCU CAA U). Control siRNAs were obtained from Life Technologies; 
sequences are as follows: CGU ACG CGG AAU ACU UCG ATT and UCG AAG UAU 
UCC GCG UAC GTT. 
Cell lysis buffers: 0.1% NP40 (10% glycerol, 50mM HEPES, 150 mM NaCl, 2mM EDTA, 
0.1% NP-40) containing protease inhibitor mixture (Thermo Scientific) and phosphatase 
inhibitor (Thermo Scientific). RIPA buffer (1% NP-40, 0.1% SDS, 0.25% sodium 
deoxycholate, 150mM NaCl, 10% glycerol, 25mM Tris, 2mM EDTA). Additionally, NRF2 
ubiquitination experiments were performed in the presence of 2mM N-ethylmaleimide. 
Cell Staining Buffers: cytoskeletal buffer (5 mM PIPES, pH 6, 137 mM NaCl, 5 mM KCl, 
1.1 mM Na2HPO4, 0.4 mM KH2PO4, 0.4 mM MgCl2, 0.4 mM NaHCO3, 2 mM EGTA, 
50mM glucose). 
Antibodies employed for W. blot analysis: anti-FLAG M2 monoclonal (Sigma), anti-HA 
monoclonal (Roche), anti-FAM117b (ProteinTech, 21768), anti-MAD2L1 (Bethyl, 
Montgomery TX, A300-301A), anti-MCM3 (Bethyl, A300-192A), anti-SLK (Bethyl, A300-
499A), anti-βactin polyclonal (Sigma, A2066), anti-βtubulin monoclonal (Sigma, T7816), 
anti-KEAP1 polyclonal (ProteinTech, Chicago IL), anti-DPP3 polyclonal (abcam, 
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Cambridge MA, 97437), anti-GFP (abcam, ab290), anti-NRF2 H300 polyclonal (Santa Cruz, 
Santa Cruz CA), and anti-VSV polyclonal (Bethyl, A190-131A). 
Quantitative PCR primers: GCLM (F: ACAGCGAGGAGCTTCATGATTG, R: 
CTCCCTGACCAAATCTGGGTTG), HMOX1 (F: 
GGCCAGCAACAAAGTGCAAGATTC, R: AGCAACTGTCGCCACCAGAAAG), 
GAPDH (F: ATGGGGAAGGTGAAGGT, R: AAGCTTCCCGTTCTCAG). 
Affinity Pulldowns and Western Blotting 
For Streptavidin and FLAG affinity purification, cells were lysed in 0.1% NP-40 lysis 
buffer. Cell lysates were cleared by centrifugation and incubated with streptavidin resin (GE 
Healthcare) or FLAG resin (Sigma) before washing with lysis buffer and eluting with 
NuPAGE loading buffer (Life Technologies). For siRNA, HEK293T cells were transiently 
transfected and lysed in RIPA buffer 60 h post-transfection. All antibodies and buffers used 
for Western analysis are listed in Supplemental Methods.  
 
Plasmids, Expression Vectors, and Site-directed Mutagenesis 
Expression constructs in the SBPHA backbone were generated with standard PCR 
techniques. Constructs for DPP3 and DPP3Y318F were a generous gift from Maja Abramić. 
The reporter gene fusion construct for human hNQO1-ARE-luciferase was a kind gift from 
Jeffrey Johnson. The SLK-HA construct was a generous gift from Dr. Andrey Cybulsky. 
Expression constructs for ETGE-containing proteins were obtained from Open Biosystems 
and cloned into a custom lentiviral vector (pHAGE-CMV-FLAG-DEST). ETGE deletion 
mutants were generated by PCR-based mutagenesis and sequence verified prior to use 
(GENEWIZ). 
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ARE-luciferase Quantification 
For DNA, cells were transfected with expression constructs, FLAG-KEAP1, FLAG-
NRF2, hNQO1-ARE luciferase, and a control plasmid containing Renilla luciferase driven 
by a constitutive cytomegalovirus (CMV) promoter. Approximately 24 h post-transfection, 
NRF2-mediated transcription was measured as the ratio of Firefly to Renilla luciferase 
activity (Promega Dual-Luciferase Reporter Assay System). For siRNA, HEK293T cells 
stably expressing the ARE-luciferase and Renilla control reporters were transfected with 
siRNA. Approximately 60 h post-transfection, activation was measured. For the assay 
depicted in Figure 6E, treatment with 50 µM tBHQ was performed 48 h post-transfection, 
and activation was measured 60 h post-transfection. 
 
Cell-based NRF2 ubiquitination experiments 
HEK293T stably expressing SBPHA-KEAP1 cells were transfected with VSV-UB1, 
FLAG-NRF2, and SBPHA-DPP3. Venus-NPM1 was used such that each condition received 
the same mass of DNA. Cells were lysed in 0.1% NP-40 lysis buffer. 
 
RNA Isolation, Reverse Transcription, and Semi-quantitative Real Time-PCR 
Total RNA from cells was harvested in TRIzol (Life Technologies) reagent according 
to the manufacturer’s instructions. RNA was quantified by UV spectrophotometry, and 
cDNA was created using the RevertAid First Strand cDNA synthesis Kit (Fermentas). PCR 
was performed in triplicate with 30 cycles of amplification with 1 s denaturation at 95 °C and 
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5 s annealing at 60 °C, on an ABI 7900HT Fast Realtime PCR machine. Quantitative light 
cycler PCR primers are listed in the Supplemental Methods. 
 
Crystallographic Modeling 
The coordinates for the KEAP1-NRF2 peptide complex and DPP3 were downloaded 
from the RCSB Protein Data Bank (PDB IDs 1X2R and 3FVY, respectively).  The 
superposition of the ETGE motifs of NRF2 and DPP3 was done in PyMOL (The PyMOL 
Molecular Graphics System, Version 1.3, Schrödinger, LLC).  PyMOL was used to prepare 
the images used in Figure 4D-G. 
 
Affinity Purification and Mass Spectrometry 
For Streptavidin and FLAG affinity purification, cells were lysed in 0.1% NP-40 
lysis. Cell lysates were incubated with Streptavidin or FLAG resin and washed 5X with lysis 
buffer. The precipitated proteins were trypsinized directly off beads using the FASP Protein 
Digestion Kit (Protein Discovery). For tandem purification of the FLAG-KEAP1 and 
SBPHA-DPP3 complex (Figure 3B), protein complexes were eluted after the first affinity 
purification with either 150 µg/µl FLAG peptide or 50 mM biotin.  
 
Protein Identification, Filtering and Bioinformatics 
Filtering of false interactions from non-tandem, wild-type experiments was 
accomplished using SPOTLITE, with an internal lab dataset of 158 Streptavidin experiments 
on 60 different baits, and using a 10% FDR for the entire dataset.  FLAG-based APMS data 
were not scored with SPOTLITE because our FLAG-specific reference dataset is 
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prohibitively small. Proteins identified in tandem or mutant experiments were accepted if 
they passed the SPOTLITE filtering on the non-tandem, wild-type experiments. Unfiltered 
data and associated SPOTLITE results are provided as Table S1.  
Protein Identification, Filtering and Bioinformatics: All raw data were converted to mzXML 
format before a search of the resultant spectra using SorcererTM-SEQUEST® (build 4.0.4, 
Sage N Research) and the Transproteomic Pipeline (TPP v4.3.1). Data were searched against 
either the human UniProtKB/Swiss-Prot sequence database (Release 2011_08) or the human 
IPI database (Version 3.87), both supplemented with common contaminants, i.e. porcine 
(Swiss-Prot P00761) and bovine (P00760) trypsin, and further concatenated with its reversed 
copy as a decoy (40,494 total sequences). Search parameters used were a precursor mass 
between 400 and 4500 amu, up to 2 missed cleavages, precursor-ion tolerance of 3 amu, 
accurate mass binning within PeptideProphet, semi-tryptic digestion, a static 
carbamidomethyl cysteine modification, and variable methionine oxidation. False discovery 
rates (FDR) were determined by ProteinProphet and minimum protein probability cutoffs 
resulting in a 1% FDR were selected individually for each experiment. 
PeptideProphet/ProteinProphet results for each AP-MS experiment were stored in a local 
Prohits database. Prohits performed the mapping of UniProtKB/IPI accession identifiers to 
Entrez Gene IDs. These results were then imported into Cytoscape v2.8.2 for network 
visualization and SPOTLITE for interaction prediction. Gene Ontology annotations were 
imported from NCBI Entrez Gene through Cytoscape. Known protein-protein interactions 
were extracted from the BioGRID database (Release 3.1.89). 
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Motif Analysis 
Identification of enriched 4-mer amino acid sequences was performed using a 1-tail 
Fisher’s exact test (Table S2). We individually tested each of the 13265 4-mer sequences 
present among the KEAP1 interactors, taking into account the number of interacting proteins, 
interacting proteins having the motif, total proteins in the UniProtKB/SwissProt database, 
and the total number of proteins having the motif within UniProtKB/SwissProt. Bonferroni 
correction was applied due to multiple hypothesis testing. 
 
Immunostaining 
For subcellular localization of exogenously expressed proteins, cells were co-
transfected with the indicated plasmids and plated on 10ug/ml fibronectin-coated coverslips. 
Cells were fixed in 4% paraformaldehyde in cytoskeletal buffer for 15 minutes, and 
coverslips were mounted to slides using the Prolong Gold antifade reagent (Molecular 
Probes). Images were acquired using a Zeiss LSM5 Pascal Confocal Laser Scanning 
Microscope equipped with a 63X/1.42 Oil PlanApo objective lenses. Localization of 
endogenous KEAP1 was determined by immunostaining cells as described above, except: 1) 
cells were fixed in 4% PFA in cytoskeletal buffer for 15 minutes and permeabilized with 
0.1% Triton in PBS for 5 minutes, 2) after blocking in 1% BSA/PBS for 1h, cells were 
double stained for KEAP1 (Proteintech) and flag (Sigma) at 4oC, overnight, followed by 
incubation with FITC-conjugated-donkey anti-rabbit IgG and RRX-conjugated-donkey anti-
mouse IgG (Jackson ImmunoResearch Laboratories) at room temperature for 2h and 3), 
images were acquired using a Zeiss LSM710 Spectral Confocal Laser Scanning Microscope. 
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2.D. RESULTS 
2.D.1 Proteomic analysis of the KEAP1 protein interaction network. 
We defined the KEAP1 protein interaction network by affinity purification and 
shotgun mass spectrometry (APMS) (Fig. 2.1.B and S2.1). In total, the KEAP1 complex was 
analyzed 13 times, where variations in affinity purification, detergent solubilization and cell 
treatment helped to maximize comprehensive network mapping. True interactions were 
identified from false positives using SPOTLITE, a novel probabilistic scoring algorithm that 
couples direct and indirect data to identify false positive interactions within APMS data (Fig. 
2.1.B) (manuscript under review).  Of 42 high confidence KEAP1-interacting proteins 
identified, 17 contain an ETGE, ESGE or both. To determine if this motif is enriched within 
the KEAP1 protein interaction network (PIN) beyond chance observation, we performed a 
Fisher’s exact test. The ETGE motif was identified as the only significant 4 amino acid 
sequence within the KEAP1 PIN (Table S.2.2). Together, these data support and expand the 
‘ETGE’ competition model of KEAP1 regulation.   
2.D.2 The ETGE motif is required for binding to KEAP1. 
We selected eight ETGE-containing proteins and validated their association with 
KEAP1 (Fig. 2.2.A-B).  Western blot analysis of affinity purified KEAP1 protein complexes 
revealed the presence of endogenously expressed DPP3, FAM117B, MCM3,  SLK and 
MAD2L1 (Fig. 2.2.B). Expression of exogenous TSC22D4 and WDR1 also showed 
interaction with KEAP1 (Fig. 2.2.C). To map the domain within KEAP1 responsible for 
binding the ETGE proteins, full-length KEAP1, the KEAP1 KELCH domain, or the KEAP1 
BTB domain were purified and endogenous associated proteins were detected by Western 
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blot.  With the exception of WDR1 and TSC22D4 which bound only full length KEAP1, 
DPP3, FAM117B, MCM3, SLK and MAD2L1 bound the KELCH domain of KEAP1 (Fig. 
2.2.B-C).  To directly evaluate a role for the ETGE motif in binding KEAP1, we generated 
ETGE-deletion mutants for FAM117B, MCM3, TSC22D4, WDR1, DPP3 and SLK.  Like 
WTX and PALB2, deletion of the ETGE (∆ETGE) motif within these proteins abrogated 
KEAP1 binding (Fig. 2.2.D and E).  Finally, functional impact of the ETGE-containing 
proteins on NRF2-mediated transcription was evaluated.  Of the proteins tested, DPP3 and 
TSC22D4 strongly activated NRF2-mediated transcription in an ETGE-dependent manner, 
the former of which was previously identified as an activator of NRF2-dependent 
transcription in a gain-of-function screen [29] (Fig. 2.2.F).  Over-expression of SLK also 
activated NRF2-mediated transcription, although this activation was independent of the 
ETGE motif (Fig. S2.1).   
 
2.D.3 DPP3 is a KEAP1 interacting protein. 
The protein dipeptidyl peptidase III (DPP3) had the greatest impact on NRF2-
dependent transcription and was the most abundant protein within the KEAP1 PIN (Fig. 
2.2.F) [30].  To further explore DPP3, we defined and compared the DPP3 PIN to the 
KEAP1 PIN (Fig. 2.3.A).  With the exception of the observed interaction between KEAP1 
and DPP3, the integrated PIN revealed no common interacting proteins.  We also defined the 
PIN for DPP3∆ETGE; as expected KEAP1 was not observed.  To more rigorously characterize 
the KEAP1-DPP3 protein complex, we performed sequential affinity purifications for 
FLAG-KEAP1 and SBPHA-DPP3.  Using HEK293T cells stably expressing both proteins, 
we purified FLAG-KEAP1 complexes and then from the resulting eluate, purified DPP3 with 
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Streptavidin (Fig. 2.3.B, top).  The reciprocal sequential purification was done and analyzed 
by APMS (Fig. 2.3.B, bottom).  Despite observing over 1500 spectral counts representing 
each bait protein, the only protein identified in both APMS experiments was SQSTM1, 
represented by 15 and 1 total spectra, respectively (Fig. 2.3.B).  Together these data argue 
that the KEAP1-DPP3 complex is largely exclusive from other interacting proteins. 
 
We next tested whether endogenously expressed DPP3 and KEAP1 associate.  First, 
endogenous DPP3 was detected within FLAG-KEAP1 affinity purified protein complexes 
from HEK293T cells (Fig. 2.3.C).  Second, endogenous KEAP1 affinity purified with 
SBPHA-DPP3 (Fig. 2.3.D). Finally, we detected KEAP1 within immunopurified endogenous 
DPP3 protein complexes (Fig. 2.3.E).  In addition to these studies in HEK293T cells, DPP3 
was also detected within KEAP1 protein complexes isolated from H2228 lung cancer cells 
(Fig. 2.3.F).  As protein complex purification is subject to post-lysis interactions, we 
determined if DPP3 and KEAP1 co-localized within cells. Although discrete subcellular 
localizations were not observed, exogenously expressed DPP3 co-localized with both 
exogenous and endogenous KEAP1 protein; DPP3∆ETGE also co-localized with KEAP1 (Fig. 
2.3.G and 2.3.H).  Comparing transfected versus untransfected cells, the expression of DPP3 
did not affect KEAP1 subcellular localization (Fig. 2.3.G).  Finally, we tested whether the 
catalytic activity of DPP3 affected its association with KEAP1. Stably expressed wild-type 
(WT) and the catalytically inactive (Y318F) mutant [31] of DPP3 bound endogenous KEAP1 
(Fig. 2.3.D), indicating that the catalytic activity of DPP3 is not required for KEAP1 binding.  
Consistent with this, wild-type DPP3 or DPP3Y318F similarly activated NRF2-dependent 
transcription when over-expressed (Fig. 2.3.I). 
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2.D.4 The ETGE motif is required for DPP3 binding to KEAP1. 
Like WTX, PALB2, NRF2 and most of the ETGE-containing proteins evaluated, 
endogenous DPP3 associated with the KELCH domain of KEAP1 (Fig. 2.4.A). To validate 
that the ETGE motif is required for this binding, constructs encoding SBPHA-DPP3 or 
SBPHA-DPP3∆ETGE were transiently transfected into cells stably expressing FLAG-tagged 
full length KEAP1 or the KELCH domain. Wild-type DPP3 bound full length KEAP1 and 
the KELCH domain; however, DPP3∆ETGE was unable to bind KEAP1 or the KEAP1 
KELCH domain (Fig. 2.4.B). Similarly, whereas endogenous KEAP1 failed to immunopurify 
with DPP3∆ETGE, it did co-purify with DPP3-WT and the catalytic mutant DPP3Y318F (Fig. 
2.4.C).  These data were confirmed by APMS of DPP3∆ETGE and DPP3Y318F. Deletion of the 
ETGE motif within DPP3 may render the protein unstable and/or misfolded, which could 
account for lack of binding to KEAP1. To address this possibility, we tested the ability of a 
DPP3 alanine mutant to bind KEAP1.  Like DPP3∆ETGE, alanine point mutations within the 
domain (ETGEAAGE) abolished KEAP1 binding (Fig. 2.4.D).   
 
Crystallographic modeling revealed that NRF2 binds KEAP1 near the central pore of 
the KELCH β-propeller (Fig. 2.4.E) [10, 13, 32]. Using the crystal structure of DPP3, we 
asked if the ETGE motif within DPP3 and NRF2 adopt similar tertiary conformations. The 
ETGE motif in DPP3 lies on an unstructured loop on the surface of the protein (Fig. 2.4.F) 
[33].  It is therefore in a sterically favorable position to bind to KEAP1, as opposed to being 
buried within the globular domains. Similar to the NRF2 peptide, three tyrosine residues and 
one phenylalanine residue defines the binding surface that accommodates the specific 
conformation of the ETGE peptide of DPP3 (Fig. 2.4.G). Strikingly, the ETGE motif of 
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DPP3 and NRF2 adopt identical conformations when superimposed, suggesting that the 
ETGE motif of both proteins may interact with KEAP1 in a similar manner (Fig. 2.4.H) (root 
mean square deviation ≈ 0.05 Å between Cα atoms). 
 
2.D.5 DPP3 competes with endogenous NRF2 for binding to KEAP1. 
We tested whether DPP3 association with KEAP1 displaces NRF2.  As homodimeric 
KEAP1 binds a single NRF2 molecule via two amino acid motifs (Fig. 2.1.A), competition 
experiments required the isolation of monomeric KEAP1.  We created two double stable cell 
lines: the first expressed both SBPHA-KEAP1 and FLAG-KEAP1, and the second expressed 
SBPHA-KEAP1 and the FLAG-tagged BTB domain of KEAP1.  Sequential affinity 
purification with streptavidin and FLAG resins purified KEAP1 homodimer or a KEAP1-
BTB “pseudo-monomer”, allowing us to test whether DPP3 competes with NRF2 for KEAP1 
binding (Fig. 2.5.A).  Compared to a truncated form of WTX that does not interact with 
KEAP1 [25], DPP3 over-expression resulted in reduced NRF2 binding to the pseudo-
monomer KEAP1 but not to the KEAP1 homodimer (Fig. 2.5.B; compare lanes 3 and 4 to 
lanes 7 and 8).  In contrast, when DPP3∆ETGE was introduced into each double-stable cell line, 
NRF2 binding to both the KEAP1-KEAP1 homodimer and KEAP1-BTB heterodimer was 
maintained (Fig. 2.5.C; compare lane 5 to 6). These findings suggest that DPP3 competes 
with NRF2 for binding to KEAP1 in an ETGE-dependent manner. 
 
The ‘hinge-and-latch’ model predicts that loss of binding of the NRF2 DLG motif to 
KEAP1 results in a reduction of NRF2 ubiquitination and subsequent degradation. Given that 
DPP3 competes for binding to KEAP1 via the ETGE motif (Fig. 2.5.A-C), we tested if DPP3 
80  
over-expression reduced NRF2 ubiquitination in an ETGE-dependent manner. Affinity 
purification of exogenous NRF2 followed by Western blot analyses revealed relative levels 
of NRF2 ubiquitination.   As the amount of wild-type DPP3 increased, ubiquitination of 
NRF2 decreased, as compared to control (Fig. 2.5.D; compare lanes 2 and 6).  Consistent 
with its inability to bind KEAP1, DPP3∆ETGE did not reduce NRF2 ubiquitination (Fig. 
2.5.E). These data suggest that over-expression of DPP3 alters the architecture of NRF2 
bound to dimeric KEAP1, and ultimately decreases NRF2 ubiquitination. 
 
2.D.6 DPP3 activates NRF2 signaling in an ETGE-dependent fashion. 
To establish functional significance of DPP3 as a regulator of NRF2 activity, we 
determined whether DPP3 gain-of-function and loss-of-function impacted NRF2 
transcriptional activity.  Over-expression of DPP3, but not DPP3∆ETGE or DPP3ala∆ 
significantly induced NRF2-dependent expression of an antioxidant responsive firefly 
luciferase reporter (Fig. 2.6.A). For loss-of-function, we designed and tested the silencing 
efficacy of three non-overlapping siRNAs targeting DPP3 (Fig. 2.6.B).  siRNA-mediated 
silencing of DPP3 suppressed NRF2-mediated transcription of the ARE reporter, similar to 
that of NRF2 silencing (Fig. 2.6.C).  To validate this phenotype using endogenous NRF2 
readouts, qPCR was employed to monitor the expression of two well-established NRF2 
target genes: heme oxgenase-1 (HMOX1) and glutamate-cysteine ligase modifier (GCSm).  In 
agreement with the reporter data, DPP3 siRNAs reduced HMOX1 and GCSm transcript levels 
similar to that of NRF2 silencing (Fig. 2.6.D).  Finally, the model predicts that DPP3 gain-of-
function or loss-of-function would not affect NRF2 activity after treatment with a pathway 
agonist, as NRF2 would already be in a sterically unfavorable conformation for KEAP1-
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mediated ubiquitination and degradation (Fig. 2.1.A). Consistent with this hypothesis, neither 
DPP3 siRNAs (Fig. 2.6.F) nor over-expression of DPP3 (Fig. 2.6.G) were able to suppress 
NRF2-mediated transcription after treatment with the small molecule, tert-butylhydroquinone 
(tBHQ).  
 
2.D.7 DPP3 expression and DNA copy number positively correlates with NRF2 activity in 
squamous cell lung cancer. 
To establish physiological significance for DPP3 in controlling KEAP1-NRF2 
signaling, we evaluated DPP3 mRNA abundance and gene alterations in squamous cell lung 
carcinoma, using data from the TCGA consortium (15).  First, we found that DPP3 mRNA 
expression is increased in lung SQCC as compared to matched normal tissue (Fig. 2.7.A). Of 
the four established lung SQCC subtypes, DPP3 expression is highest in primitive-type 
tumors (Fig. 2.7.A and S.2.2) [34].  Second, DPP3 genomic copy number and mRNA 
expression positively correlated, suggesting that DPP3 gene amplification may drive DPP3 
over-expression in lung SQCC (Fig. 2.7.B). Third, when segregated by genotype, DPP3 
mRNA levels were higher in NRF2 wild-type lung SQCC as compared to tumors with 
mutated NRF2, which is consistent the proposed DPP3-competition model (Fig. 2.7.C). 
Surprisingly, DPP3 mRNA abundance was found to be increased in KEAP1 mutant tumors 
as compared to KEAP1 wild-type tumors (Fig. 2.7.D).  This co-occurrence might be 
explained if the mutations in KEAP1 are hypomorphic, resulting in a partially compromised 
ability to suppress NRF2. If so, the presence of DPP3 may further drive NRF2 activity. To 
test this hypothesis, we cloned and expressed five distinct KEAP1 mutations from the TCGA 
lung SQCC dataset and evaluated their impact on NRF2 function.  In both HEK293T cells 
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and KEAP1-/- mouse embryo fibroblasts, all five KEAP1 mutants displayed reduced but not 
absent activity in suppressing NRF2, thus supporting the notion that these somatic mutations 
are hypomorphic (Fig. 2.7.E and Fig. S2.3).  Impressively, over-expression of DPP3 further 
activated NRF2 in the presence of all five KEAP1 hypomorphs (Fig. 2.7.F).  Importantly, the 
KEAP1 somatic mutants analyzed maintained association with both DPP3 and NRF2 (Fig. 
S2.3). These data support a model wherein somatic mutation of KEAP1 partially impairs its 
ability to suppress NRF2, and the presence of ‘ETGE’-containing proteins like DPP3 may 
further drive pathway activity in KEAP1 mutant tumors.      
   
Finally, we tested whether DPP3 expression associated with NRF2 transcriptional 
activity across the lung SQCC cohort, as defined by the expression of a gene set signature 
consisting of 15 NRF2 target genes [3]. DPP3 expression and the NRF2 signature score 
strongly associated (Fig. 2.7.H).  Together, these data suggest that through competitive 
binding to KEAP1, DPP3 genomic amplification and over-expression may promote NRF2 
activity in squamous cell carcinoma of the lung. 
 
2.E. DISCUSSION 
Aberrant KEAP1/NRF2 signaling has emerged as a critical regulatory pathway in a 
multitude of disease pathologies, most notably cancer. Although substantial progress has 
been made to define how reactive cysteines within KEAP1 govern its ability to ubiquitinate 
NRF2, the role of proteins peripheral to the KEAP1/NRF2/CUL3 core complex has only just 
begun to be explored.  Recent studies have revealed four proteins that bind KEAP1 or NRF2 
and ultimately inhibit NRF2 ubiquitination.  Of these, WTX and PALB2 employ an ETGE 
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motif to directly bind KEAP1, thus displacing and stabilizing NRF2.  Given these discoveries 
and the likelihood that KEAP1-associated proteins contribute to NRF2 perturbation in human 
disease, particularly when genomic alterations within KEAP1 and NRF2 are lacking, we 
sought to establish the ETGE motif as a defining characteristic in KEAP1 associated proteins 
that functionally control NRF2 stability.   
 
We found that the ETGE motif defines the most frequently observed four amino acid 
sequence within the KEAP1 protein interaction network (Table S2.2; Fisher’s exact test, 1-
tail, p=5.8e-13). Of 13 ETGE containing proteins identified, we tested 7 and found that all 
required the ETGE motif to bind KEAP1 (Fig. 2.2.E).  Aside from this ETGE-dependent 
KEAP1 binding however, we noted very few similarities.  For example, with the exception of 
WTX, DPP3, and PALB2, none of the proteins have been previously reported to contribute 
or respond to oxidative stress.  Additionally, functional annotations for identified proteins are 
surprisingly diversified: DNA replication and licensing (MCM3, MCMBP), cytoskeletal 
dynamics (SLK, WDR1), transcription (TSC22D4), and apoptosis (SLK) [35-45]. Within the 
context of our data, these observations suggest that each ETGE protein may function to 
control KEAP1 activity or be controlled by KEAP1 in a context-dependent fashion.   
 
Because it robustly activates NRF2-mediated transcription (Fig. 2.6.A), binds KEAP1 
with near exclusivity (Fig. 2.3.A and B) and has established catalytic activity, we chose to 
focus our mechanistic studies on DPP3.  Although DPP3 possesses exopeptidase activity in 
vitro [33, 46], we were unable to reveal a role for its catalytic activity in either contributing 
to the KEAP1 interaction (Fig. 2.3.D and 2.4.C) or regulating NRF2-mediated transcription 
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(Fig. 2.3.I). That said, our studies did not examine the temporal effects of DPP3 expression 
on NRF2 activity, but rather assessed pathway activity at steady-state. Focused studies are 
needed to determine whether DPP3 catalytic activity functions to control KEAP1 and NRF2 
dynamics, as well as pathway activity in vivo. Given the pressing need of identifying new 
drug targets within the KEAP1-NRF2 pathway, the possibility of targeting DPP3 catalytic 
function to control KEAP1-NRF2 remains an important opportunity.  
 
The ETGE motif of DPP3 resides in a flexible loop on the surface of the protein and 
adopts a similar conformation to the NRF2 ETGE peptide when bound to KEAP1 (Fig. 2.4.F 
and G).  Loss of this motif, through deletion or point mutation, abrogates the KEAP1-DPP3 
protein interaction (Fig. 2.4), perturbs the interaction between NRF2 and KEAP1 (Fig. 2.5), 
as well as alters NRF2 ubiquitination (Fig. 2.5). We interpret these data to support a model 
wherein DPP3 competes the low-affinity DLG motif of NRF2 off of the KEAP1 KELCH 
domain, resulting in a complex of KEAP1, DPP3, and NRF2. Additional experiments are 
needed to determine protein stoichiometry within complexes containing KEAP1, NRF2, and 
DPP3. These experiments will reveal whether competitors like DPP3 specifically compete 
off the DLG of NRF2, as opposed to the ETGE motif; based on the relative affinities of the 
DLG and ETGE motifs, competition with the DLG motif of NRF2 is most probable [10-11].  
 
In cancer, over-expression of an ETGE-containing protein may promote NRF2 
activity in the absence of inactivating KEAP1 mutations or activating NRF2 mutations.  
Indeed, high NRF2 activity in tumors lacking KEAP1 or NRF2 mutation has been reported in 
ovarian cancer, sarcoma and squamous cell lung cancer [5, 17, 47]. After defining the ETGE-
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containing proteins within the KEAP1 protein interaction network (Fig. 2.1), we surveyed 
their expression and DNA copy number across tumor samples taken from the TCGA SQCC 
lung cohort.  DPP3 demonstrated copy number gains and mRNA over-expression, and 
importantly both of which positively correlated with NRF2 activity (Fig. 2.7). Whether 
genomic amplification of DPP3 constitutes a ‘driver’ event in cancer remains an important 
question for future research. Interestingly, two studies have demonstrated DPP3 over-
expression in ovarian cancer. Given our data in lung SQCC, DPP3 expression may similarly 
be driven by genomic amplification in ovarian carcinoma, possibly functioning as a NRF2 
agonist [48-49].   
 
Our cancer genomic analyses and functional annotation of cancer-derived mutations 
in KEAP1 suggest that some KEAP1 somatic mutations are hypomorphic, resulting in partial 
NRF2 activation. This contrasts NRF2 mutation, which we believe yields a maximally 
activated pathway, one insensitive to KEAP1 modifiers such as DPP3. This hypothesis is 
supported by the following: 1) DPP3 genomic amplification and mRNA over-expression was 
largely restricted to NRF2 wild type tumors, 2) DPP3 over-expression positively associated 
with KEAP1 mutant tumors, 3) DPP3 over-expression in the presence of mutant KEAP1 
further activated NRF2 signaling, and 4) as a tumor suppressor frequently targeted in cancer, 
KEAP1 is somewhat unique in that it is rarely deleted through homozygotic loss. Therefore, 
from a therapeutic and prognostic perspective, KEAP1 mutant tumors are not equivalent to 
NRF2 mutants. Future studies are needed to challenge this model.  For example, does forced 
DPP3 expression drive NRF2 activity in mouse models of lung cancer, and would synergy be 
seen between DPP3 expression and KEAP1 mutation in vivo? Given that multiple different 
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cancer types have recently been found to exhibit constitutive NRF2 activation—some of 
which in the absence of NRF2 or KEAP1 mutations—our data collectively support a model 
where the expression of ETGE-containing proteins drive NRF2-mediated signaling via a 
competitive binding mechanism. 
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tion of the sequential affinity purification approach employed to purify a KEAP1-KEAP1 
homodimer or KEAP1-BTB domain pseudo-monomer. (B) HEK293T cells stably 
expressing FLAG-KEAP1 and SBPHA-KEAP1 or FLAG-BTB and SBPHA-KEAP1 
were transfected with VSV-DPP3-WT or VSV-WTX1-211 truncation mutant before 
sequential streptavidin and FLAG affinity purification and Western blot. (C) HEK293T 
cells stably expressing FLAG-BTB and SBPHA-KEAP1 were co-transfected with VSV-
WTX(1-211), VSV-DPP3 or VSV-DPP3∆ETGE. Protein complexes were affinity purified 
with Streptavidin then FLAG and analyzed by Western blot. (D and E) HEK293T cells 
stably expressing SBPHA-KEAP1 were co-transfected with VSV-UB1, FLAG-NRF2, and 
either SBPHA-DPP3-WT, SBPHA-DPP3∆ETGE or negative control Venus-NPM1. 
NRF2 was FLAG affinity purified and analyzed by Western blot. 
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Figure 2.6. DPP3 is an activator of NRF2-mediated transcription. (A) HEK293T 
cells were transfected with the indicated plasmid along with constitutively expressed 
Renilla luciferase and the NQO-1 promoter driving Firefly luciferase (NQO1-ARE). 
Cells were lysed and luciferase values were normalized to Renilla. Error bars represent 
standard deviation from the mean over 3 biological replicates, * p<0.05; Students 
T-test as compared to NPM1. (B) HEK293T cells were transfected with 10nM of the 
indicated siRNA. Protein lysate was analyzed by Western blot for the indicated endog-
enous protein. (C) HEK293T cells stably expressing the ARE reporter and Renilla 
luciferase were transfected with the indicated siRNA.  Error bars represent standard 
deviation from the mean from 3 biological replicates. * p<0.05; Students T-test as 
compared to CNT. (D and E) HEK293T cells were transfected with siRNAs against the 
indicated mRNAs before mRNA isolation and qPCR for the indicated endogenous 
target genes. Relative expression was calculated based on expression of endogenous 
target gene transcript normalized to GAPDH. Error bars represent standard deviation 
from the mean from 3 biological replicates. * p<0.05; Students T-test as compared to 
CNT. (F and G) HEK293T cells were transfected with the indicated siRNAs or plas-
mids. Cells were treated with 50uM tBHQ 18 h priors to lysis. Error bars represent 
standard deviation from the mean from 3 biological replicates. * p<0.05; Students 
T-test.
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Figure 2.7. DPP3 expression positively associates with NRF2 activity in squamous 
cell lung cancer. (A) DPP3 mRNA abundance in 175 squamous cell lung carcinomas 
and 27 matched normal tissues (p=4.601e-14; Kruskal-Wallis test). Normal or lung 
SQCC subtype is indicated by color. With respect to tumor subtype, DPP3 is over-
expression is enriched within the primitive subtype (p=0.03334; Kruskal-Wallis test; see 
also Figure S2). (B) DPP3 mRNA expression positively correlates with DPP3 genomic 
copy number (Spearman rank correlation). (C) Correlation of DPP3 mRNA expression 
with NRF2 mutational status (p=0.00141; Kruskal-Wallis test). (D) Correlation of DPP3 
mRNA expression with KEAP1 mutational status (p=0.03718; Kruskal-Wallis test). (E 
and F) HEK293T cells were transiently transfected with NQO1-ARE-luciferase reporter, 
constitutively active Renilla reporter and the indicated expression plasmids (* P<0.05 
across at least three biological triplicate experiments) (G) DPP3 mRNA expression 
positively associates with NRF2 target gene expression (Spearman rank correlation test). 
The NRF2 gene signature consists of 15 genes (3). Triangles represent tumors with 
NRF2 mutations. (See also Figure S2 and S3).
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transcription. HEK293T cells were transiently 
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reporter, constitutively active Renilla luciferase, 
and the indicated expression plasmids. Data plotted 
represent triplicate biological replicte experiments. 
(p<0.05).
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Figure S2.3. DPP3 promotes NRF2 activity in the presence of hypomorphic 
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before lysis and FLAG affinity purification. Western blot analysis was performed to 
visualize the association of endogenous NRF2 and DPP3. Cells were trated with 
10uM MG132 4 hours prior to lysis. 
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Table S2 1. Sequence enrichment among KEAP1 interactors Sequence P-value proteomea Rank Sequence containing proteinsb ETGE 5.80e-13* 1 ATP6V0A2, DPP3, MCM3, NFE2L1, NFE2L2, OTUD1, SLK, TSC22D4, WDR1 IREL 1.31e-5 2 MCMBP, SASS6, SLK, TSC22D4, UNK ESGE 4.03e-3 220 DFFA, MAD2L1, PGAM5 a Fisher’s exact test using human proteome as background (see methods). b Interactions passing a 10% FDR within SPOTLITE were used for testing. * Signi icant using Bonferroni adjusted alpha level of 3.77e
i
f -6 (0.05 / 13265). 
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III. CHAPTER THREE: CANCER-DERIVED MUTATIONS IN THE KEAP1 
UBIQUITIN LIGASE IMPAIR NRF2 DEGRADATION BUT NOT 
UBIQUITINATION 
 
3.A. OVERVIEW 
Recent cancer genomics and functional analyses define the NRF2 transcription 
factor as an oncogene. Mutations in NRF2 localize to one of two binding interfaces, both 
of which mediate docking with KEAP1, an E3 ubiquitin ligase that promotes its 
proteasome-dependent degradation. Somatic mutations within KEAP1 are also common 
in human cancer, and expectedly co-mutation of KEAP1 and NRF2 is not observed. 
Consistent with its role as a tumor suppressor, mutations within KEAP1 are distributed 
throughout the full-length of the protein; whether, how and to what extent specific 
mutations affect KEAP1 activity is largely not known. Here we functionally and 
biochemically characterized 18 KEAP1 mutations taken from The Cancer Genome Atlas 
lung squamous cell carcinoma tumor set. Three mutations behaved as wild-type KEAP1, 
and are likely passenger events.  The R554Q, W544C, N469fs, P318fs, and G333C 
mutant proteins did not bind NRF2 or suppress NRF2 activity. The remaining mutations 
exhibited hypomorphic suppression of NRF2, binding both NRF2 and CUL3.  Proteomic 
study revealed that the R320Q, R470C, G423V, D422N, G186R, S243C, and V155F 
mutations resulted in an increased association between KEAP1 and NRF2. Intriguingly, 
these ‘superbinder’ mutants do not suppress NRF2 transcriptional activity and show 
reduced KEAP1-mediated degradation of NRF2.  Cell-based and in vitro biochemical 
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analyses demonstrate that despite its inability to suppress NRF2 activity, the R320Q 
‘superbinder’ mutant maintains its ability to ubiquitinate NRF2.  These data connect 
KEAP1 genotype with NRF2 activity in human tumors, and provide new insight into 
KEAP1 mechanics.  
 
3.B INTRODUCTION 
In contrast to the mutational clustering seen in oncogenes, where a few residues 
are frequently affected, mutations in tumor suppressor proteins lack focal enrichment. 
This creates uncertainty as to the impact of specific mutations on protein function; 
mutations may be phenotypically silent ‘passenger’ events, they may result in a spectrum 
of hypomorphs, or produce a functionally dead protein. Catalogued associations between 
specific cancer genotypes and protein function will instruct many principles of cancer 
biology and oncology, including patient stratification for targeted therapy.   
 
The Cancer Genome Atlas (TCGA) recently reported the characterization of 178 
squamous cell lung carcinomas (SQCC), revealing at least 10 recurrently mutated genes. 
Among these were activating mutations in the NFE2L2 (NRF2) oncogene and presumed 
loss-of-function mutations within the KEAP1 tumor suppressor gene, at 15% and 12% of 
tumors, respectively [1]. KEAP1 functions as a substrate recognition module within the 
CUL3-based E3 ubiquitin ligase, which targets the NRF2 transcription factor for 
proteasomal degradation [2]. Regardless of tissue origin, nearly all somatic mutations 
within NRF2 fall to either the ETGE or the DLG motif, two regulatory short amino acid 
sequences within NRF2 that contact KEAP1 [3]. As such, these mutations liberate NRF2 
 104 
from KEAP1-mediated ubiquitination. Comparatively, a survey of cancer genomic data 
revealed 213 somatic mutations dispersed across the full length of the KEAP1 protein 
(Fig. S3.1), a pattern consistent with the mutational spread often seen in tumor suppressor 
genes. Like many discoveries from genomic sequencing efforts, the functional 
consequences of these KEAP1 mutations are largely not known.  
The lung SQCC analysis revealed that as expected, KEAP1 mutations and NRF2 
mutations do not co-occur in the same tumor, and that tumors with KEAP1 or NRF2 
mutations express relatively high levels of NRF2-target mRNAs [1, 4]. NRF2 target 
genes include a host of stress response genes, such as heme oxygenase 1 (HMOX1), 
NADPH dehydrogenase quinone 1 (NQO1), and genes involved in gluthathione synthesis 
[5]. The expression of these genes strengthens the cellular defense system to neutralize 
reactive oxygen species (ROS), clear xenobiotic agents, and reprogram protein 
degradation machinery to restore homeostasis. Recent studies also establish a role for 
NRF2 in modulating anabolic pathways to suit the metabolic demands of cancer cell 
growth, effectively yielding an increase in cancer cell proliferation [6]. Although 
comprehensive data are not complete, several studies have reported that NRF2 activity 
correlates with poor prognosis and chemotherapeutic resistance [7-9]. 
 
The now established importance of KEAP1-NRF2 in promoting cancer cell 
growth and survival underscores the need to elucidate how cancer evolution leads to 
pathway activation. Several mechanisms are easily recognized from cancer genomic 
studies: activating mutations in NRF2 free it from KEAP1 association [10], copy number 
amplifications of the NRF2 genomic locus increases protein expression, and KEAP1 
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promoter hypermethylation decreases its mRNA and protein expression [11-12]. What 
remains uncertain is which somatic mutations within KEAP1 affect its function, to what 
degree do they impact function, and mechanistically how its function is compromised. 
Recent efforts from several groups have identified correlations between cancer genotype 
and phenotype, and these findings may have a significant impact on clinical interventions 
[13-17]. With these concepts in mind, we functionally tested and biochemically 
characterized KEAP1 mutations found within lung SQCC. Our data connects cancer-
derived KEAP1 genotypes with NRF2 phenotype. Unexpectedly, we found that many 
KEAP1 mutant proteins bind and ubiquitinate NRF2, but do not promote its proteasomal 
degradation or suppress its transcriptional activity. 
 
3.C. MATERIALS AND METHODS 
Tissue culture, transfections, and siRNAs.  
HEK293T, A549, and H2228 cells were obtained from the American Tissue and 
Culture Collection, which authenticates cells line using short tandem repeat analysis. Cell 
lines were not passaged for more than 6 months after resuscitation. The KEAP1−/− MEFs 
were kindly provided by Thomas Kensler and Nobunao Wakabayshi. HEK293T cells 
were grown in Dulbecco's Modified Eagle's Medium, supplemented with 10% FBS and 
1% GlutaMAX (Life Technologies) in a 37°C humidified incubator with 5% CO2. 
KEAP1−/− mouse embryo fibroblasts (MEF) were cultured in IMDM supplemented with 
10% FBS. A549 and H2228 cells were grown in RPMI supplemented with 10% FBS. 
Expression constructs were transfected in HEK293T cells with Lipofectamine 2000 (Life 
Technologies). A549 cells and KEAP1−/− MEFs were transfected with Fugene HD 
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(Roche). Transfection of siRNA was done with Lipofectamine RNAiMAX (Life 
Technologies). siRNA sequences for CUL3 are as follows: (A) 5’-GGU CUC CUG AAU 
ACC UCU CAU UAU U, (B) 5’-GAA UGU GGA UGU CAG UUC ACG UCA A, (C) 
5’-GGA UCG CAA AGU AUA CAC AUA UGU A. 
 
Antibodies and buffers employed for Western blot analysis: 
anti-FLAG M2 monoclonal (Sigma), anti-HA monoclonal (Roche), anti-βactin 
polyclonal (Sigma, A2066), anti-βtubulin monoclonal (Sigma, T7816), anti-KEAP1 
polyclonal (ProteinTech, Chicago IL), anti-GFP (abcam, ab290), anti-NRF2 H300 
polyclonal (Santa Cruz, Santa Cruz CA), anti-SLK (Bethyl, A300-499A), anti-DPP3 
(abcam, ab97437), anti-MCM3 (Bethyl, A300-123A), anti-WTX [18], anti-IKKβ (Cell 
Signaling, 2678), anti-p62/SQSTM (Santa Cruz, sc25575), HMOX1 (abcam, ab13248), 
anti-CUL3 (Cell Signaling, 2759), anti-MEK1/2 (Cell Signaling, 8727), anti-histone 3 
(Cell Signaling, 4499), anti-GST (Cell Signaling, 2622), and anti-VSV polyclonal 
(Bethyl, A190-131A). 0.1% NP-40 lysis buffer: 10% glycerol, 50mM HEPES, 150 mM 
NaCl, 2mM EDTA, 0.1% NP-40; RIPA buffer: 0.1% NP-40, 0.1% SDS, 10% glycerol, 
25mM Tris HCl, 0.25% sodium deoxycholate, 150mM NaCl, 2mM EDTA. 
 
Affinity purification, cell fractionation, and Western blotting.  
For FLAG affinity purification, cells were lysed in 0.1% NP-40 lysis buffer. Cell 
lysates were cleared by centrifugation and incubated with FLAG resin (Sigma) before 
washing with lysis buffer and eluting with NuPAGE loading buffer (Life Technologies). 
For immunoprecipitation of endogenous NRF2, cells were lysed in 0.1% NP-40 lysis 
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buffer. Cell lysates were cleared by centrifugation, and pre-cleared for 1 hour with 
Protein A/G resin (Pierce). Lysates were then incubated with NRF2 H-300 antibody 
(Santa Cruz) overnight at 4 degree Celsius, and then incubated for 1 hour with Protein 
A/G resin before eluting with NuPAGE loading buffer. For siRNA, HEK293T cells were 
transiently transfected and lysed in RIPA buffer 60 hours post transfection. All antibodies 
and buffers used for Western analysis are listed in Supplementary Methods. Cell 
fractionation was performed using the NE-PER Nuclear and Cytoplasmic Extraction 
Reagent kit (Thermo Scientific). 
 
Plasmids, expression vectors, and site-directed mutagenesis.  
Expression constructs for the KEAP1 mutants were generated by PCR-based 
mutagenesis and sequence verified before use (GENEWIZ). The P318fs mutation was 
generated by PCR-based mutagenesis (Stratagene Quick Change) and sequence verified 
prior to use. The reporter gene fusion construct for human hNQO1-ARE-luciferase was a 
kind gift from Jeffrey Johnson.  
 
ARE luciferase quantification.  
Cells were transfected with expression constructs, FLAG-KEAP1, FLAG-NRF2, 
hNQO1-ARE luciferase, and a control plasmid containing Renilla luciferase driven by a 
constitutive cytomegalovirus (CMV) promoter. Approximately 24 hours post-
transfection, NRF2-mediated transcription was measured as the ratio of Firefly to Renilla 
luciferase activity (Promega Dual-Luciferase Reporter Assay System).  
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NRF2 ubiquitination experiments.  
Ubiquitination of NRF2 under denaturing conditions was performed in HEK293T cells 
stably expressing FLAG-KEAP1 wild type or R320Q, VSV-UB1, FLAG-NRF2, and 
Venus-NPM1. Cells were first lysed in denaturing buffer (25mM Tris, 150mM NaCl, 1% 
SDS, 1mM EDTA), then diluted with 0.1% NP-40 buffer, followed by 
immunoprecipitation of NRF2. For in vitro ubiquitination studies, GST-tagged wild-
type Keap1 and the R320 mutant were over-expressed in Hi5 insect cells and purified 
using a glutathione affinity column. After removal of the GST tag, the proteins were 
further purified by ion exchange chromatography. For the in vitro ubiquitination assay, 
wild-type KEAP1 or the R320 mutant was mixed with recombinant human E1, UbcH5, 
CUL3-RBX1, ubiquitin and GST-tagged NRF2 NEH2 domain (GST-NRF2-Neh2) in 
buffer containing 40 mM Tris-HCl pH 8.0, 5 mM MgCl2, 2 mM DTT and 4 mM ATP.  
Ubiquitination was carried out at 37 °C and the products were analyzed by Western blot 
with anti-GST antibody. 
 
Immunostaining.  
HEK293T cells were cotransfected with the indicated plasmids and plated on 10 
μg/mL fibronectin-coated coverslips. Cells were fixed in 4% paraformaldehyde in 
cytoskeletal buffer for 15 minutes, and coverslips were mounted to slides using the 
Prolong Gold antifade reagent (Molecular Probes). Images were acquired using a Zeiss 
LSM5 Pascal Confocal Laser Scanning Microscope equipped with ×63/1.42 Oil PlanApo 
objective lenses. 
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Affinity purification and mass spectrometry.  
For streptavidin and FLAG affinity purification, cells were lysed in 0.1% NP-40 
lysis. Cell lysates were incubated with streptavidin or FLAG resin and washed 5 times 
with lysis buffer. The precipitated proteins were trypsinized directly on beads using the 
FASP Protein Digestion Kit (Protein Discovery).  
 
Protein identification, filtering, and bioinformatics.  
All raw data were converted to mzXML format before a search of the resultant 
spectra using SorcererTM-SEQUEST® (build 4.0.4, Sage N Research) and the 
Transproteomic Pipeline (TPP v4.3.1). Data were searched against the human 
UniProtKB/Swiss-Prot sequence database (Release 2011_08) supplemented with 
common contaminants, i.e. porcine (Swiss-Prot P00761) and bovine (P00760) trypsin, 
and further concatenated with its reversed copy as a decoy (40,494 total sequences). 
Search parameters used were a precursor mass between 400 and 4500 amu, up to 2 
missed cleavages, precursor-ion tolerance of 3 amu, accurate mass binning within 
PeptideProphet, semi-tryptic digestion, a static carbamidomethyl cysteine modification, 
variable methionine oxidation, and variable phosphorylation of serines, threonines, and 
tyrosines. False discovery rates (FDR) were determined by ProteinProphet and minimum 
protein probability cutoffs resulting in a 1% FDR were selected individually for each 
experiment. PeptideProphet/ProteinProphet results for each APMS experiment were 
stored in a local Prohits database. To determine an interacting protein's abundance 
relative to WT, prey spectral counts were bait normalized by dividing by the bait spectral 
count, followed by calculating the number of standard deviations from WT (similar to a 
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Z-score), where the standard deviation was computed for each prey individually. 
Unfiltered data and spectral count normalizations are provided as Supplementary Table 
S1. 
 
3.D. RESULTS 
3DB.1 Connecting cancer-derived KEAP1 mutations with NRF2 activity. 
A search of the literature and public domain revealed 213 somatic mutations in 
KEAP1, observed across 17 cancer types and multiple cell lines (Table S3.1). Mapping 
these mutations onto the KEAP1 primary amino acid sequence revealed a relatively 
uniform distribution of affected residues (Fig. 3.1.A). The distribution of mutations 
specifically found in squamous cell lung carcinoma further reiterated the lack of a 
‘mutation cluster region’ (Fig. 3.1.A, blue ovals). Of the 18 mutations found in lung 
SQCC, only two mutations resulted in a truncated protein product (N469fs and P318fs). 
The remaining 16 missense mutations included the addition of three new cysteine 
residues (G333C, W544C, and S243C), which might alter KEAP1 reactivity to 
electrophilic agents. One mutation, V155F occurred in two separate tumors, and 
interestingly, none of the mutations in KEAP1 were in residues that directly interface 
with NRF2 [19]. Given the importance of KEAP1-NRF2 signaling in cancer and our 
inability to predict the functional consequences of KEAP1 mutation, we cloned and 
comparatively evaluated each of the 18 lung SQCC mutations. 
 
To test whether cancer-derived mutations in KEAP1 affect NRF2-driven 
transcription, we used an engineered reporter system, wherein the luciferase gene is 
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expressed in a NRF2-dependent manner. Ectopic expression of wild-type KEAP1 
suppressed NRF2-dependent luciferase expression in HEK293T cells (Fig. 3.1.B). By 
comparison, the KEAP1 mutants displayed variable suppression of NRF2-driven 
transcription. Specifically, L231V, S224Y, and R71L suppressed NRF2 as well as wild-
type KEAP1; these genotypes represent possible passenger mutations within KEAP1.  By 
contrast, N469fs, P318fs, and G333C exhibited a null phenotype. Most surprisingly, of 
the 18 mutants examined, 12 retained partial ability to suppress NRF2-driven 
transcription. To further validate these data, we tested the panel in the KEAP1 mutant 
lung adenocarcinoma cell line A549 and in KEAP1 knockout mouse embryo fibroblasts 
(MEFs). In all three cell lines tested, we observed a largely consistent pattern of KEAP1-
mediated NRF2 suppression (Fig. 3.1.C and D).  These data further suggest that the 
genotype-phenotype relationships observed in HEK293T cells were not influenced by 
endogenously expressed wild-type KEAP1 protein.   
 
At its core, this work sought to isolate and functionally annotate specific KEAP1 
genotypes so that clinical correlations and predictions might be drawn from genome 
sequence data alone. As such, we tested whether the relative activities of each KEAP1 
mutant correlated with the expression of 15 NRF2 target genes within the lung SQCC 
TCGA cohort [1, 4]. Comparing luciferase activity (Fig. 3.1.B-D) to the NRF2 
transcriptional gene signature, we found that mutants that suppress like wild-type KEAP1 
associate with decreased NRF2 activity, whereas mutants unable to suppress NRF2 
correlate with increased NRF2 target gene expression (p=0.049; two-sided Wilcoxon 
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Rank Sum Test) (Fig. S3.1.A). Any attempt to further segregate mutations based on 
luciferase activity did not show a statistically significant correlation in the patient data.  
 
3.D.2 Biochemical characterization of the KEAP1 mutants. 
Next, we sought molecular insight into how specific mutations differentially 
impacted KEAP1 function. First, we determined whether the mutants expressed at levels 
similar to wild-type KEAP1, as non-synonymous mutations often impair protein folding 
to decrease protein stability. Transient expression from plasmid DNA indicates that the 
majority of KEAP1 mutants expressed at levels similar to wild-type protein (Fig. 3.2.A 
and S3.1.B). Further study is required to determine if the reduced expression of mutants 
R554Q, W544C, N469fs, P318fs, G480W, and G333C is due to altered protein or mRNA 
stability. To extend these data, the subcellular localization of KEAP1 and each KEAP1 
mutant was evaluated in HEK293T cells; all mutants exhibited a localization pattern 
indistinguishable from wild-type KEAP1 (Fig. S3.1.C).  
 
KEAP1 functions as a critical sensor of oxidative stress, wherein multiple 
cysteine residues act as biosensors for ROS and xenobiotic molecules [10, 20-21]. In 
cells, KEAP1 is thought to exist as a homodimer, creating a 2:1 stoichiometry with the 
NRF2 substrate. Following cysteine modification, either by reactive oxygen species or 
electrophilic agents like tert-butylhydroquinone (tBHQ), a conformational change within 
the KEAP1 homodimer creates an SDS-resistant form which is readily visualized under 
denaturing electrophoresis [22-23]. When treated with the pathway agonist, all 18 
mutants formed an SDS-resistant dimer, suggesting that the mutations do not impair 
 113 
dimerization (Fig. 3.2.A). To more rigorously test this, wild-type KEAP1 tagged with 
streptavidin binding peptide and the hemagglutinin epitope (SBPHA) was transfected into 
HEK293T cells stably expressing each FLAG-tagged KEAP1 mutant. FLAG affinity 
purification of the mutant protein, followed by Western blot for the HA-tagged wild-type 
protein was performed to evaluate KEAP1 dimerization (Fig. 3.2.B). Each KEAP1 
mutant protein retained the ability to homodimerize with wild-type KEAP1.  
 
The most likely molecular explanation for how KEAP1 mutations compromise its 
ability to suppress NRF2 is that the mutations impact either the KEAP1-NRF2 
association or the KEAP1-CUL3 association.  We evaluated whether the KEAP1 mutants 
maintain their ability to interact with endogenous CUL3. Affinity purification and 
Western blot analysis revealed that all of the KEAP1 mutants interact with CUL3 (Fig. 
3.2.C and S3.2.A). Further analysis is needed to determine if the subtle differences in 
CUL3 binding reflect differential affinities or expression variability (Fig 3.2.C, compare 
lanes 15, 16, 20). Next we determined if the KEAP1-NRF2 association was maintained 
among the mutants. Western blot analysis of affinity purified KEAP1 and mutant KEAP1 
protein complexes showed that the R554Q, W544C, N469fs, P318fs, and G333C mutants 
failed to bind NRF2 (Fig. 3.3.A and S3.2.B and S3.2.C). Surprisingly, however, the 
remaining 13 KEAP1 mutants retained NRF2 binding. Together, these data suggest that 
with the exception of R554Q, W544C, N469fs, P318fs, and G333C, SQCC-derived 
KEAP1 mutants maintain their ability to bind both NRF2 and CUL3. 
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Mass spectrometry-based proteomic analysis of KEAP1 revealed 42 high 
confidence associated proteins [4].  To gather a global perspective of how the mutations 
affect KEAP1 protein interactions, we performed two experiments.  First, we tested the 
association of 7 high confidence interacting proteins by affinity purification and Western 
blot analysis. The data show a distinct pattern among the KEAP1 mutants; those that do 
not bind NRF2 fail to bind several of the known interactors, including SLK, AMER1 
(WTX), MCM3, DPP3, and IKBKB (IKKβ) (Fig. 3.3.A and S3.2.C). Interestingly, all of 
these proteins contain an ETGE motif [4]. Two mutations, G480W and S224Y, show 
decreased binding to SLK, MCM3, and DPP3 as compared to NRF2 (Fig. 3.3.A, lanes 8, 
15). Second, we employed affinity purification and shotgun mass spectrometry to define 
and compare the protein interaction network for wild-type KEAP1 and the following 
mutants: R554Q, R320Q, R470C, G480W, G423V, D422N, G186R, S243C, and V155F 
(Fig. 3.3.B and S3.2).  The unbiased proteomic screens confirm the Western blot results 
and further expand the pattern of altered protein interactions.  
 
3.D.3 A class of KEAP1 mutants with increased NRF2 binding. 
We were particularly intrigued with a subset of mutants that consistently bound 
more NRF2 than wild-type KEAP1. Although we collectively refer to these mutants as 
the ‘superbinders’, relative protein affinity is not meant to be inferred. The superbinder 
mutants include R320Q, R470C, G423V, D422N, G186R, S243C and V155F (Fig. 3.3.A 
and S3.2.C, lanes 3, 5, 6, 9, 14, 16, 20). Label-free mass spectrometry comparing wild-
type KEAP1 and two of these mutants (R320Q and R470C) further confirmed an 
increased abundance of NRF2 with these mutant protein complexes as compared to wild-
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type KEAP1. For comparative purposes, we also performed quantitative proteomic 
analysis on two non-superbinder mutant proteins: R554Q, which cannot bind NRF2 and 
G480W, which binds NRF2 similarly to wild type (Fig. 3.3.B). With the exception of 
R554Q, in which no NRF2 was detected, both R554Q and G480W exhibited a protein 
interaction network similar to wild-type KEAP1 (Fig. 3.3.A).  
 
Despite an increased level of associated NRF2, the superbinder mutants were 
unable to suppress NRF2-mediated transcription of an artificial reporter gene (Fig. 3.1.B-
D). To confirm this using endogenous metrics of NRF2 activity, HEK293T cells, H2228 
cells or A549 cells were transiently transfected with wild-type KEAP1 or the superbinder 
mutants before Western blot analysis of NRF2 and the NRF2 target gene HMOX1. 
Transient expression of each superbinder strongly increased the levels of NRF2 and 
HMOX1 in the H2228 and A549 cell lines (Fig. 3.4.A and B). Subcellular fractionation 
of the HEK293T cells further revealed that KEAP1 superbinder expression increased the 
levels of NRF2 within the nuclear compartment (Fig. 3.4.C and S3.3). 
 
3.D.4 KEAP1 ‘superbinder’ mutants facilitate NRF2 ubiquitination but not degradation. 
Our functional and biochemical examination revealed 7 KEAP1 mutations that 
show significantly impaired ability to suppress NRF2, but yet unexpectedly bind more 
NRF2 than wild-type KEAP1. To gain further insight, we evaluated NRF2 protein 
turnover and ubiquitination following KEAP1 superbinder expression. Using a 
cycloheximide pulse-chase approach, NRF2 protein half-life was evaluated in HEK293T 
cells stably expressing: 1) wild-type KEAP1, 2) the R320Q superbinder, 3) R470C 
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superbinder, 3) R554Q which does not bind NRF2, or 5) G480W which behaves like wild 
type. The expression of R320Q or R470C dramatically stabilized the NRF2 protein as 
compared to wild type or G480W (Fig. 3.5.A). The increased NRF2 stability occurred as 
a result of binding R320Q or R470C, as unbound NRF2 in the flow-through eluate 
showed elevated levels but dynamic turnover (Fig. 3.5.B, compare flow-through to 
KEAP1 affinity purification). Together, these data suggest that the superbinder mutations 
within KEAP1 result in the stabilization of KEAP1-associated NRF2 and elevated levels 
of free NRF2, although the free NRF2 is still subject to dynamic turnover.  
 
Given the increased NRF2 association and protein stability, we hypothesized that 
R320Q and other superbinder mutants impair NRF2 ubiquitination. To test this, we 
performed two complementary experiments to evaluate NRF2 ubiquitination by wild-
type KEAP1 or the R320Q superbinder. First, Western blot analysis of 
immunoprecipitated NRF2, after denaturation, showed robust ubiquitination by both 
wild-type KEAP1 and R320Q (Fig. 3.5.C). Second, we performed in vitro ubiquitination 
reactions using purified proteins (Fig. 3.5.D). Remarkably, both experimental approaches 
demonstrate that wild-type KEAP1 and R320Q ubiquitinate NRF2. 
 
3.E. DISCUSSION 
With some latitude, we can classify the 18 KEAP1 mutations into three classes.  
First, the L231V, S224Y, and R71L mutations did not impact the KEAP1-NRF2 
association or the suppression of NRF2 activity. These mutations likely represent 
passenger events within KEAP1, at least with respect to NRF2. Second, and not 
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surprisingly, the frame shift mutations N469fs and P318fs, as well as G333C, R554Q and 
W544C did not bind NRF2 and did not suppress NRF2-mediated transcription. These 
genotypes represent null or near-null alleles.  Third, the remaining ten mutations fell 
within a hypomorphic phenotypic range, with suppression occurring between 30-60% of 
the wild-type KEAP1. Biochemically, the hypomorphic mutants displayed either reduced 
NRF2 binding or surprisingly, increased binding (the superbinders). 
 
Mutations in tumor suppressor genes often results in complete loss of protein 
expression or the expression of a truncated protein product [24]. It is therefore intriguing 
to consider why KEAP1 is rarely lost through genomic deletion, despite being located 
between the SMARCA4 and STK11 tumor suppressor genes on 19p (cBioPortal). A 
number of loosely connected observations raise the possibility that KEAP1 may exert 
cancer-relevant functions that extend beyond regulation of oxidative stress and NRF2. 
First, we found that many KEAP1 mutations result in a hypomorphic phenotype, rather 
than a genetic null. Second, in general, these hypomorphic mutations do not affect the 
global KEAP1 protein interaction network, suggesting that some KEAP1 protein 
interactions are retained in the absence of NRF2 suppression (Fig. 3.3.B). Indeed, 
KEAP1 associated proteins regulate a number of disparate cellular processes, including 
cell cycle, migration, and apoptosis [4, 25-33]. Third, while the presence and importance 
of NRF2-independent KEAP1 functions remain unknown, we and others have established 
that several KEAP1 interacting proteins drive NRF2 activation via a competitive binding 
mechanism [4, 18, 34-36]. Previously, we found that hypomorphic KEAP1 mutants can 
be further inactivated by the ETGE-containing competitive binding protein, DPP3.  
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Coupled with the observed over-expression of DPP3 in lung squamous cell carcinoma, 
these observations suggest that from the perspective of cancer cell fitness, the presence of 
a hypomorphic KEAP1 mutation may be more valuable than a null mutant. 
 
The most surprising and perhaps exciting discovery we observed was the 
identification of the ‘superbinders’—those that do not suppress NRF2-mediated 
transcription, exhibit enhanced binding to NRF2, and facilitate NRF2 ubiquitination. 
Three points of discussion are appropriate.  First, by what mechanism could the 
‘superbinder’ mutations affect NRF2 stability? Several possibilities exist, including an 
increased affinity between KEAP1 and NRF2 as a means to suppress substrate turn-over. 
Analogously, the expression of a superbinder variant SH2 domain antagonizes epidermal 
growth factor signaling via competitive inhibition [37]. That said, although studies are 
ongoing, the lack of a focal enrichment within the tertiary structure casts some doubt on 
this possibility (Fig. 3.5.E). CRL E3 ubiquitin ligases cycle through an active and 
inactive state, and this neddylation-dependent transitioning is required for substrate 
turnover. A second possibility is that the superbinder mutations simply slow the rate of 
CUL3 neddylation. Finally, proteasome-mediated substrate degradation requires several 
steps, including recognition, unfolding, translocation, and deubiquitination prior to 
proteolysis [38]. The striking observation that the enhanced NRF2 binding class of 
KEAP1 mutants ubiquitinate NRF2 suggests that the mutations functionally hinder one of 
the steps prior to proteolysis, but after ubiquitination. Here, immediate questions include 
whether the superbinder mutations affect the ubiquitin chain linkage on NRF2 or whether 
they perturb the interaction of KEAP1 with the proteasome. All three of these putative 
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mechanisms to describe the superbinder phenotype would inactivate KEAP1 and stabilize 
NRF2 in a manner consistent with the widely accepted “saturation model” [21]. 
Importantly, as the KEAP1 mutants described in this study exhibit hypomorphic 
phenotypes, the superbinders could represent a novel mechanism cancer cells employ to 
enhance cellular fitness without compromising all cellular functions of multifunctional 
proteins.  
 
Second, it is now widely accepted that elevated levels of NRF2 are associated 
with enhanced cell viability in several tumor types [7, 39-41]. Although we show that 
‘superbinder’ mutations result in NRF2 transcriptional activation, further studies are 
required to determine whether this KEAP1 mutant class is capable of enhancing cancer 
cell fitness in vivo, and whether that depends upon prolonged activation of NRF2. 
Additionally, given emerging evidence identifying other putative KEAP1 substrates in 
cancer-relevant pathways, such as IKKβ within NF-κB signaling [5, 42], investigating 
how—if it all—superbinder mutations impact these proteins could also have clinical 
significance. Looking at the full set of KEAP1 mutant tumors and the expression of 15 
NRF2 target genes, a marginal but statistically significant difference was observed 
between phenotypically ‘silent’ KEAP1 mutations and mutations which suppress 
KEAP1-driven NRF2 degradation (Fig. S3.1.A). Our attempts to more precisely correlate 
KEAP1 genotype with the cell-based phenotypic scoring failed to reach statistical 
significance. This is not surprising given the multitude of signaling and metabolic inputs 
that control KEAP1.     
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Third, from a structural perspective, we noted weak correlation between the 
tertiary position of a mutation and whether the mutation produced a KEAP1 superbinder 
(Fig. 3.5.E). Although speculative, the superbinder mutations appear to be localized at 
positions that might orient the relative position of IVR and KELCH domains; 
experiments testing this model are ongoing. Intriguingly, of the 181 missense mutations 
reported in KEAP1, 6 directly target the R320 superbinder residue, making it the most 
commonly affected amino acid in KEAP1 (Fig. 3.1.A).  Beyond the superbinder 
mutations, mapping all SQCC 19 mutations onto the KEAP1 structure failed to reveal a 
discernible pattern. Likewise, side-chain biochemistry for the mutations varies widely, 
including those within the superbinder class. Cysteine reactivity depends upon the local 
chemical microenvironment, which is largely dictated by the surrounding amino acids in 
a protein tertiary structure. Hence, for a cysteine-dependent biosensor like KEAP1, 
oncogenesis may partially suppress KEAP1 activity by selecting for mutations which add 
cysteines (S243C, G333C, R470C) or which reduce the relative pKa of existing 
cysteines, making them more sensitive to electrophilic attack [43]. Clearly, spatial 
constraints preclude the random addition of cysteines as a means to increase the reactivity 
of KEAP1 to oxidative stress. New cancer-derived cysteines of functional importance 
would occupy specific localizations within the folded protein. By extension of this idea, 
cancer-derived mutations that create ‘hyperactive’ cysteines within KEAP1 would be 
expected to produce a hypomorphic phenotype, as we have observed. Further study is 
needed to support these ideas, perhaps through the functional and biochemical 
characterization of the other 213 cancer-derived mutations in KEAP1.  The resulting data 
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may better enable predictions of genotype-phenotype relationships; based on the data 
presented here, it is not possible to derive functional conclusions from mutation location 
or residue substitution.  
 
In summary, we describe the functional and biochemical characteristics of 18 
mutations in the E3 ligase adaptor protein KEAP1, which were found in patient-derived 
lung squamous cell carcinomas.  We show that while most of these mutations maintain 
similar protein interactions to wild-type KEAP1, all but three exhibit hypomorphic or 
null activity with respect to suppression of NRF2-mediated transcription. Intriguingly, a 
subset of these mutations exhibit enhanced binding to NRF2 despite an inability to 
suppress NRF2 activity. Functional analysis of one of these mutants, R320Q, revealed 
that these mutants are still able to ubiquitinate NRF2, but appear to be unable to facilitate 
its degradation. Further studies are required to elucidate the mechanism of this class of 
KEAP1 mutations, including how they interact with the proteasome, as well as whether 
these mutants enhance viability of cancer cells via prolonged activation of NRF2. 
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Figure 3.1. Mutations in KEAP1 positively correlate with 
increased NRF2 activity. (A) Probability density function of 
KEAP1 mutations were approximated using kernel density estima-
tion. Mutations from SQCC are annotated above; mutations from 
the literature and public domain are represented by red hash 
marks. B-D, HEK293T cells (B), KEAP1 knockout mouse embryo 
fibroblasts (C), and A549 cells (D) were transiently transfected 
with the indicated plasmids along with constitutively expressed 
Renilla, and the NQO1 promoter driving Firefly luciferase. Cells 
were lysed and luciferase values were normalized to Renilla. Error 
bars represent SD from the mean over three biological replicates. 
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Figure 3.2. SQCC KEAP1 mutants retain the ability to 
dimerize and interact with the CUL3 E3 ubiquitin ligase. 
(A) HEK293T cells were transiently transfected with the 
indicated KEAP1 mutant plasmids, and treated with 50uM 
tert-butylhydroquinone (tBHQ) for one hour. Cells were lysed 
in RIPA buffer and expression of FLAG tagged mutants was 
analyzed by Western blot for the indicated proteins. (B) 
HEK239T cells stably expressing the indicated FLAG-tagged 
KEAP1 mutants were transiently transfected with SBPHA-
KEAP1. Cells were lysed in 0.1% NP-40 buffer and affinity 
purification of the FLAG-tagged protein complexes were 
analyzed by Western blot for the indicated proteins (SBP, 
streptavidin binding peptide; HA, Hemagglutinin). (C) 
FLAG-tagged protein complexes were affinity purified from 
HEK293T cells stably expressing the indicated KEAP1 
mutants and analyzed by Western blot for the indicated 
proteins.
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Figure 3.3. KEAP1 mutant proteins exhibit differential binding to 
interacting proteins. (A) HEK293T cells stably expressing the indicated 
KEAP1 mutants were treated with 10 uM MG132 for one hour, followed by 
FLAG affinity purification. Protein complexes of the FLAG-tagged mutants 
were analyzed by Western blot for the indicated proteins. Red lines indicate 
KEAP1 mutants that were analyzed by mass spectrometry as indicated in 
(B). B, APMS experiments were performed via affinity purification of 
streptavidin-tagged KEAP1 mutants from stable HEK293T cells followed 
by MS analysis of the bound proteins. Colors represent normalized spectral 
counts – semi-quantitative values that reflect protein abundance – from the 
APMS experiments. Proteins displayed are previously identified high-
confidence KEAP1 interactors.
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Figure 3.4. Expression of KEAP1 superbinder 
mutants enhances nuclear localization of NRF2. 
(A) H2228 cells were co-transfected with the indi-
cated FLAG-tagged KEAP1 mutant plasmid and 
NRF2 plasmid. Cells were lysed in RIPA buffer and 
analyzed by Western blot for the indicated proteins. 
(B) A549 cells were transiently transfected with the 
indicated KEAP1 mutants, and protein lysates were 
analyzed as described in (A). (C) HEK293T cells 
were transiently transfected with the indicated 
FLAG-tagged KEAP1 mutants. Cells were fraction-
ated into nuclear and cytoplasmic fractions and 
lysates were analyzed by Western blot for the indi-
cated proteins. 
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Figure 3.5. KEAP1 superbinder mutants cannot degrade NRF2 but maintain the 
ability to ubiquitinate NRF2. (A) HEK293T cells stably expressing the indicated 
FLAG-tagged KEAP1 mutants were transiently transfected with NRF2. Cells were 
treated with 50 ug/mL cycloheximide (CHX) for the indicated time, and cell lysates were 
analyzed by Western blot for the specified proteins. (B) HEK293T cells stably expressing 
the indicated FLAG-tagged KEAP1 mutants were treated with CHX as described in (A). 
FLAG affinity purification was performed to isolate protein complexes containing the 
indicated KEAP1 mutants. Whole cell lysate (INPUT), affinity purified complexes 
(IP:FLAG), and eluate (FLOWTHROUGH) were analyzed by Western blot for the 
indicated proteins. Values represent NRF2 quantitation relative to FLAG-tagged KEAP1 
expression. (C) HEK293T cells stably expressing either FLAG-tagged wild-type KEAP1 
or the R320Q mutant were transfected as described in (A). Cells were lysed under dena-
turing conditions, and then diluted to physiological pH in 0.1% NP-40 lysis buffer. 
Immunopurification of NRF2 was performed, and protein complexes were analyzed by 
Western blot. (D) Purified KEAP1 or the R320 mutant was mixed with recombinant 
human E1, UbcH5, CUL3-RBX1, ubiquitin and GST-tagged NRF2 NEH2 domain.  
Ubiquitinated NRF2 was detected by Western blot analysis. (E) The BTB and IVR 
domains of Keap1 (green) were modeled by the I-TASSER server. The BTB domain of 
the second copy of KEAP1 within the dimer is shown in cyan.  Superbinder residues are 
shown in red spheres. R320 is located in a predicted short linker connecting the BTB-
IVR domain and KELCH domain.  
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Figure S3.1. SQCC KEAP1 mutant characterization. 
(A) Activity of KEAP1 mutants, as based on luciferase activity 
(B-D), positively correlates with NRF2 target gene expression 
(P=0.049, Kruskal-Wallis test). (B) HEK293T cells were 
transiently transfected with the indicated FLAG-tagged KEAP1 
mutants and cell lysates were analyzed by Western blot. 
(C) HEK293T cells were transiently transfected with the indicated 
FLAG-KEAP1 mutants and stained for FLAG. Scale, 20 um. 
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Figure S3.2. KEAP1 mutants differentially bind to interacting proteins. 
(A) Validation of CUL3 siRNAs used to identify endogenous CUL3 band in Western 
blot. HEK293T cells were transfected with 10nM of the indicated siRNAs to CUL3. 
Cell lysates were analyzed by Western blot. (B) Mutant P318fs* (as seen in Figures 2, 
3A, 4A and B, S1, and S2C) was originally synthesized incorrectly. The correct mutant, 
P318fs, was synthesized and HEK293T cells were transfected followed by affinity 
purification for the tagged mutant protein. Cell lysates and affinity purified protein 
complexes were analyzed by Western blot to assess expression of the P318fs mutant, as 
well as NRF2 association. (C) HEK293T cells stably expressing the indicated FLAG-
tagged KEAP1 mutants were affinity purified and lysates were analyzed by Western 
blot. 
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CHAPTER IV: DISCUSSION 
 
4.A. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that 
inhibit NRF2 ubiquitination 
In this study we demonstrate that proteins within the KEAP1 interaction network 
containing the ETGE amino acid sequence comprise a group of interactors that compete with 
NRF2 for binding to the KELCH domain of KEAP1. Some of the proteins identified, such as 
DPP3, are able to indirectly activate NRF2 signaling via a competitive binding mechanism, 
which suggests that the low affinity DLG motif of NRF2 is displaced from KEAP1 by the 
ETGE motif of the competitive interactor. Data suggestive of a competitive binding 
mechanism for activation of NRF2 outside of oxidative stress has been supported for several 
years [1-4]. Our study conclusively demonstrates that the ETGE motif is overrepresented in 
the KEAP1 PIN, and that competitive binding is likely a ubiquitous mechanism for NRF2 
activation.  
 
4.A.1 Exploring the potential role of DPP3 expression in cancer 
With respect to DPP3, this paper further supports the notion that overexpression of 
DPP3 may have a defined role in cancer cell survival and progression. DPP3 is 
overexpressed in ovarian and endometrial cancer, and this expression correlates with poor 
prognosis for ovarian cancer [5, 6]. A role for aberrant KEAP1-NRF2 signaling in ovarian 
cancer progression, malignancy, and chemotherapeutic resistance has also emerged [7], and 
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although not directly linked in the literature, it is possible that DPP3 overexpression may 
contribute to enhanced NRF2 activation in this pathology. Prior to our study, expression of 
DPP3 had not been investigated in lung cancer. While further studies are required to confirm 
that DPP3 is overexpressed, particularly at the protein level, we were surprised to find a 
strong correlation between DPP3 mRNA expression and the NRF2 gene signature in the 
squamous cell lung carcinoma TCGA dataset (Fig. 2.7) [3, 8]. Co-expression of DPP3 with 
KEAP1 mutations from the TCGA sequencing consortium was also found to further activate 
NRF2-mediated transcriptional activity (Fig. 2.7.F). This data further supports both the 
competitive binding mechanism for NRF2 activation, as well as speculation that KEAP1 
mutations are largely hypomorphic with respect to suppression of NRF2. While the 
importance of overexpression of ETGE-containing proteins, like DPP3, in KEAP1 mutant 
backgrounds will be discussed in a later section, several other unanswered questions remain 
with respect to the function and regulation of both DPP3 and other ETGE-containing 
proteins. 
 
4.A.1.a Validation of the Competitive Binding Model 
The competitive binding model is built on the foundation that the ETGE motif of 
NRF2 is required for KEAP1 interaction, whereas the DLG motif is largely required only for 
ubiquitination and degradation [9-11]. When the DLG motif is “latched” onto one of the 
KELCH domains of the KEAP1 homodimer, the seven lysine residues within the N-terminal 
alpha helix of NRF2 are in a sterically favorable conformation for ubiquitination. 
“Unlatching” the DLG following an oxidative stress-induced conformational change in 
KEAP1 results in a sterically unfavorable condition for NRF2 ubiquitination. In the 
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competitive binding model, an ETGE-containing interacting protein would act similarly to 
cysteine modification by ROS to dissociate the DLG of NRF2 from KEAP1. While this 
model most ideally agrees with current data describing the KEAP1-NRF2 interaction—
namely by the relative affinities of DLG and ETGE, the observed maintained KEAP1-NRF2 
interaction under both oxidative stress [12-14], and expression of ETGE-containing proteins 
[1-4]—we cannot rule out the possibility that ETGE-containing proteins could completely 
liberate NRF2 from KEAP1. The following experiments may be performed to validate the 
competitive binding model. Note that DPP3 will be used as an example ETGE-containing 
protein in the following experiments, however any confirmed KEAP1 ETGE interacting 
protein could be used as well. 
 
In vitro binding to establish formation of a KEAP1-NRF2-DPP3 complex 
In vivo experiments suggest that DPP3 can bind to the KEAP1-NRF2 complex to 
form a trimer (Fig. 2.5.C); however, in vitro binding assays will validate the existence of this 
putative protein complex. Equal molar ratios of affinity-tagged KEAP1, NRF2, and DPP3 
should be incubated in buffered Tris using the following combinations: KEAP1 and NRF2 
only, KEAP1 and DPP3 only, KEAP1, NRF2, and DPP3, and NRF2 and DPP3 only. 
Purification of KEAP1 using the appropriate affinity bead resin, followed by Western blot 
analysis can be used to determine which protein complexes exist after in vitro binding.  
 
The expected results of this experiment would include identification of an interaction 
between KEAP1 and NRF2, as well as KEAP1 and DPP3. Additionally, this experiment will 
further establish the presence of a KEAP1-NRF2-DPP3 trimer, in agreement with the data 
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presented in Figure 2.5.C.  A follow-up to this experiment would include modulating levels 
of the DPP3, while keeping KEAP1 amounts consistent. For example, while holding KEAP1 
and NRF2 amounts constants, increasing amounts of DPP3 should be added, followed by 
affinity purification and analysis of protein complexes by Western blot. A non-specific 
protein such as GST, as well as DPP3-∆ETGE or the alanine mutant of DPP3 should be used 
as negative controls. One would expect to not see displacement of NRF2 until concentrations 
of the DPP3 are prohibitively high, while formation of a KEAP1-NRF2-DPP3 complex is 
observed in Western blot. It should be noted, however, that while in vitro binding 
experiments are more than sufficient for identifying a KEAP1-NRF2-DPP3 trimer, it does 
not account for the relative endogenous amounts of each protein. Consequently, titrating 
levels of DPP3 may entirely displace NRF2 from KEAP1, even if this is an extremely 
unlikely event in vivo. Collection of the flowthrough for each fraction after affinity 
purification may be used to determine if and/or when the DPP3 fully displaces NRF2, as 
NRF2 protein would be detectable in Western blot of the eluate. 
 
Surface Plasmon Resonance to identify KEAP1-NRF2-DPP3 complex, and determine the 
affinity of NRF2 and DPP3 for binding to KEAP1 
Surface Plasmon Resonance (SPR) is a technique that uses changes in reflected light 
to determine dynamics of biomolecular interactions in a liquid. Changes in the refractive 
index of the liquid at the surface of the crystal, which are detected because at least one 
protein component is immobilized on the surface, alter how light is reflected. Consequently, 
these changes in reflected light can be extrapolated to determine how protein-protein 
interactions are changing within the solution [15].  
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To identify dynamic changes in the KEAP1-NRF2 complex, purified KEAP1 should 
be immobilized on the surface of the SPR crystal. A solution containing purified NRF2 will 
be flowed over the surface, followed by a solution containing purified DPP3. Purified DPP3-
∆ETGE or alanine mutant may be used as negative controls. In a typical SPR assay in which 
the binding affinity of a protein or ligand is determined, after flowing solution containing the 
ligand over the SPR surface, a buffer solution is used to cause dissociation of the ligand. 
Flowing a solution with purified DPP3 over the SPR surface after NRF2 should not cause 
dissociation of NRF2 at low concentrations of DPP3, but will cause subtle changes in the 
refractive index of the liquid if DPP3 binds to KEAP1 with NRF2. If increasing molar 
solutions of DPP3 are used, however, one may expect to see an additional change in the 
refractive index, which may result from DPP3 inducing full displacement of NRF2. Although 
once again exceedingly high concentrations of DPP3 may fully displace NRF2 from KEAP1, 
which may be irrelevant at endogenous concentrations, utilization of SPR will further 
validate the formation of a KEAP1-NRF2-DPP3 complex. 
 
SPR can also be employed to determine the binding affinities of DPP3 and NRF2 for 
KEAP1. Similar to the experiments previously outline, KEAP1 would be immobilized on the 
SPR crystal surface, but rather than sequentially flowing solutions containing both NRF2 and 
DPP3 over the surface, a single solution containing only NRF2 or DPP3 would be used. To 
dissociate NRF2 or DPP3 from KEAP1 and find the Kd for each protein, a peptide designed 
by the Kuhlman lab (KEAP1 monobody), which binds to KEAP1 with greater affinity than 
the ETGE peptide of NRF2 [16] will be used. This experimental design can be further 
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augmented to establish whether DPP3 or NRF2 would dissociate first from KEAP1. Briefly, 
after flowing a solution of NRF2 and DPP3 over immobilized KEAP1 to establish a KEAP1-
NRF2-DPP3 trimer, a solution of increasing concentrations of KEAP1 monobody will 
flowed over the SPR surface. We would expect the lower affinity protein to dissociate first. If 
DPP3 dissociates prior to NRF2, we can conclude that endogenously, it is likely that DPP3 
only competes with the DLG motif of NRF2, thus supporting the competitive binding model. 
In the event NRF2 dissociates first, we will still be unable to refute complete displacement of 
NRF2 from KEAP1. This observation would not prove the competitive binding model 
incorrect; it would simply add an additional component in which complete dissociation of 
NRF2 is possible, and likely dependent on the relative affinities of NRF2 and the ETGE-
containing protein of interest.  
 
4.A.1.b Weighing the odds for a role of DPP3 peptidase activity in KEAP1-NRF2 signaling 
Interest in DPP3 as a regulator of KEAP1-NRF2 activity was two-fold. First, DPP3 
was already published as a pathway activator and our gain-of-function assays agreed with 
this observation. Second, it has a confirmed catalytic activity as a peptidase [17-19], and is 
therefore a potential therapeutic target if the peptidase activity is required for activation of 
NRF2. Particularly intriguing was that the peptidase activity of DPP3 was specific to the N-
terminus of a substrate. The DLG motif of NRF2 comprises residues 29-31, and is largely 
considered to be more critical for regulation of NRF2 degradation and stabilization than that 
ETGE motif [9, 11]. In the event DPP3 is a processive peptidase, it could cleave residues 
from the N-terminus of NRF2 through the DLG motif. Should this occur, even if DPP3 
dissociated from KEAP1, the N-terminus of NRF2 could not re-bind to KEAP1, thus 
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perpetuating NRF2 activation via the saturation model. While this model would not likely 
affect initial activation of NRF2, as this occurs via competitive binding and displacement of 
the DLG, it could prolong activation of NRF2, particularly if DPP3 interaction with and 
dissociation from KEAP1 does not permanently alter tertiary complex structure like is 
thought to occur with cysteine modification [20, 21]. 
 
Several biochemical and structural properties of DPP3 support the hypothesis that its 
catalytic activity could possibly impact modulation of KEAP1-NRF2 pathway activity. First, 
the substrate binding cleft of DPP3 is very large, which indicates it could accommodate a 
diverse set of substrates [22]. Furthermore, it has been proposed that the large binding pocket 
of DPP3 may be indicative of substrate specificity being attained by interaction with other 
proteins [22, 23]. Interaction with KEAP1 via the ETGE motif could mediate the 
“specificity” required for NRF2 to be a DPP3 substrate. Second, another factor mediating N-
terminal peptidase specificity is recognition of a four to five amino acid stretch in the 
substrate that occurs around a scissile bond in the active site of the peptidase [23, 24]. Unlike 
most peptidases in the same family, DPP3 does not have this requirement, further suggesting 
that DPP3 has the potential to act on a wide range of substrates. Finally, the DLG and ETGE 
regions of NRF2 are thought to be largely unstructured. Consequently, accommodating the 
region containing the DLG into the substrate binding cleft of DPP3 is likely more easily 
attained than if the region had a defined secondary structure, such as the alpha helix that 
separates the DLG and ETGE.  
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The experiments presented in Chapter Two suggest that the catalytic activity of DPP3 
is not required for activation of NRF2 (Fig. 2.3.I and 2.4.C). One potential criticism of this 
data, however, is that all of the experiments were performed at steady state. To more 
rigorously test if the catalytic activity of DPP3 catalytic activity affects NRF2 stability, a cell 
extract-based degradation assay could be employed. Incubating S35-labeled NRF2 with 
KEAP1 and either wild-type DPP3 or the Y318F catalytic mutant would allow for DPP3 to 
cleave the N-terminus of NRF2 once bound to KEAP1 [4]. Following exposure to DPP3, the 
labeled NRF2 would be added to cell free extracts for determination of half-life. If DPP3 
cleaves NRF2, a prolonged NRF2 half-life would be expected in samples treated with wild-
type DPP3 compared to the Y318F mutant. A caveat of this assay is that a prolonged NRF2 
half-life could also be indicative of a DPP3-mediated cleavage event in KEAP1 that renders 
KEAP1 inactive. To help resolve this issue, incubation of recombinant NRF2 with wild-type 
or Y318F mutant DPP3 prior to addition to the cell-free extract can be done. Additionally, 
mass spectrometry-based techniques, such as N-terminal specific labeling with a reagent like 
N-hydroxysuccinimide [25], of NRF2 pre- and post-incubation with DPP3 would reveal N-
terminal cleavage events specific to NRF2.  
 
In addition to our experimental data suggesting the catalytic activity of DPP3 does 
not enhance NRF2 activity, additional biochemical characteristics of DPP3 suggest the 
probability of NRF2 being a substrate is very low. First, currently the only known 
endogenous substrates of DPP3 are enkephalins, a family of pentapeptides that modulate 
nociception [26-28]; cleavage of enkephalins by DPP3 results in their subsequent 
degradation [26]. DPP3 cleaves strictly at the N-terminus and only two amino acid residues 
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at a time [22, 23]. Coupled with the proposed substrates consisting only of pentapeptides, it is 
unlikely that DPP3 acts processively. In addition, despite having a comparatively large 
substrate binding cleft, the accepted length of peptides that can fit in this pocket is limited to 
3-10 residues, and the C-terminus of a putative substrate will encounter much greater steric 
hindrance due to the shape of the cleft [23, 29]. The alpha helix of NRF2 begins at residue 
39; further structural studies would be required to validate this secondary structure would not 
fit within the binding cleft of DPP3, although the scenario is unlikely.  
 
4.A.1.c Investigating whether DPP3 enhances cell viability 
Overexpression of NRF2 is associated with enhanced cell viability in response to 
chemotherapeutic insult [30-32], and similarly, siRNA-mediated knockdown of NRF2 
enhances sensitivity to chemotherapeutic insult [32]. As DPP3 activates NRF2-mediated 
transcription, it stands to reason that overexpression of DPP3 should also enhance cell 
viability.  
 
To establish if DPP3 can mediate cell viability in a NRF2-dependent manner, DPP3 
wild-type and DPP3-∆ETGE should be overexpressed, followed by treatment with several 
chemotherapeutics, such as doxorubicin, cisplatin, and etoposide. Cell viability may be 
assessed with multiple assays, including MTT and caspase 3/7, as well as Western blot 
analysis for apoptotic markers (cleaved PARP, caspase-3). In addition to cell viability, assays 
that measure cytosolic redox should be used to evaluate whether DPP3 overexpression also 
reduces global intracellular ROS levels. These assays would be set up similarly to viability 
assays, but use of oxidation-sensitive dyes, such as DCF (dichlorofluorescein), are used to 
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assess redox status. Although the model of DPP3-mediated NRF2 activation acknowledges a 
phenotype associated with DPP3 overexpression, endogenous DPP3 may promote some level 
of basal NRF2 activation. A role for endogenous levels of DPP3 supporting a basal level of 
NRF2 activation is supported by Figure 2.6, which demonstrates siRNA-mediated 
knockdown of DPP3 reduces NRF2-mediated transcription. For completeness, siRNA-
mediated knockdown of DPP3 should also be assessed in the previously described assays for 
its potential to decrease cell viability and intracellular redox potential.   
 
4.A.1.d Exploring the role of DPP3 in tumorigenesis: would a mouse model be worthwhile?  
An emerging model of cancer progression states that mutations in “driver genes” that 
support cellular proliferation and growth compound to ultimately result in a malignant tumor. 
Importantly, a “gateway” mutation must first occur, after which subsequent mutations further 
promote tumorigenesis [33]. Collectively, this model suggests that malignant progression is 
not the result of one mutation, but rather the combination of several mutagenic events that 
increase global cancer cell fitness. In addition to mutation, other genetic events, like copy 
number amplification, translocation, and promoter modifications, also contribute to 
tumorigenesis. These genes may be referred to as “epi-driver genes”, rather than “mut-driver 
genes”. Typically, epi-driver genes are not frequently mutated, and mut-driver genes are not 
associated with epigenetic events [33]. Intriguingly, NRF2 appears to fall into a classification 
as both an epi-driver gene and a mut-driver gene. Several cancers have been found to have 
mutations in the DLG or ETGE motif [34-36], suggesting NRF2 has a role as a mut-driver 
gene. Other cancers define NRF2 as an epi-driver gene, as KEAP1 inactivation or NRF2 copy 
number amplification result in increased expression of NRF2 [37-42]. Still, other cancers 
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such as lung cancer, exhibit both activating mutations in NRF2, in addition to NRF2 
overexpression [8, 39-41, 43-46].  
 
While the exact role that NRF2 plays in tumorigenesis has yet to be fully elucidated, 
several studies demonstrate that NRF2 expression promotes cell survival and tumor growth, 
particularly with concurrent KRAS mutations [47, 48]. The growing acceptance of the 
competitive binding model as a biologically relevant mechanism for activating NRF2 
provides an interesting opportunity to investigate how NRF2 as a driver gene is affected by 
other genetic events to contribute to tumor progression. DPP3 expression correlates with 
both poor prognosis in ovarian cancer [5] and NRF2 gene signature in squamous cell lung 
cancer [3]; however, based on the data presented in Chapter Two, it is unlikely that DPP3 
overexpression alone will be able to promote tumorigenesis. Introducing DPP3 into a mouse 
xenograft model that couples NRF2 overexpression with a gateway mutation, such as an 
activating KRAS mutation, could provide valuable insight into how ETGE-containing 
proteins affect cancer cell survival in vivo.  
 
Incorporating DPP3 overexpression into a cancer model with NRF2 would aid in 
elucidating whether correlations with DPP3 and poor prognosis, such as that in ovarian 
cancer, are indicative of an underlying mechanism of promoting cancer cell fitness. 
Performing these experiments in Nrf2 knockout animals would also confirm that any 
correlation between DPP3 expression and prognosis is indeed NRF2-dependent. 
Furthermore, linking DPP3 overexpression with NRF2 activation in a tumor model would 
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certainly establish a greater clinical relevance for the competitive binding model, and provide 
precedence for potentially investigating other ETGE-containing proteins in a similar manner.  
  
4.A.2 The ETGE-dependent interactors: Novel substrates, KEAP1-NRF2 pathway 
modulation, and NRF2-independent functions of KEAP1 
The experiments presented in Chapter Two introduce several other ETGE-containing 
proteins, some of which may have a functional role in activation of NRF2 signaling, or in 
modulating putative NRF2-independent functions of KEAP1. An interesting observation of 
the KEAP1 PIN, particularly with respect those proteins that contain an ETGE motif, is that 
these proteins function in a highly diverse set of cellular functions. It should be noted that 
whereas some of these functions could be linked to signal transduction pathways and 
processes known to be associated with KEAP1 and NRF2, still others impact biological 
pathways that currently have no correlation to KEAP1-NRF2 signaling. Whether the 
endogenous function of these interacting proteins impacts, or is impacted by, interaction with 
KEAP1 requires further study. Validation of proteins such as TSC22D4 and SLK as NRF2 
activators may not only expand the growing list of competition-based pathway agonists, but 
also may illuminate currently unappreciated pathways in which NRF2 activation has a role. 
Proteins like WDR1, FAM117B, and MCM3, which appear to not significantly affect NRF2 
activation, may be suggestive of NRF2-independent functions of KEAP1.  
 
4.A.2.a Are ETGE-containing interactors novel KEAP1 substrates? 
There are currently five known substrates for KEAP1: NRF2, IKKβ, BCL-2, BCL-
XL, and PGAM5. With the exception of BCL-2, which interacts with KEAP1 via three 
 147 
residues that do not share homology to an ETGE motif [49], substrates bind to KEAP1 via an 
ETGE motif, or in the case of BCL-2, indirectly through PGAM5 [50]. Consequently, it is 
reasonable to speculate that some of the ETGE-containing proteins within the KEAP1 PIN 
are novel substrates of KEAP1. Determining which, if any, of these ETGE proteins are novel 
substrates of KEAP1 will provide valuable clues into which cellular pathways are affected by 
KEAP1-NRF2 signaling, or by NRF2-independent functions of KEAP1. Several experiments 
can be conducted to facilitate validation of novel KEAP1 substrates: 
 
Investigating enhanced stability of ETGE-containing proteins under proteasome inhibition or 
siRNA-mediated knockdown of KEAP1 
Treating cells with a proteasome inhibitor such as bortezomib or MG132, or 
transfecting cells with siRNAs to KEAP1 causes stabilization of NRF2. This same approach 
may be used to determine if any of the ETGE-containing proteins are stabilized in a manner 
similar to NRF2. A complement to this experiment would be detecting levels of ETGE-
containing protein expression in Keap1 knockout mouse embryo fibroblasts (MEF). 
Expression of NRF2 is elevated in Keap1-/- MEFs, and the expectation is that other ETGE 
proteins would also exhibit elevated expression in this cell line if they were KEAP1 
substrates. Finally, it is well established that treatment with proteasome inhibitors increases 
the amount of NRF2 that is bound to KEAP1 following KEAP1 immunoprecipitation. Any 
ETGE-containing proteins that are novel KEAP1 substrates should have the same pattern of 
increased interaction with KEAP1 following inhibition of the proteasome. Although NRF2 
has a short half-life, which allows for relatively rapid detection of stabilization after 
proteasome inhibition, it should not be assumed that other putative KEAP1 substrates exhibit 
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the same rapid turnover. Consequently, several time points should be selected to evaluate the 
half-life of putative substrates, as well as changes in intracellular levels following 
proteasome inhibition to account for slower turnover. 
 
Determining half-life and KEAP1-mediated ubiquitination of ETGE-containing interactors 
The experiments described above address only steady state expression of ETGE 
proteins; however, to fully vet the possibility that these proteins are novel KEAP1 substrates, 
investigating half-life and ubiquitination status is required. Determining whether the half-life 
of ETGE proteins is affected by pathway modulation can be accomplished with a pulse-chase 
experiment in which de novo protein synthesis is inhibited with cycloheximide. For example, 
siRNA-mediated knockdown of KEAP1 should increase the half-life of an ETGE protein that 
is a substrate of KEAP1. However, the half-life of a ∆ETGE mutant would not be expected to 
change following knockdown of KEAP1.  
 
Lastly, should any of the ETGE-containing proteins show promise as a KEAP1 
substrate, analysis of KEAP1-dependent ubiquitination should be performed. Two 
approaches may be taken—an in vitro ubiquitination assay, and cell-based ubiquitination. For 
analysis of cell-based ubiquitination, the ETGE protein of interest, tagged ubiquitin, and 
KEAP1 or a negative control protein are transfected into KEAP1-deficient cells, such as 
Keap1-/- MEFs. Following a brief treatment with MG132, cells are lysed under denaturing 
conditions. After titrating the lysate back to physiological pH, ubiquitinated protein 
complexes of the ETGE-containing protein can be analyzed by either immunoprecipitation of 
the ETGE protein, or by affinity purification of the tagged ubiquitin. Substrates of KEAP1 
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should only show ubiquitin laddering in cells that were transfected with KEAP1, and not the 
negative control protein. A complementary assay to this would be to perform the same 
experiment in cells with endogenous KEAP1. Rather than comparing transfected KEAP1 or 
negative control protein, siRNAs to KEAP1 or a scramble control are compared. Conditions 
in which KEAP1 siRNAs are used are expected to have reduced ubiquitination of ETGE 
proteins that are KEAP1 substrates.  
 
An in vitro ubiquitination assay should also be performed to eliminate any 
experimental artifacts that may occur due to other endogenous proteins present in cell lysate. 
Briefly, recombinant CUL3, KEAP1, ubiquitin, the ETGE protein of interest, and an E1 and 
E2 are combined and incubated to allow ubiquitination to occur, followed by 
immunoprecipitation of the ETGE protein. Ubiquitin-dependent laddering of the ETGE 
protein should only occur when KEAP1 is included in the reaction. 
 
4.A.2.b Novel regulators of KEAP1-NRF2 signaling: TSC22D4 and SLK 
In addition to DPP3, TSC22D4 and SLK were the only ETGE-containing proteins 
that also activated NRF2-mediated transcription. The ability to activate NRF2 is where any 
commonalities stop, however, as these proteins have very disparate cellular functions from 
each other. Further study is required to both validate TSC22D4 and SLK as novel activators 
of KEAP1-NRF2 signaling, as well as determine whether KEAP1 interaction impacts cell 
function. 
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TSC22D4: a transcription factor with links to modulation of metabolic pathways 
TSC22D4 is part of the larger TSC22D leucine zipper transcription factor family, and 
collectively these proteins act in several diverse cellular functions. For example, TSC22D1 
exhibits tumor suppressor activity, and TSC22D3 antagonizes cellular proliferation in an 
AP1- and NFκB-dependent manner [51-53]. Functional roles for TSC22D4 are largely 
unknown; however, studies demonstrate that TSC22D4 plays a role in modulating apoptosis 
in neuronal cells [52], as well as lipid metabolism. Specifically, TSC22D4 is induced in 
mouse models of cancer cachexia and impair lipogenesis in liver [53]. Furthermore, 
TSC22D4 was found to regulate several lipogenic genes in both mouse and human 
hepatocytes.  
 
Follow-up studies investigating whether the metabolic changes induced by TSC22D4 
can be linked to the NRF2-mediated metabolic reprogramming employed by cancer cells 
could provide insight into how TSC22D4 acts as a positive regulator of NRF2 signaling. As 
depicted in Figure 2.2.F, overexpression of TSC22D4 activates NRF2. Consequently, 
siRNAs to TSC22D4 should be used to determine if suppression of NRF2-mediated 
transcription occurs following knockdown of TSC22D4. Furthermore, gain-of-function and 
loss-of-function for TSC22D4 followed by quantitative PCR for metabolic genes regulated 
by NRF2, including G6PD, PGD, TKT, ME1, and TALDO1, can be performed to determine 
if TSC22D4 contributes to NRF2-dependent metabolic changes.  
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SLK: an ETGE-independent activator of NRF2-mediated transcription 
While only three of the ETGE-containing proteins—DPP3, TSC22D4, and SLK—
activate NRF2 above control, all of the ETGE proteins have a subtle but reproducible 
reduction in NRF2 transcriptional activity when the ETGE motif is deleted (Fig. 2.2.F). The 
one exception is SLK (Ste20-like kinase), which not only still activates the NRF2 reporter 
when the ETGE motif is deleted, but also does so to a greater degree than wild-type SLK 
(Fig. S.2.1.A). Intriguingly, SLK-∆ETGE cannot bind to KEAP1, despite maintaining the 
ability to activate NRF2 (Fig. 2.2.E). The only other ETGE protein we investigated that 
exhibits a similar pattern of activation is NRF2 itself, which begs the question of whether 
SLK is the ETGE-containing protein most likely to be a novel KEAP1 substrate. In addition 
to potentially acting as a KEAP1 substrate, SLK has been implicated in several biological 
processes, which warrant investigation into any role SLK may have in modulating KEAP1-
NRF2 signaling.  
 
Ste20-like kinase (SLK) is a serine/threonine kinase that has physiological roles 
primarily linked to regulating cytoskeletal dynamics. Co-immunoprecipitation experiments 
show that SLK interacts with tubulin and polymerizing microtubules during normal adhesion 
and cell spreading [54]. Overexpression of SLK disrupts actin stress fibers, and decreases 
focal adhesion stability [54-56]. In addition to regulating the cytoskeleton, SLK has been 
found to induce apoptosis in some cell lines [57, 58], and its expression and activation is 
increased during kidney development [59], as well as acute ischemic injury in the kidney [59, 
60]. Furthermore, SLK associates with the mitotic spindle during mitosis [61, 62], and 
siRNA-mediated knockdown or use of a kinase dead construct have been shown to inhibit 
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cell cycle progression, particularly through G2 [61]. Downstream signaling targets of SLK 
include upregulation of c-Jun N-terminal kinase (JNK), p53, and p38 MAPK cascades [56, 
57, 63]. Collectively, beyond regulation of the cytoskeleton, studies of SLK demonstrate that 
it is capable of mediating cellular processes involved in cell survival during development, 
injury, and repair.  
 
The emerging functional roles that SLK has in regulating conditions of cellular stress 
are particularly appealing considering that SLK also activates NRF2-mediated transcription. 
Moreover, several cytosolic kinases have been found to phosphorylate NRF2 and modulate 
NRF2 function, including the SLK downstream target p38 MAPK kinases. To investigate 
whether the kinase activity of SLK impacts NRF2 signaling, a kinase dead mutant of SLK 
can be used in luciferase-based assays for NRF2 function. Furthermore, in vitro 
phosphorylation experiments comparing wild-type and kinase dead SLK will establish 
whether NRF2 is a kinase substrate. Some debate exists as to whether p38 MAPK-mediated 
regulation of NRF2 is activating or suppressing [64-66]. Similar experiments as those 
previously described can be performed to determine if 1) SLK acts upstream of p38 MAPK 
kinases rather than directly on NRF2, and 2) whether activating effects of p38 MAPK 
signaling on NRF2 occur via SLK. 
 
Despite an appealing link between SLK-mediated regulation of stress pathways and 
activation of NRF2, we cannot rule out the possibility that the KEAP1-SLK interaction is 
affecting cytoskeletal dynamics in some manner. Gain-of-function and loss-of-function 
studies for KEAP1 to determine if modulating KEAP1 expression can affect cytoskeletal 
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phenotypes associated with SLK function, including focal adhesion stability and turnover, 
actin network stability, and actin stress fiber stability should be performed for completeness. 
Furthermore, with respect to both TSC22D4 and SLK, it is possible that activation of NRF2 
is entirely independent of the function of either gene, and, like DPP3, is due solely to the 
competitive binding model. More thorough study of whether SLK and TSC22D4 are found to 
be overexpressed in cancer, as we found with DPP3, will help parse the likelihood that the 
observed interactions between KEAP1 and these proteins is due to competitive binding only, 
or if they also serve to regulate other functions of KEAP1 and NRF2.  
 
4.A.2.c NRF2-independent functions of KEAP1: does KEAP1 regulate cell cycle? 
The KEAP1 protein interaction network consists of a variety of proteins with very 
disparate cellular functions; however, we found several proteins involved in cell cycle 
regulation. The cell cycle-related proteins, including minichromosome maintenance complex 
component 3, (MCM3), MAD2 mitotic arrest deficient-like 1 (MAD2L1), and 
minichromosome maintenance complex binding protein (MCMBP), comprise the only group 
of proteins from the KEAP1 PIN with obviously linked functions. Consequently, we are 
particularly intrigued by the possibility that KEAP1 has a defined role in cell cycle regulation 
and progression. MCM3 is one of several MCM proteins in the pre-replication complex, 
which is critical for initiation of genomic replication [67-69]. While MCMBP is not an 
ETGE-containing protein, it is a validated component of the KEAP1 PIN, and also 
participates in the replication complex with MCM3 [70, 71]. Finally, MAD2L1 is a 
component of the mitotic spindle assembly checkpoint, which inhibits anaphase until 
chromosomes are properly aligned on the metaphase plate [72-74]. Collectively, if one or all 
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of these proteins are either novel substrates of KEAP1, or use interaction with KEAP1 for 
their functional roles, it suggests that KEAP1 may have a previously unappreciated role in 
cell cycle progression. 
  
Experiments to determine whether MCM3 and MAD2L1, the two ETGE-containing 
proteins, are putative KEAP1 substrates as described above, may be complicated by the fact 
that those experiments are performed in a heterogeneous cell population. Synchronizing the 
cell population with a treatment such as nocodazole, prior to performing experiments correct 
for this possible impediment, because it will provide a homogeneous population of cells for 
each phase in the cell cycle.  Identifying whether MCM3 and MAD2L1 are substrates in 
synchronized cell populations will require immunoprecipitation of KEAP1 during various 
stages of the cell cycle. The results of these co-immunoprecipitation assays will not only 
potentially illuminate if MCM3 and MAD2L1 are KEAP1 substrates, but the findings will 
also indicate whether the KEAP1-MCM3 and KEAP1-MAD2L1 interaction is cell cycle 
dependent. Additionally, Western blot analysis of synchronized cell populations will reveal 
whether KEAP1 expression is regulated in a cell cycle-dependent manner.  
 
In conjunction with identifying protein interaction dynamics during the cell cycle, 
modulation of KEAP1 protein levels by siRNA-mediated knockdown, or overexpression will 
illustrate whether KEAP1 expression is required for normal cell cycle progression. 
Thymidine incorporation assays, which are a direct measure of cell proliferation and DNA 
synthesis during mitosis can be employed. Briefly, cells stably expressing KEAP1, or 
transfected with siRNAs to KEAP1 will be arrested with nocodazole. Upon release following 
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nocodazole washout, synchronized cells will be analyzed for thymidine incorporation. If 
modulation of KEAP1 expression impacts cell cycle progression in some manner, the 
expected results would be increased or decreased thymidine incorporation in KEAP1 gain-of-
function or loss-of-function samples compared to negative control.  
 
4.B Cancer-derived Mutations in the KEAP1 Ubiquitin Ligase Impair NRF2 
Degradation but not Ubiquitination 
Chapter Three describes the characterization of 18 mutations in KEAP1 that were found 
in patient-derived squamous cell lung carcinomas. Beyond determining that these mutants are 
largely unable to promote NRF2 degradation and suppress NRF2 transcriptional activity, 
several additional observations were made: 
a) Mutations in KEAP1 are primarily hypomorphic with respect to modulation of NRF2 
activity. 
b) With few notable exceptions, the protein interaction networks of KEAP1 mutants are 
comparable to wild-type KEAP1. 
c) The relative expression of KEAP1 mutant alleles compared to wild-type varied, 
although at this time it is not known whether these differences are due to mRNA or 
protein instability. 
d) KEAP1 mutants can be grouped into several general classes based on suppression of 
NRF2 activity and biochemical characteristics. 
Not only may these observations impact how KEAP1-NRF2 signaling is viewed as a cancer-
relevant pathway, but also our findings, as well as similar studies, may alter how mutations in 
cancer are approached from a global therapeutic perspective. Specifically, our data suggests 
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that any given group of mutations in a given gene are not equal with respect to the functional 
consequence each mutation has on cancer cell fitness. Consequently, the context in which a 
mutation occurs—including temporal regulation, relative allelic expression, and incidence of 
other mutations or expression differences of interacting proteins—is likely more important 
than the a single mutation alone.  
 
4.B.1 Mutations in KEAP1 are largely hypomorphic 
A particularly interesting, and somewhat surprising, observation regarding mutations 
in KEAP1 was that 13 of the 18 mutations exhibited hypomorphic activity with respect to 
suppression of NRF2-mediated transcription. The two frameshift mutations (N469fs and 
P318fs), both of which result in a truncated protein product, behave as an inactive protein. It 
should be noted, however, that the most “null” phenotype of these mutants was observed in 
HEK293T cells, which have an intact endogenous KEAP1-NRF2 pathway. The other two 
cell lines tested, A549 and Keap1-/- MEFs, have a hypomorphic and absent endogenous 
pathway, respectively. Further study is required to determine if the two truncating mutations 
are dominant negative. Not only is there a precedent for mutations in KEAP1 to act as 
dominant negative proteins [75], but the relatively low expression of the truncation mutations 
(Fig. 3.2.A and S3.2.B) paired with the nearly null transcriptional phenotype (Fig. 3.1.B-D) 
even in cells with intact KEAP1-NRF2 signaling, suggest these mutations may be dominant 
negative mutants as well. Only three of the mutants, L231V, S224Y, and R71L, as well as an 
incidental incorrectly made mutation P318L, suppress NRF2 as well as wild-type KEAP1. 
These mutations likely represent silent, or “passenger” mutations. 
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The remaining 13 mutations cannot suppress NRF2-mediated transcription as well as 
wild-type KEAP1, but also fall short of a null phenotype or the GFP negative control. We 
consider these mutations to be hypomorphic. As depicted in Figure 3.2.A, the relative 
stability of the KEAP1 mutants is variable as evidenced by some differences in protein 
expression. Therefore, we cannot rule out the possibility that the observed differences in 
transcriptional assays may be due to discrepancies in expression. By and large, however, 
most of the mutants express as well as wild-type KEAP1, so we are reasonably comfortable 
defining these mutations as hypomorphic.  
 
As stated in Chapter Three, the relative abundance of hypomorphic mutations in 
KEAP1 within the lung squamous cell carcinoma cohort begs the question of why there 
seems to be a preference for hypomorphic mutations over null mutations. Indeed, the 
abundance of hypomorphic mutations is unlikely to be related to some requirement for basal 
NRF2 suppression, as activating mutations in NRF2 occurred in 19% of the same lung 
squamous cell cohort in which mutations in KEAP1 were found [8]. Furthermore, it is well 
established that constitutive NRF2 activity promotes cancer cell survival and proliferation [7, 
31, 32, 34, 36, 44, 46, 76-81], so it stands to reason that alternative forces may be driving the 
“decision” of a cancer cell to not fully activate NRF2 via complete inactivation of KEAP1. 
These somewhat counterintuitive observations regarding KEAP1 mutation status can be 
reconciled by considering some putative advantages these hypomorphic mutations have by 
maintaining interaction with other binding partners, as well as accounting for potential 
NRF2-independent functions of KEAP1.  
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As shown in Figure 2.7.E and F, co-expression of DPP3 can enhance NRF2-mediated 
transcriptional activity in a KEAP1 mutant background. Not only does this data further 
support the notion that these KEAP1 mutations are hypomorphic, but it also introduces the 
possibility that any deficiency in augmented NRF2 activity from KEAP1 hypomorphic 
mutation can be compensated for by modulating expression of other competitive binding 
proteins. This hypothesis is further supported by the observation that DPP3 is overexpressed 
in lung squamous cell carcinoma (Fig. 2.7.A-D). Intriguingly, recent evidence suggests 
DPP3 is also overexpressed in head and neck squamous cell carcinoma (Fig. 4.1), which also 
shows significant mutation of KEAP1 and NRF2. These observations imply that 
overexpression of ETGE competitive binding proteins may be a ubiquitous mechanism of 
augmenting NRF2 activity in KEAP1 hypomorphic tumors. The growing number of 
competitive binding proteins with defined roles in cancer survival and proliferation, as well 
as specific examples of known competitive binding proteins, like DPP3, being overexpressed 
in cancers with dysregulated KEAP1-NRF2 activity undoubtedly warrants further 
exploration of how competitive binding proteins may affect hypomorphic KEAP1 
phenotypes.  
 
While interaction with competitive binding proteins enables further activation of 
NRF2 signaling in hypomorphic KEAP1 backgrounds [3], it is likely this means of activation 
represents only a compensatory mechanism for hypomorphic phenotypes, rather than an early 
driving force behind selection. Alternative substrates of KEAP1 may account for the 
proposed selective advantage of hypomorphic mutations, as alternative substrates are the 
most likely source of NRF2-independent functions of KEAP1. In support of this hypothesis 
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is the observation that mutations in KEAP1 rarely occur in residues that interface with NRF2, 
which are presumably the same residues that would interface with alternative substrates that 
also bind via an ETGE motif. As shown in Table S3.1, only 4 of the 213 annotated 
mutations—R483H, R415G, S555-60∆, and Y334H—would result in a change of a residue 
that interfaces with NRF2; it should be noted that only the S555-60∆ would likely not result 
in a mutant KEAP1 phenotype [10, 21, 34, 82]. While only speculative thus far, if KEAP1 
has a role in cell cycle progression, it is feasible that KEAP1 E3 ligase activity is required for 
progression to the next phase of the cell cycle. In this case, maintaining some ability to 
functionally contribute to cell cycle events through hypomorphic activity may achieve an 
ideal balance for cancer cells—pro-survival effects of enhanced NRF2 signaling and 
supported NRF2-independent functions of KEAP1.   
 
A caveat of the aforementioned hypothesis, however, is that all known KEAP1 
substrates would only serve to benefit cancer cell survival if KEAP1 function were impaired. 
Constitutive activation of NFκB, for example, is largely considered a pro-survival and pro-
proliferative pathway in the context of cancer [83-85]. KEAP1 acts to suppress NFκB 
signaling through degradation of IKKβ; thus, KEAP1 inactivation through mutations would 
be favored [86]. Furthermore, impaired KEAP1 function supports the anti-apoptotic effects 
of both BCL-2 and BCL-XL by freeing them from degradation so that they can bind pro-
apoptotic BAX [49, 50, 87, 88]. Along these same lines, if KEAP1 functions to degrade a 
protein that acts at a cell cycle checkpoint decreased KEAP1 activity would slow cell cycle 
progression—an undesirable phenotype for a cancer cell.  A potential resolution to this 
problem would be to account for the importance of timing in acquiring mutations in KEAP1. 
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The concept that KEAP1 and NRF2 are driver genes is becoming more widely 
accepted. The current paradigm of driver genes and passenger genes focuses on the idea that 
only genes that further support cancer cell fitness can be considered driver genes. Another 
important consideration in this hypothesis, however, is when a mutation may occur. 
Mutations in NRF2 are an excellent example of how temporal appearance of a mutation may 
also be critical to cancer cell fitness. As described in Chapter One, activation of NRF2 can be 
both anti- and pro-tumorigenic, depending on the context in which the activation occurs [31]. 
Expression of NRF2 can prevent transformation of a normal cell into a cancer cell by 
mitigating ROS that may otherwise result in cancer-driving DNA mutations. Conversely, 
when a cell has already become autonomous with respect to growth and proliferation, 
constitutive activation of NRF2 promotes tumorigenesis by reducing ROS and driving 
transcription of cell survival and drug efflux genes. Consequently, it is unlikely that NRF2 
could act as a gateway mutation in tumorigenesis. Indeed, this is supported by the inability of 
constitutive NRF2 activation to result in tumor formation [89, 90].    
 
With respect to KEAP1, however, one can imagine a different scenario. Like 
activating mutations in NRF2, inactivating mutations in KEAP1 that result in a null 
phenotype, are likely not advantageous as gateway or early mutations in tumorigenesis, 
because they could result in early chemopreventive NRF2 activity. However, activation of 
the other substrates via mutational inactivation of KEAP1, namely IKKβ, could certainly be 
desirable from the perspective of cancer cell fitness. Hypomorphic mutations in KEAP1 have 
the potential to act as early driver mutations by contributing to pathways such as NF-κB 
signaling, as well as the enhanced stability of anti-apoptotic proteins like BCL-2 and BCL-
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XL. Constitutive NRF2 activation in this context will be reduced, possibly to the point of not 
supporting any anti-tumorigenic effects. At later stages of tumor progression, augmented 
NRF2 activation through alternative means, such as competitive binding proteins, would then 
facilitate cancer cell fitness.  
 
Further experiments are required to determine exactly how hypomorphic mutations in 
KEAP1 may be more advantageous to inactivating mutations. It is likely that the selective 
processes behind hypomorphic mutations in KEAP1 are influenced by several factors, 
including the relative contributions of each pathway that is mediated by KEAP1 has in cancer 
progression. The major question that remains is whether these hypomorphic KEAP1 
mutations enhance cancer cell viability, and if so, if the mechanism is NRF2-dependent. 
Furthermore, as mentioned in Chapter Three, a group of these hypomorphic mutations that 
we have termed “superbinders” appears to have an interesting—and potentially novel—
mechanism mediating the inability to fully suppress NRF2. Experimental interrogation of 
these mutants will hopefully provide the insight required to elucidate how NRF2 function is 
affected, and whether this mutant class represents a novel mechanism of KEAP1-NRF2 
regulation employed in cancer. 
 
4.B.2 KEAP1 mutants: effects on cell viability and tumorigenesis, and the contribution of 
relative expression 
4.B.2.a Cell viability and tumorigenesis 
The data presented in Chapter Three demonstrate that 15 of the 18 KEAP1 mutations 
cannot suppress NRF2-mediated transcription (Fig. 3.1.B-D). Furthermore, a more detailed 
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analysis of several of these mutants shows that HMOX1 is upregulated, and NRF2 localizes 
to the nucleus following KEAP1 mutant expression (Fig. 3.4 and S3.3). Constitutive 
activation of NRF2 has been shown to enhance cell viability following chemotherapeutic 
insult. As elevated levels of NRF2 are observed following expression of KEAP1 mutants, it 
stands to reason that KEAP1 mutant expression should also correlate with resistance to 
chemotherapeutic insult. While conducting studies for the data presented in Chapter Three, 
we attempted several permutations of cell viability assays. We were unable to detect any 
robust or statistically significant differences between the KEAP1 mutants and wild-type 
KEAP1 (Fig. 4.2.A and B). Furthermore, contrary to previously published reports, wild-type 
NRF2 was unable to cause an appreciable rescue from cell death in our hands (Fig. 4.2.C and 
D). The following sections outline not only the experimental conditions and assays in our 
attempts to evaluate cell viability, but also describe how we may improve the assays for 
future analysis of KEAP1 mutant function in cell survival. 
 
Cell-based assays: PrestoBlue, Caspase-3/7 Glo, and Cell Titer Glo 
We first chose to pursue high-throughput assays to evaluate cell viability for several 
reasons: 1) Variations of these assays were used to establish the phenotype that NRF2 
expression is able to enhance cell survival following apoptotic insult [32], 2) several assays 
for a variety of cell viability measures (mitochondrial respiration, ATP production, caspase 
activation, loss of membrane integrity) are commercially available, which would provide the 
most complete panel of cell survival, and 3) to produce the most clinically-relevant data, we 
would test a several chemotherapeutics that are currently used in the clinic to treat lung 
cancer.  
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The assays chosen were as follows: 
A. PrestoBlue (Invitrogen). This assay uses a resazurin-based dye, similar to MTT, in 
which reduction of resazurin in the mitochondria produces a fluorogenic molecule. In 
this assay, cell viability is directly correlated with mitochondrial respiration. 
B. CellTiter Glo (Promega). A luminescent signal is produced proportionally to the 
amount of ATP present. Similar to the PrestoBlue assay, CellTiter Glo will provide a 
measure of the number of cells present, which is proportional to viable cells within a 
sample. 
C. Caspase-3/7 Glo (Promega). This assay provides a direct measure of apoptosis. It 
contains a proluminescent molecule that includes the consensus sequence for caspase 
cleavage. The luminescent readout produced is directly produced to the amount of 
active caspases present within a sample.  
 
The experimental setup included a negative control protein, such as GFP or 
nucleophosmin (NPM1), wild-type KEAP1, KEAP1 mutants, and usually wild-type NRF2 or 
NRF2-∆ETGE as positive controls. Regardless of the assay employed, or the apoptotic insult, 
we were unable to detect any considerable pro-survival effect when the KEAP1 mutants were 
expressed (Fig. 4.2).  
 
The most likely explanation for why we are unable to observe any type of rescue 
following expression of NRF2 is related to the cell line. All high-throughout assays were 
performed in HEK293T cells, which we suspect already have a higher basal level of KEAP1-
NRF2 pathway activity. Initially we employed these cells because they are highly 
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transfectable, which allows for analysis of a more homogeneous cell population, and are 
amenable to creation of stable cell lines without the need for transduction. Experiments that 
establish the pro-survival role of NRF2, however, use other cell lines, including A549 and 
several breast cancer lines [32]. Future experiments to evaluate the effect KEAP1 mutants 
have on cell viability should include alternative cells lines, and creation of stable cell lines by 
virus should be employed to achieve greater homogeneity among the cell population. 
Furthermore, in addition to including either NRF2 or NRF2-∆ETGE as theoretical 
maximums for viability, a NRF2 siRNA control should also be included, as this would set a 
theoretical minimum.  
 
It should also be noted that in addition to high-throughput assays to assess cell viability, 
Western blotting for apoptotic markers were also attempted. These experiments were 
conducted in several different cell lines, including HEK293T, A549, H2228, and H1299; 
however, regardless of the cell line used, we were unable to detect any differences in 
viability (Fig. 4.2). All Western blot analyses were performed with transient transfections. 
Follow up studies should include a similar experimental design, except with cell lines stably 
expressing KEAP1 mutants. 
 
4.B.2.b Clinically relevant models of cell viability 
High-throughput assays have the advantage of screening several different 
experimental conditions relatively quickly, which is ideal for evaluating 18 separate 
mutations following treatment with multiple clinically relevant drugs. These assays are 
effective at measuring a cells ability to survive chemotherapeutic insult, but they do not 
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necessarily assess the transformative properties of the gene(s) being assessed, nor do they 
provide insight into the proliferative abilities of these cells following insult. Anchorage-
independent growth assays and colony formation (clonogenic) assays can surrogate as 
measures of cell transformation and proliferative capacity, respectively.  
 
Anchorage-independent growth assays make use of immortalized cells that are unable 
to divide unless plated on a surface. Neither KEAP1 nor NRF2 have been shown to have 
transformative properties, and restoration of NRF2 expression has been shown to inhibit 
colony formation in anchorage-independent growth assays [91]. Consequently, it is unlikely 
that expression of a KEAP1 mutant alone will affect colony formation in an anchorage-
independent growth assay. However, pairing expression of a KEAP1 mutant with expression 
of a protein already known to promote colony formation, such as KRAS, may illuminate an 
additive or synergistic effect KEAP1 mutant expression and cell proliferation. As with the 
high-throughput cell based assays, a negative control protein, wild-type KEAP1, and wild-
type NRF2 and NRF2-∆ETGE should be included. Experimental conditions that include 
NRF2 are expected to have the most robust effect of enhancing colony formation. KEAP1 
mutants that behave in transcriptional assays like wild-type KEAP1 should also be evaluated, 
as enhanced colony formation with these mutants may indicate NRF2-independent functions 
of KEAP1 that support cancer cell proliferation. 
 
Clonogenic assays can be used as a complementary technique to anchorage-
independent growth experiments. Unlike anchorage-independent growth assays, however, it 
is possible that pairing KEAP1 mutations with KRAS expression may be unnecessary. In 
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clonogenic assays cells are plated directly onto a cell culture medium, possibly rendering 
addition of a gene that induces anchorage-independent growth superfluous. Additionally, 
clonogenic assays are easily paired with cellular insult. Briefly, cell populations expressing 
KEAP1, mutant KEAP1, NRF2/NRF2-∆ETGE, or negative control protein are treated with 
chemotherapeutic drug. The cells are then re-plated at very low confluency into a separate 
vessel without drug and allowed to grow into colonies. As NRF2 regulates expression of 
several drug efflux genes, the expectation is that cells expressing NRF2 or KEAP1 mutants 
will form colonies, whereas wild-type KEAP1 and the negative control will not. The same 
assay can be performed but rather than re-plating cells in drug-free media, maintaining them 
in sub-lethal doses. 
 
The gold standard in assessing whether a gene or mutation impacts tumor progression 
is utilization of mouse xenograft models. Similar to the anchorage-independent growth assay, 
it is likely that KEAP1 mutants will have to be paired with expression of an oncogene, such 
as KRAS. Rather than assessing if KEAP1 mutants promote tumorigenesis alone, these 
experiments would determine if KEAP1 mutants have the ability to enhance oncogene-
mediated tumor growth. Again, the expected results are that inclusion of NRF2, or KEAP1 
mutants that result in activated NRF2 will result in larger tumors than KRAS alone. 
Additionally, other genes known to impact xenograft models that are specifically correlated 
with squamous cell lung carcinoma, such as platelet derived growth factor receptor (PDGFR) 
and fibroblast growth factor receptor (FGFR), may also be studied for an additive effect with 
KEAP1 mutants [92-94]. Finally, response to chemotherapeutic treatment in mouse models 
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expressing KEAP1 mutants can be used to evaluate whether there are practical therapeutic 
implications for determining KEAP1 mutational status in a clinical setting.  
 
4.B.2.c The impact of allelic expression of KEAP1 mutants on cell viability  
As discussed in the introduction, at least a 75% reduction in KEAP1 activity is 
required to see a phenotypic effect on NRF2 [95]. Studies conducted on the importance of 
graded KEAP1 expression were conducted in mice with floxed wild-type Keap1 alleles. 
Floxed alleles resulted in reduced expression of Keap1, even when only one allele was 
floxed, resulting in “knockdown” animals. Knockdown animals were viable, but still 
exhibited lessened phenotypes of the knockout animals, including hypertrophy of the 
esophagus and upper stomach. An interesting observation of these animals, however, was 
that they demonstrate greater resistance to hepatotoxicity compared to wild-type animals 
[95]. Furthermore, administration of the glutathione precursor N-acetylcysteine prior to 
hepatotoxic stress had a protective effect, whereas an inhibitor of GCL sensitized both 
knockdown and wild-type animals to hepatotoxicity. These results are suggestive of a NRF2-
mediated mechanism of protection in the knockdown animals.  
 
Given the importance of KEAP1 expression with respect to NRF2 activity, it is 
intriguing to think about how the relative expression of KEAP1 mutant and wild-type alleles 
affects tumorigenesis and cancer cell viability in heterozygous tumors. As shown in Table 
1.1, lung squamous cell tumors exhibit a wide variation of allelic expression. From a 
therapeutic standpoint, whether a tumor achieves a 75% reduction in KEAP1 activity—either 
by homozygous KEAP1 mutation, or a combination of preferentially expressed mutant allele 
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to wild-type—may have a significant impact on chemotherapeutic response. Therefore, 
understanding how these KEAP1 mutants may affect NRF2 activity in knockdown animals, 
and cell lines derived from knockdown animals may, in fact, be the most clinically relevant 
analysis of KEAP1 mutations.  
 
The experiments detailed in this section are still adequate for addressing the 
importance of relative allelic expression of KEAP1. Rather than performing assays in non-
specific cell lines like HEK293T, however, a floxed Keap1 allele background should be used. 
Specifically, KEAP1 mutants should be stably introduced into MEFs derived from Keap1+/+, 
Keap1flox/+, Keap1flox/-, and Keap1-/- animals. Viability assays, including high-throughput and 
anchorage-independent growth and clonogenic assays, should be performed to evaluate the 
impact of KEAP1 mutant expression in a knockdown background using the experimental 
designs previously described.  
 
4.B.3 Mutant Classification: limitations, superbinder identification, and determining 
mechanism of the superbinder mutant class 
4.3.a Limitations of KEAP1 mutant classification 
Initial characterization of the TCGA KEAP1 mutants revealed that the mutants could 
be binned into four classes based on luciferase activity and NRF2 binding. The classes were 
as follows:  
Class I—unable to suppress NRF2-mediated transcriptional activity, bound NRF2 to an equal 
or lesser extent than wild-type KEAP1 
Class II—unable to suppress NRF2-mediated transcriptional activity, unable to bind NRF2 
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Class III—unable to suppress NRF2-mediated transcriptional activity, bound more NRF2 
than wild-type KEAP1 
Class IV—behaved similarly to wild-type in both transcriptional assays and Western blot 
analysis 
The ultimate goal of utilizing mutational data from resources such as the TCGA sequencing 
consortium is having the ability to predict functional outcomes based on a particular 
genotype. Establishing a predictive genotype-phenotype relationship could direct therapeutic 
interventions without first requiring rigorous characterization of mutant behavior in a 
laboratory setting. Classifying mutations based on objective, quantifiable criteria, like 
luciferase activity and substrate affinity, is appealing because it offers the first steps towards 
predicting how a mutation may affect global cellular fitness in the context of cancer. 
However, further interrogation of individuals within a particular mutant class revealed 
greater variability than we initially anticipated. Much of the observed variability is 
attributable to limitations of the experiments used to establish the different mutant classes. 
 
The four mutant classes were derived from two criteria—NRF2 binding and 
luciferase activity. Luciferase activity was described in a binary fashion, wherein any mutant 
that exhibited luciferase activity above wild-type control was considered a non-suppressor. 
Binding to NRF2 was assessed with Western blot analysis, and described on a graded scale; 
however, this scale was largely subjective, as we did not evaluate binding with a quantitative 
means, such as LI-COR or measurement of pixel density. The main limitation of both of 
these classification methods was that neither accounts for differences in mutant expression. 
Mutants unable to bind NRF2, for example, consistently expressed at lower levels than other 
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mutants or wild-type KEAP1. Consequently, drawing conclusions about the function of these 
mutants is difficult without first normalizing to mutant expression. Furthermore, the 
luciferase assay used to evaluate KEAP1-mediated suppression of NRF2 is highly variable, 
and extremely dependent on expression of the KEAP1 mutant constructs. Future studies 
should include Western blot analysis of the cell extracts used in luciferase assays to ensure 
the mutants are, at the very least, expressed.  
 
In addition to limitations regarding the expression of the KEAP1 mutants, we must 
also account for variability among cell lines. As shown in Figure 3.1.B-D, each cell line 
tested exhibited the same relative pattern of suppression among KEAP1 mutants; however, 
the absolute values varied greatly between cell lines. Some of this variability can be ascribed 
to transfection efficiency of the cell lines used. Another consideration is the presence of 
endogenous KEAP1, particularly when there is a precedent for mutations in KEAP1 to act as 
a dominant negative [75]. Furthermore, in cell lines such as A549, which has both a 
homozygous KEAP1 mutation and reduced KEAP1 expression due to promoter methylation 
[41], it is difficult to predict whether these factors may impact exogenously expressed 
KEAP1 mutant function. As previously stated, the relative pattern of suppression among 
KEAP1 mutants is approximately equal, including suppression observed in KEAP1 knockout 
MEFs (Fig. 3.1.C), where the possible effects of endogenous KEAP1 are not an issue.  
  
Even in a hypothetical situation where KEAP1 mutants are expressed equally in a 
luciferase assay, relating mutant function in a luciferase assay to the relative suppressive 
abilities of that mutation in a tumor for use in classification may not be feasible. As depicted 
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in Figure Table 1.1 the relative allelic expression of the wild-type and mutant allele can vary 
widely. Unless the tumor is homozygous mutant, attempting to achieve a comparable wild-
type KEAP1 to mutant KEAP1 in a luciferase assay is likely not practical or useful for 
classification purposes. Indeed, when we attempted to correlate NRF2 gene signature of 
tumors with the luciferase activity of the corresponding mutant, further stratifying luciferase 
activity (beyond “suppressor” or “non-suppressor”) did not improve the p-value (Fig. 
S.3.1.A). This is not to say that luciferase assays are not useful in characterizing KEAP1 
mutant biology. Rather, luciferase assays to assess KEAP1 mutant function should be used as 
a complementary experimental tool in mutant characterization, and perhaps if luciferase 
assays will be used in mutant classification, they can be kept at a binary “suppressor” or 
“non-suppressor” variable. 
 
4.3.b Identification of the KEAP1 superbinder mutant class  
The KEAP1 superbinder class was initially defined as the class of mutants that was 
unable to suppress NRF2-mediated transcription in a luciferase-based assay, but bound more 
NRF2 than wild-type KEAP1 when KEAP1 was affinity purified. Quantitative analysis 
reveals that with the exception of S243C, superbinders bind at least twice as much NRF2 as 
wild-type (Fig. 4.3). We chose one of the superbinder mutants—R320Q—for further 
characterization, and found that NRF2 has an extended half-life when R320Q is expressed. 
The observed extended half-life seen in Western blot is not exclusively due to more NRF2 
being bound to KEAP1 (Fig. 3.5.B). The most surprising characteristic of the superbinders, 
however, is that they do not appear to impede NRF2 ubiquitination (Fig. 3.5.C and D). Given 
the unique nature of this particular group of KEAP1 mutants, we investigated several other 
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characteristics, including protein interaction network changes, NRF2 binding affinity, and 
interaction with the proteasome, to provide insight into the potential mechanism of these 
mutants.  
 
Protein interaction network differences of the superbinder mutants 
With the exception of NRF2, the superbinder mutants do not exhibit vastly different 
protein interaction networks compared to wild-type KEAP1. Quantitative mass spectrometry 
analysis of the superbinders R320Q and R470C reveals that most KEAP1 interacting 
proteins, particularly ETGE-containing interactors, are present, although the relative amounts 
vary slightly compared to wild-type KEAP1 (Fig. 3.3.B). Furthermore, in a panel of five 
known protein interactors, the superbinders exhibit a remarkably consistent binding pattern to 
wild-type (Fig. 3.3.A, lanes 3, 5, 6, 9, 14, 16, 20). Two notable exceptions are reduced 
binding of IKKβ and MCM3 to G186R (Fig. 3.3.A, lane 14). Further quantitative analysis, 
including quantifying affinity purification and Western blot for the superbinder mutants, 
should be performed to validate the perceived similarities in the PIN for these mutants. At 
this time, however, the data regarding superbinder protein-protein interactions suggest that 
the most critical characteristic of these mutants regarding function and global cellular impact 
can be attributed to NRF2 interaction and degradation. 
 
Identifying differential binding affinities for the NRF2 superbinder mutants 
One possibility to explain why the superbinders bind more NRF2 than wild-type is 
that the mutation causes a structural and/or biochemical change in KEAP1 that enhances the 
affinity for NRF2. A change such as this could explain not only the greater amount of NRF2 
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bound to KEAP1, but also if the affinity of KEAP1 for NRF2 impacts proteasomal delivery 
and degradation of NRF2, it could also explain why NRF2 turnover appears to be slower 
with superbinder KEAP1 (Fig. 3.5.A and B). To begin to address the relative affinities of 
KEAP1 superbinder mutants, affinity purification followed by stringent salt wash was 
performed. The expected result of this experiment is that NRF2 would dissociate from wild-
type KEAP1 at lower molarity salt than a superbinder mutant, because it would be more 
tightly bound to superbinder KEAP1. As shown in Figure 4.4, no appreciable difference was 
detected in the amount of NRF2 bound to affinity purified KEAP1 after stringent salt washes. 
It should be noted, however, that even at the highest concentration of salt, a substantial 
amount of NRF2 was bound to wild-type KEAP1. Consequently, it is possible that the 
experimental conditions require a higher concentration of salt, such that a more dynamic 
range of NRF2 dissociation from wild-type KEAP1 is achieved.  
 
4.3.c Determining the mechanism of KEAP1 superbinder mutants 
To ensure a comprehensive analysis of mutations in KEAP1, the experiments outlined 
in Chapter Three for the R320Q superbinder mutant to further characterize function, 
including NRF2 localization, NRF2 half-life, and NRF2 ubiquitination should be performed 
for all 18 KEAP1 mutants. At this time, however, the KEAP1 superbinder mutant class 
appears to be unique among the other mutants found in the lung squamous cell carcinoma 
dataset. Currently 7 of the 18 mutations are considered to be superbinder mutants. Although 
this group could become more stratified following further characterization, given the current 
data these mutants comprise the largest and most consistent group of KEAP1 mutants in the 
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lung squamous cell cohort. Consequently, we are interested in determining if KEAP1 
superbinder mutants represent a novel mechanism of NRF2 activation in cancer.  
 
Increased affinity for NRF2 vs. inefficient interaction with the proteasome 
An initial step in understanding the superbinder mechanism of action is 
differentiating between whether these mutants actually have an enhanced affinity for NRF2, 
or whether the KEAP1-NRF2 complex cannot be as easily degraded via the proteasome, 
perhaps due to conformational changes that impair interaction with the proteasome. The 
saturation model predicts that inactivation of KEAP1 permits newly translated NRF2 to 
evade degradation, thus activating NRF2 transcription. Therefore, the outcome of either an 
increased affinity for NRF2 or a slower rate of turnover due to inefficient proteasomal 
recognition would be the same with respect to intracellular NRF2 activation. The 
significance in distinguishing between increased affinity or impaired turnover lies in 
considering NRF2-independent functions of KEAP1, as well as elucidating how KEAP1—
and E3 ligases as a protein class—interact with the proteasome to facilitate substrate 
degradation. 
 
An enhanced affinity for NRF2 may limit how easily NRF2 is released to the 
proteasome to undergo proteolysis. In turn, a decreased rate of NRF2 proteolytic degradation 
has the potential to disrupt the rates of degradation of other KEAP1 substrates as described in 
the saturation model. Additionally, as all known KEAP1 substrates bind to the KELCH 
domain like NRF2, it is also possible that the affinity for alternative substrates may also be 
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increased. The overall effects of changes in substrate affinity will likely need to be studied on 
an individual basis.  
 
To determine if KEAP1 superbinder mutants have differential affinities for NRF2, 
surface plasmon resonance (SPR) experiments may be used. Wild-type KEAP1 and a 
superbinder mutant such as R320Q will be immobilized on the surface. Recombinant NRF2 
would then be flowed over the immobilized KEAP1 to determine binding affinity. The same 
KEAP1 monobody as described earlier can be used to facilitate NRF2 dissociation for 
determination of Kd. Previously we have utilized this KEAP1 binding peptide to detect 
differential binding affinities of NRF2 between wild-type KEAP1 and the R320Q mutant. 
Similar to the salt washes in Figure 4.4, no appreciable difference was detected between 
wild-type KEAP1 and R320Q (Fig. 4.5). However, while we were able to detect NRF2 
dissociation from KEAP1, it was not complete (Fig. 4.5, lanes 20, 23-26). Furthermore, at the 
highest concentrations unbound peptide was detectable in the flowthrough (Fig. 4.5, lanes 20 
and 26), suggesting that the concentration of KEAP1 monobody was approaching a 
saturating level. It is also somewhat puzzling as to why the majority of NRF2 remains bound 
to KEAP1 despite the suggestion that peptide concentration is saturating (Fig 4.5, lanes 20 
and 26). Flaws in experimental design could explain this discrepancy. Immunoprecipitation 
samples were prepared from whole cell lysate, which yields an unknown amount of purified 
KEAP1; consequently it is difficult to determine what concentrations of peptide are needed 
to adequately titrate NRF2 from KEAP1. This experiment should be repeated using 
recombinant R320Q, wild-type KEAP1, and NRF2 to eliminate disparities in purification for 
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each mutant, as well as artifacts that may result from using protein purified from whole cell 
lysate. 
 
Another alternative is that the KEAP1 superbinder mutants are unable to facilitate 
delivery of NRF2 to the proteasome for degradation. As stated in the introduction, several 
regulatory events precede the peptide bond cleavage step of proteasome-mediated 
proteolysis. One of these upstream events includes recognition of a proteasome substrate, 
which occurs through protein interactions with regulatory factors, or ubiquitin receptors, 
associated with the proteasome [96, 97]. Mutations that alter E3 ligase structure to sterically 
impede association, or mutate residues required for interaction with these factors would 
result in an equilibrium shift towards NRF2 bound to KEAP1.  
 
We previously tested interaction of wild-type KEAP1 compared to superbinder 
R320Q with one of these factors, CDC48/p97, which is known to assist in segregating 
ubiquitinated substrates from unmodified partners [96, 98]. As depicted in Figure 4.6 (lanes 
5-8) no obvious difference between wild-type KEAP1 and R320Q was observed. Despite not 
detecting any decreased binding of CDC48/p97 associated with R320Q, several other 
ubiquitin receptors have been shown to mediate substrate recognition by the proteasome [96, 
97]. Quantitative mass spectrometry analysis comparing wild-type KEAP1 with a 
representative superbinder, such as R320Q, may provide clues as to which of these other 
regulatory protein interactions may be altered due to KEAP1 mutation. In addition to mass 
spectrometry analysis, a limited siRNA screen of ubiquitin receptors may be performed. 
Briefly, the luciferase reporter for NRF2 activity (hQR41) can be used to initially distinguish 
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putative hits, as wild-type KEAP1 should no longer be able to suppress NRF2-mediated 
activity if a required ubiquitin receptor was knocked down. Validation of hits would include 
transfecting cells with the siRNA to a specific ubiquitin receptor, followed by affinity 
purification of KEAP1. The prediction would be that wild-type KEAP1 would behave 
similarly to a superbinder mutant if that particular ubiquitin receptor was mediating NRF2 
recognition in a KEAP1-dependent manner.  
 
USP15: KEAP1 ubiquitination and KEAP1-CUL3 complex formation 
Ubiquitination of KEAP1 is an established means of KEAP1-NRF2 pathway 
regulation [99]. The theory behind this regulation rests on the observation that following 
treatment with some pathway agonists, such as tBHQ, ubiquitination switches from NRF2 to 
KEAP1 [100]. A switch in ubiquitination destabilizes the KEAP1-NRF2-CUL3 complex, as 
ubiquitinated KEAP1 cannot associate with CUL3 as we as the deubiquitinated form [99, 
100]. Importantly, ubiquitination of KEAP1 does not target it for degradation; rather, 
ubiquitinated KEAP1 cannot assemble into the KEAP1-CUL3 ligase complex as efficiently.  
Recently it has been proposed that the deubiquitinase USP15 is responsible for maintaining 
KEAP1 in the deubiquitinated form to facilitate NRF2 degradation. Indeed, overexpression 
of USP15 promotes NRF2 degradation, and siRNA-mediated knockdown activates NRF2-
mediated transcription [100]. Furthermore, USP15 expression stabilizes the KEAP1-CUL3 
interaction, which drives ubiquitination and degradation of NRF2. USP15 has also been 
shown to be required for the processing of ubiquitinated substrates that are bound to 
CDC48/p97 [100, 101]. Given these observations, an altered interaction with USP15 may be 
a possible mechanism to describe the KEAP1 superbinder mutant phenotype.  
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Superbinder mutations may result in a structural change in KEAP1 that impedes 
interaction with USP15. In this event, KEAP1 ubiquitination may be enhanced under basal 
conditions, thus destabilizing the KEAP1-CUL3 E3 ubiquitin ligase complex and promoting 
NRF2 stabilization. To begin analyzing the role of USP15 in superbinder function, KEAP1 
ubiquitination status should be assessed. Immunoprecipitation of either wild-type KEAP1 or 
R320Q under denaturing conditions, followed by Western blot analysis for ubiquitination 
will determine if there is a difference in ubiquitination under basal conditions. If USP15 
cannot interact with R320Q, the anticipated result is increased ubiquitination of R320Q 
compared to wild-type. Complementary to this experiment, knockdown of USP15 by siRNA 
transfection should eliminate any difference between wild-type KEAP1 and R320Q 
ubiquitination. In addition to analysis of KEAP1 ubiquitination status, co-
immunoprecipitation should be performed to compare USP15 association with wild-type 
KEAP1 and the R320Q mutant.  
 
One piece of data that argues against USP15 regulating KEAP1 deubiquitination is 
Figure 3.5.C, in which in vivo ubiquitination of NRF2 is approximately equal between wild-
type and R320Q. In an in vitro ubiquitination assay, R320Q also performs as well as wild-
type KEAP1 in ubiquitinating NRF2, but as this experiment was conducted with recombinant 
protein, we may assume that the ubiquitination status of the mutant and wild-type were equal. 
The experiment depicted in Figure 3.5.C was performed in HEK293T cells, which contain 
endogenous KEAP1. As KEAP1 acts as a homodimer, it is possible that the presences of 
wild-type KEAP1-R320Q heterodimers may be able to compensate for R320Q homodimers 
that may not function as efficiently in the KEAP1-CUL3 complex due to enhanced 
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ubiquitination. Future studies should include in vivo experiments in KEAP1-/- MEFs to 
eliminate any possible compensatory mechanism from endogenous wild-type KEAP1.  
A.
B.
Figure 4.1. DPP3 is overexpressed in head and neck squamous cell carci-
noma. (A) Gene expression and copy number analysis for head and neck 
squamous cell carcinoma subtypes. Tumor subtypes are displayed as columns; 
basal (BA), mesenchymal (MS), atypical (AT), classical (CL). (B) DPP3 
expression (y axis) versus DPP3 copy number (x axis). Hetloss., heterozygous 
loss; Amp., amplification.
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Figure 4.2. KEAP1 mutations do not significantly impact cell viability. (A) 
HEK293T cells stably expressing wild-type KEAP1 (KEAP1-WT) were treated with 
Etoposide for 48 hours. Cell viability was measured by mitochondrial repiration 
(PrestoBlue, Invitrogen) and compared to the parental line (293T/17). (B) HEK293T 
cells stably expressing a subset of KEAP1 mutations were treated with Etoposide for 
48 hours. Cell viability was measured by total intracellular ATP (CellTiterGlo, 
Promega) and compared to the parental line (293T/17). Wild-type KEAP1, WT (C) 
A549 cells were transiently transfected with wild-type KEAP1 (WT), KEAP1-R320Q 
mutant (R320Q), NRF2, or negative control GFP for 24 hours. Cells were then treated 
with Etoposide for 12 hours, followed by Western blot for markers of apoptosis. 
PARP, cleaved PARP; CASP3, cleaved caspase-3. (D) A549 cells were transiently 
transfected with wild-type KEAP1 (WT), KEAP1-R470C mutant (R470C), KEAP1-
R320Q mutant (R320Q), NRF2, or negative control nucleophosmin (NPM1) for 24 
hours. A 12 hour pre-treatment with Sulforaphane (20uM) was also performed (Sulf). 
Cells were then treated with Etoposide for 48 hours, followed by Western blot for 
markers of apoptosis. PARP, cleaved PARP. 
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Figure 4.3. KEAP1 superbinder mutants bind 
more NRF2 than wild-type KEAP1. HEK293T 
cells were transiently transfected with wild-type 
KEAP1 (WT) or a mutant construct. Affinity 
purification of KEAP1 followed by Western blot for 
NRF2 was performed to assess NRF2 binding. 
Relative abundance of NRF2 binding for the 
superbinder mutants (annotated with red lines) was 
performed using ImageJ. NRF2 binding was 
normalized to the amount of KEAP1 (FLAG).
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Figure 4.4. Wild-type KEAP1 and the R320Q superbinder 
bind NRF2 with similar affinities. HEK293T cells stably 
expressing wild-type KEAP1 (KEAP1-WT) or the R320Q 
mutant (KEAP1-R320Q) were lysed in 0.1% NP-40 lysis buffer 
(see Chapter 2 Materials and Methods for recipe), followed by 
affinity purification for KEAP1. The affinity resin was washed 
in 0.1% NP-40 lysis buffer with the indicated concentrations of 
NaCl and protein complexes were analyzed by Western blot to 
assess NRF2 binding.
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Figure 4.5. The KEAP1 monobody cannot compete NRF2 off of wild-type KEAP1 or 
the R320Q superbinder mutant. HEK293T cells stably expressing wild-type KEAP1 
(KEAP1-WT) or the R320Q superbinder mutant (KEAP1-R320Q) were lysed in 0.1% 
NP-40 lysis buffer (see Chapter 2 Materials and Methods for recipes) and affinity purified 
for KEAP1. The affinity resin was resuspended in lysis buffer, and then incubated with 
negative control (FN3), or the indicated increasing concentrations of monobody for 1 
hour at 4 degrees Celsius. Flowthrough was retained for Western blot analysis 
(FLOWTHROUGH). The affinity resin was then washed five times with lysis buffer. 
Western blot analysis was performed to assess NRF2 binding. The FN3 negative control 
peptide and KEAP1 monobody are detected by immunoblot for GST. 
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Figure 4.6. Wild-type KEAP1 and the R320Q 
superbinder mutant associate with p97 equally. HEK293T 
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